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Cancer is the name given to a class of diseases characterized by an imbalance in cell
proliferation and apoptosis, or programmed cell death. Once cancer has reached detectable
sizes (106 cells or 1 mm3), it is assumed to have spread throughout the body, and a systemic
form of treatment is needed. Chemotherapy is commonly used, and it affects both healthy
and diseased tissue. This creates a dichotomy for clinicians who need to develop treatment
schedules which balance toxic side effects with treatment efficacy. The optimal treatment
schedule — where schedule is defined as the amount and frequency of drug delivered —
is the most efficacious schedule evaluated during clinical trials. In this work, a model–
based approach for drug treatment schedule design was developed. Cancer chemother-
apy modeling is typically segregated into drug pharmacokinetics (PK), describing drug
absorption, distribution throughout an organism, and metabolism and pharmacodynamics
(PD), which delineates cellular proliferation, and drug effects on the organism. This work
considers two case studies: (i) a preclinical study of the oral administration of the antitumor
agent 9-nitrocamptothecin (9NC) to severe combined immunodeficient (SCID) mice bearing
subcutaneously implanted HT29 human colon xenografts; and (ii) a theoretical study of
intravenous chemotherapy from the engineering literature.
Metabolism of 9NC yields the active metabolite 9-aminocamptothecin (9AC). Four dif-
ferent PK model structures were constructed to describe the plasma concentration versus
time profiles of 9NC and 9AC: three linear models at a single dose level (0.67 mg/kg 9NC);
and a nonlinear model for the dosing range 0.44 – 1.0 mg/kg 9NC. Untreated tumor growth
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was modeled using two approaches: (i) exponential growth; and (ii) a switched exponential
model transitioning between two different rates of exponential growth at a critical size.
All of the PK/PD models considered here have bilinear kill terms which decrease tumor
sizes at rates proportional to the effective drug concentration and the current tumor size.
The PK/PD model combining the best linear PK model with exponential tumor growth
accurately characterized tumor responses in ten experimental mice administered 0.67 mg/kg
of 9NC QD×5×2 (Monday-Friday for two weeks) repeated every four weeks. The nonlinear
PK model of 9NC coupled to the switched exponential PD model accurately captured the
tumor response data at multiple dose levels. Each dosing problem was formulated as a mixed–
integer linear programming problem (MILP), which guarantees globally optimal solutions.
When minimizing the tumor volume at a specified final time, the MILP algorithm delivered
as much drug as possible at the end of the treatment window (up to the cumulative toxicity
constraint). While numerically optimal, it was found that an exponentially growing tumor,
with bilinear kill driven by linear PK, would experience the same decrease in tumor volume
at a final time regardless of when the drug was administered as long as the same amount
was administered. An alternate objective function was selected to minimize tumor volume
along a trajectory. This is more clinically relevant in that it better represents the objective
of the clinician (eliminate the diseased tissue as rapidly as possible). This resulted in a
treatment schedule which eliminated the tumor burden more rapidly, and this schedule can
be evaluated recursively at the end of each cycle for efficacy and toxicity, as per current
clinical practice.
The second case study consists of an intravenously administered drug with first order
elimination treating a tumor under Gompertzian growth. This system was also formulated
as a MILP, and the different objectives were considered. The first objective was minimizing
the tumor volume at a final time — the objective the original authors considered. The
MILP solution was qualitatively similar to the solutions originally found using control vector
parameterization techniques; as much drug as possible was administered at the end of the
treatment interval. The problem was then reposed as a receding horizon trajectory tracking
problem. Once again, a more clinically relevant objective returned promising results; the
v
tumor burden was rapidly decreased. This technique could be generalized to arbitrary
drug/tumor concentrations provided a PK/PD model exists or could be derived.
vi
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1.0 INTRODUCTION
1.1 BACKGROUND
In the United States, cancer is currently the leading cause of death for persons under 85 and
accounts for ten percent of the monetary resources devoted to disease treatment [1]. There
are over 1.3 million new cases and 570,000 deaths predicted in 2005, and the economic cost
to the United States was approximately $189 billion in 2004 [1]. This result is a societal
dilemma in terms of human mortality and financial burden.
Cancer refers to a class of diseases characterized by an imbalance in apoptosis, or
programmed cell death, and the rate of cellular proliferation [2]. As the tumor mass increases,
cancer cells will induce secretion of metallo–proteases which will degrade the extracellular
matrix and encourage the creation of new vascular growth through angiogenesis [3]. While
competing with the host organism and surrounding tissues for resources, cancer cells may
invade local tissue or move about the host via the circulatory system. A tumor is said to
have metastasized when cells have successfully relocated to new tissues within the host [3, 4].
The invasive nature of cancer will eventually lead to organ failure and the death of the host
organism if left untreated.
Cancerous masses which can be reached through surgery are removed. There are several
forms of cancer in which surgery is not an option because of the location of the cancer (e.g.,
some brain tumors) or because the disease is not localized (e.g., hematological malignancies
like leukemia). Radiation therapy, which can target specific tissues, is an option for inoper-
able forms of cancer. However, once cancer has reached detectable levels it is probable that
metastases exist. For this reason a more systemic method of treatment may provide more
efficacious results.
1
Cancer cells proliferate more rapidly than cells from healthy tissues and spend more time
actively cycling in the cell–cycle (growth, DNA synthesis, mitosis, etc.) [2]. Chemotherapy
is a commonly employed systemic form of treatment which attempts to take advantage of the
rapidly proliferating nature of cancer cells. While selectivity of treatment toward diseased
over healthy tissues is desired, this objective is not always achieved. Healthy tissues, such
as white blood cells and the cells of the intestinal mucosa, also proliferate rapidly and are
affected by chemotherapeutic treatment. This creates a dichotomy for clinicians who must
balance the need to eliminate the disease with the toxic side effects of treatment. The
treatment schedule, defined as dose amount and frequency, used clinically is derived from an
empirical process which begins with preclinical evidence found during the drug development
process. Later refinement of the treatment schedule takes place throughout clinical testing
and patient treatment.
1.2 DRUG DEVELOPMENT PROCESS
The development of chemotherapeutic drug schedules is an empirical process. Information
from preclinical research as well as clinical trials in humans is used to determine drug dosing
schedules. Possible anticancer compounds are first tested in vitro in cell culture. Promising
results lead to in vivo preclinical trials, which are performed in species expected to respond
similarly to humans. Preclinical trials are used to establish optimal dosing route (e.g.,
intravenous, oral, etc.), and metrics for evaluating toxicity. This is followed by animal
studies that establish the efficacy of the drug against different forms of cancer. Efficacious
drugs with manageable toxic effects in animal models are then tested in clinical trials.
Phase I clinical trials are used to establish toxicity constraints for humans. A common
approach is to consider the species most sensitive to the drug in preclinical testing. Adminis-
tration of the drug to humans begins at one tenth the lethal dose in 10% of the most sensitive
species
(
1
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LD10
)
. Dose levels are then escalated until the dose–limiting toxicity (DLT) is
reached. One level below the DLT dose is set as the maximum tolerated dose (MTD). A
common method is to increase the dose levels according to a modified Fibonacci series [5].
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Phase II studies are then performed to establish efficacy of the anticancer compound
against specific types of cancer — most often those cancers identified as being susceptible in
preclinical trials. One third of the dose causing DLT is used as a basis for initial dose
levels, and empirical evidence is used to guide the efficacy evaluation. Since it is not
possible to evaluate every conceivable administration schedule, previous knowledge of similar
compounds, known toxicities, and logistical issues are used to establish when the drug should
be administered. The objective is to find the drug schedule which will yield the maximum
response, typically measured in terms of exposure, without violating the above constraints [6].
Statistically significant responses, such as increased survival times, are used as indications
that the compound is clinically effective.
Based on the toxicity limits from Phase I trials and demonstrable efficacy from Phase
II trials, a successful compound will then enter Phase III trials. The purpose of Phase
III trials is to evaluate a drug and corresponding schedule against the current standard of
practice for treating specific forms of cancer. This can involve a single new agent or, more
often, the new agent in combination with an approved form of chemotherapy. A successful
drug/schedule combination will be statistically more efficacious (based on disease response,
toxicity reduction, etc.) than the current gold standard.
Ultimately, the schedule on which anticancer drugs are administered is the schedule from
Phase II and Phase III trials which yields the most statistically significant results. These
schedules, derived from empirical evidence and heuristics, are considered optimal because
they were more efficacious than the others considered. However, it may be possible to employ
the data generated during the drug development process to more rigorously define an optimal
drug schedule.
1.3 MODEL–BASED CONTROL
Model–based control is currently considered the state–of–the–art in the field of process
control [7, 8, 9]. This form of control makes explicit use of system model predictions in order
to determine how manipulated variables should be changed to achieve a desired objective.
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˙ˆx = Ft(xˆ, u)
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Figure 1: Model–based control algorithm which determines input changes, u, based on
estimates of internal states, xˆ described by Ft(xˆ, u), output estimates, yˆ, given Fo(xˆ, u),
and actual output measurements y.
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This methodology is illustrated in Figure 1 for the treatment of experimental or simulated
mice. Data collected during an experiment, either real or simulated, provide the current
state of the mouse system. These measurements can include the current drug concentration,
information about toxicity (e.g., reductions in white blood cell count or body weight), the
current size of the tumor, etc. The desired response may include reductions in tumor volume
or a target body weight. The system state and desired response are provided to the controller
which utilizes a model of the system to determine the manipulated variable changes required
to obtain the desired response. When considering cancer treatment, manipulated variables
can include dose levels and the times at which the treatment should be applied. This process
operates in a closed–loop fashion, where feedback is used for altering drug administration.
Classical feedback control relies on frequent measurements to control the process in real
time. However, chemotherapy is given in cycles with periodic updates (every two weeks to
two months) with treatment alterations based on evaluations of toxicity and patient response.
The current standard of practice or gold standard of treatment is based on empirical evidence
gathered from preclinical and clinical trials carried out during the drug development process.
1.4 OVERVIEW OF MODELING APPROACHES
In the context of model–based control, useful models must be both descriptive and predictive.
However, a balance must generally be made between model complexity and predictive
accuracy. Simple models (linear relationships, cubic splines, etc.) can be developed which
characterize the current dataset but have limited predictive capacity. Depending on the
measurements available, detailed models can be constructed that offer excellent predictive
capacity [10]. For many processes, physiologically based model structures contain many
differential equations often with complex nonlinearities. Such models can prove to be
prohibitively complex from a computational perspective when the desired result is the
development of an optimal control algorithm. The goal of the present work was to develop
models of drug pharmacokinetics (PK) and pharmacodynamics (PD) which are predictive
and at the same time suitable for controller synthesis.
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1.4.1 Tumor Growth Models
Modeling for cancer systems requires two components. The first is an understanding of the
system in the absence of treatment and the second is a description of the effects of treatment.
A nominal understanding of how cancer progresses is necessary for model construction in
the case of the untreated system. Initially, cancer cells typically proliferate in an exponential
fashion. The size of the cancerous mass is measured experimentally as a volume, though
this mass is often referred to in terms of the number of cells (106cells ≈ 1mm3) [11].
As the cancerous mass increases in size, stochastic recruitment of blood vessels leads to
scarcity in nutrients [3]. In response to decreased availability of nutrients, the rate of
proliferation slows, and the population of cancer cells asymptotically approach a plateau
population [4]. Cancerous masses reaching this stage of growth are typically considered to be
under Gompertzian growth [11]. Other models have been developed in order to incorporate
reductions in proliferation rates as tumor sizes increase. These include the saturating Logistic
model [12] and the Verhulst–Perl equation [13]. Simeoni et al. demonstrated a model which
grows exponentially when tumor volumes are low and linearly as tumor volumes increase
[14].
Cell–cycle models have also been proposed [15, 16] to characterize the proliferative nature
of cancer. A schematic is shown in Figure 2. These models explicitly represent the transition
of cells between the different phases of the cell–cycle [2]. Many anticancer drugs are cycle–
specific, which means their primary effect occurs during a specific phase of the cell–cycle.
While understanding cellular proliferation at this level is ideal, acquiring data characterizing
the fraction of cells in the different phases is nontrivial. In order to determine the fraction
of cells at different phases of the cell–cycle, samples must be obtained and stained for DNA
and RNA content at different points in time [17]. Based on the amount of DNA or RNA
in different cells, the fraction of cells in a specific phase can be determined [17]. However,
using only macroscopic volumes to identify parameters in a cell–cycle model can lead to
identifiability problems. For example, consider the transition rates kS and kG1. Estimating
these parameters from tumor volume measurements could lead to two different sets of
parameters such that kS > kG1 or kS < kG1 that predict the same macroscopic behavior
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Figure 2: Typical five phase representation of the cell–cycle [2]. Cell–cycle phases are:
growth (G1), DNA synthesis (S), secondary growth (G2), mitosis (M), and quiescent (G0).
Transition rates between phases are given by ki.
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[18]. However the former would predict fewer cells in S than the latter. This can lead
to problems when considering a drug which is S–phase specific. Because the macroscopic
preclinical experimental data used in this work does not adequately inform a cell–cycle
description of tumor growth, macroscopic growth models were used exclusively.
1.4.2 Pharmacokinetic Modeling
PK models describe the effects organisms have on the drug. These effects typically include
the absorption, distribution, metabolism, and elimination of the compound [19, 20]. The
study of drug PK was first introduced by Teorell where he suggested that the major tissues
in the body could be modeled such that chemical substances were distributed throughout the
body based on the physiological construction of the organism [19, 20]. Models of this nature
are now commonly called physiologically–based pharmacokinetic (PB/PK) models [21]. This
is illustrated in the left half of Figure 3. The individual organs are treated as well–mixed
compartments where a drug is distributed homogeneously throughout the organ. Organs
with nonuniform drug distribution can be better described by partitioning the tissue into
subcompartments. Construction of these types of models can prove problematic as the data
requirements are extensive and tissue–specific data may be very difficult or impossible to
obtain clinically. For example, to obtain the average drug concentration in the kidneys of an
experimental animal, the animal is euthanized, the kidneys are removed and homogenized,
and the concentration is determined using analytical techniques (e.g., HPLC). Performing
this type of analysis is expensive and time consuming and it is simply not possible to analyze
human patients in this fashion. To reduce model complexity and better represent available
data, Teorell suggested using a more simplified model structure [19, 20]. This resulted in the
traditional compartmental model, an example of which is shown on the right side of Figure 3.
This simplified representation is used because plasma concentrations can be obtained more
easily than organ tissue concentrations. A remote compartment here is shown to account for
any higher–ordered dynamics that are observed experimentally.
The model structure of compartmental models — number of compartments, connectivity,
and the rate of transition between compartments — will depend primarily on the dynamics of
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Figure 3: PB/PK representation of drug distribution for an orally or intravenously
administered drug (left), and compartmental approximation (right).
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the data being fit. It is common to assign physiological significance to parameters in compart-
mental models. For example, a pharmacokineticist might model an orally administered drug
by adding a compartment between the “Drug” input and “Plasma” compartment on the right
side of Figure 3. The rate of drug leaving this new compartment and entering the “Plasma”
compartment might be taken as the rate of absorption from the gut into the plasma. This
may or may not be the case and cannot be established without a measurement of drug
concentration in the gut. Hence, physiological interpretations of simplified compartmental
model parameters are more often a psychological construct than a rigorous understanding of
the underlying physiology. Regardless, the class of compartmental models is widely accepted
and employed in drug development [22, 23, 24].
The necessary complexity of compartmental models is largely dictated by the PK re-
sponse found in experimental data. Linear PK models, models in which each of the rates
of transition between compartments is linear in the system state, can be used to describe
many systems. The volume of work done in this area is too numerous to enumerate here,
using the query ‘cancer PK PD’ in pubmed returns 19,162 results, but a number of software
packages provide modeling and simulation capability for a variety of model structures (e.g.
ADAPT II [25], NONMEM [23], etc.). From a control perspective, linear PK models are
typically preferred because they are more easily implemented in controller synthesis [26, 27].
However, many biological systems exhibit nonlinear behavior [21]. Modified compartmental
model structures have been developed to account for many types of nonlinearities, such as
saturable pathways. Cyclophosphamide, for example, exhibits saturable elimination, and
Michaelis–Menten kinetics have been employed to describe these effects [28]. This and other
nonlinear effects are commonly accounted for by incorporating nonlinear functionality into
transition rates between compartments. These structure selections can be simple if the data
exhibit easily identifiable characteristics (e.g., first–order response). Otherwise, there exist
few methods for rigorous determination of PK model structure. One empirical method is the
use of genetic algorithms to determine the optimal model structure based on a set of possible
structures [29]. Stepwise forward model construction begins with a simple model structure.
Elements are randomly added to the model and tested to determine if they improve accuracy.
Model contributions that improve accuracy are retained. Addition of terms is halted when
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a stopping criterion specific by the user is met (e.g. upper bound on model complexity,
fit accuracy, etc). Stepwise term elimination often follows the model construction step.
The element whose removal has the least effect on the quality of fit is removed completely
if changes in the quality of fit are below a specified threshold. This process is repeated
iteratively until no further improvement in the quality of fit can be obtained.
Compartmental models are common because they are intuitive to construct and many
tools have been developed to aid in estimation of their parameters [21, 23, 25]. They are also
popular because they answer many of the questions which concern clinicians. These include
determining the exposure of a drug, quantified as the area under the plasma concentration
versus time curve. The rate of drug clearance is another characteristic important to clinicians
because it provides an indirect measure of drug exposure. Clearance and exposure are
parameters which can be used to characterize individuals, which is important given the
disparate nature of the patent population. In this regard, individual behavior can be iden-
tified (patient–specific parameters) while also explicitly accounting for the interindividual
variability (population parameter distribution). This is accomplished by performing a pop-
ulation analysis provided measurements are available from a statistically significant number
of individuals. A population analysis provides an average PK response as well as an estimate
for the variability found in the population. Classically, statistical parameter information has
been determined in one of two ways. The first method obtains parameter estimates for all
of the data simultaneously. This is referred to as the na¨ıve pooled data approach [23]. The
other option evaluates individual parameter estimates for each data set. Individual estimates
are then used to calculate average parameter estimates. This is referred to as the two–stage
approach [23]. The na¨ıve pooled data approach is known to give poor estimates, and the two-
stage approach is considered to introduce bias [23]. A relatively new development combines
the two aforementioned methods to eliminate some of the shortcomings related to bias and
estimation. This is referred to as mixed effects modeling [30, 31] and is most commonly
associated with the Nonlinear Mixed–Effects Modeling (NONMEM) software package [23].
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1.4.3 Pharmacodynamic Modeling
1.4.3.1 General PD Modeling While PK models describe the action of the body on
the drug, PD models describe the effect of the drug on the body. In the field of oncology,
these effects can be positive (elimination of disease) or negative (elimination of the white
blood cells or other toxicity). Since the effects of drugs on organisms are being studied,
one approach uses PK models to drive a PD model [12, 32]. This means that predictions of
drug concentrations from PK models are used within the PD model. The precise use of PK
predictions will depend on how well the mechanism of drug action has been characterized
and the relationship between that mechanism and the PK predictions available.
Due to the complexity of biological systems, detailed mechanistic models can become
prohibitively complex for the same reasons found when dealing with PK models [19, 20].
For this reason, a more simplified approach assumes a causal relationship between the
concentration of a drug in the plasma, or another compartment, and the PD effect [12].
When correlating drug PK with PD, the presence of the drug as predicted by the PK
model occurs over a specified interval of time, and the duration of the effect can be similar.
Alternatively, the PD effect may occur for a fraction of the time the drug is present or can
persist for a duration much longer than that which the PK alone would predict. PD effects
can also be characterized as responding somewhat immediately to drug PK or an appreciable
time after the drug is assumed to have been eliminated. These two aspects of correlative
drug effects are shown in Figure 4.
Drugs effects occurring on the same timescale as drug PK with an immediate response
to modeled drug concentrations are the easiest to characterize. For example, intravenous
injection of insulin has a rapid effect on the level of glucose in the blood [33]. The simplest
model effect is one which is directly proportional to the concentration of the drug/plasma
concentration and can be addressed by most simulation packages capable of performing
numerical integration.
Another PD effect is one which begins at drug administration but persists for an appre-
ciable time after the drug has been eliminated. For example, this can occur when a small
amount of drug binds tightly to and saturates a receptor. Some drug can still be bound
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to the receptor even though the remaining unbound drug circulating through the body has
been eliminated. This can be accounted for by adding additional dynamics between the PK
prediction of plasma concentration and the PD effect. This leads to a prolonged exposure
at the site of action with respect to the concentration in the plasma. This adds to model
complexity, but does not affect the simulation techniques.
On the other end of the spectrum, the time between administration and effect can be
quite disparate. Consider the effects of smoking, where an individual can be exposed to
chemicals (tar, nicotine, etc.) for many years before exhibiting the more extreme negative
side effects such as cancer and emphysema. While the effects are not strictly quantifiable, few
people would dispute the correlation between smoking and the negative effects on the health
of individuals [34]. These effects could occur for the duration of exposure shifted in time
or at a different rate all together. This is an extreme example of what the pharmacological
community refers to as indirect response models [35], and one method for capturing these
effects is to place several compartments in series between the PK and PD models. An
alternative method to model such lagged effects is to account for them directly as time
delays [26].
1.4.3.2 Chemotherapeutic Effects Modeling the PD effects of chemotherapy repre-
sents a deviation from the normal growth pattern of cancer. At the most detailed level, the
interaction between the drug and the diseased tissue can be accounted for by understanding
the transport properties of the drug and it’s mechanism of action (i.e., inhibition of signal
pathways [36], anti–angiogenic effects [37], etc.). Cancer cells, like other cells, are robust
complex systems which are capable of compensating for many molecular changes introduced
by chemotherapy. Consequently, modeling a system at the intracellular level requires large
amounts of data and a clear understanding of the pathways, interactions and molecular
targets that are being affected.
Detailed physiologically–based models of chemotherapy lie on one end of a continuum.
On the other end is a correlative approach which utilizes statistical inference to associate
causal relationships between drug administration and effect. This may seem like a simplistic
approach, but it may be the only credible means of evaluating data when lacking a more
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detailed understanding of chemotherapeutic effects is unavailable. This approach focuses on
using the available data to develop mathematical descriptions of chemotherapy.
In the engineering literature, mathematical descriptions typically begin with a PK model.
To account for drug effects, plasma drug concentration predictions are usually used as
approximations for drug concentrations at the site of the tumor. This is based on the
rationale that tumors are well–perfused and have permeable capillaries [3]. The PD response
is then represented mathematically by incorporating a bilinear term proportional to both
the current size of the tumor and the concentration of the drug [12, 15, 38].
1.4.4 Camptothecin Analogs
In this work we consider the anticancer effects of 9-nitrocamptothecin (9NC). 9NC is a
member of the camptothecin family, a class of drugs derived from the camptotheca tree [39].
9NC exists in both the active lactone and inactive carboxylate forms shown in Figure 5
[39, 40]. After passing through the liver, 9NC readily converts to 9-aminocamptothecin
(9AC) which also exists in the same active and inactive forms in plasma. The camptothecin
family is characterized by the five ring structure shown in Figure 5. Camptothecins have
been investigated because of their ability to inhibit topoisomerase-I [41], thereby blocking
DNA synthesis and inhibiting tumor growth in the S phase of the cell–cycle.
Purified camptothecin is not water soluble, so it was initially given in a salt form. This
resulted in most of the drug being converted into the inactive carboxylate form and little
exposure of the active lactone form to the diseased tissues. As a result, different analogs and
delivery methods were sought to maintain stability of the lactone ring as long as possible
in plasma. Common analogs include topotecan, and irinotecan. A search of pubmed for
‘camptothecin PK PD’ returns 697 results. Several are discussed below to highlight the
types of information obtained from PK/PD analysis of camptothecins.
Topotecan was one of the first approved camptothecin analogs. This water–soluble
derivative has a lactone ring with a 2.9 hour half life in plasma after intravenous infusion [39].
Topotecan plasma concentration versus time data was modeled using a two–compartment
structure [39, 42]. More recently, Gallo et al. developed a PK model to describe the
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disposition of topotecan in plasma and tumor [43]. They developed a hybrid model which
used a compartmental model of plasma PK to drive a compartmental model of the tumor
PK. The plasma portion of the model was a standard two compartment model [25] —
drug input into a central compartment which has exchange with a peripheral compartment.
The plasma PK predictions were then used as inputs into the tumor PK model which was
three subcompartments in series: a vascular compartment, connected to an interestitial
compartment, in contact with an intracellular compartment [43]. This model to characterized
drug disposition in tumors and aided Gallo et al. in drug regimen design.
Simeoni and coworkers recently presented a series of PK driven PD models [14]. The
drugs under consideration included irinotecan, paclitaxel, and 5-florouracil. Compartmental
PK models were developed for each compound (two compartment model with a central
plasma and remote peripheral compartment was used for irinotecan) and used to drive the
PD model. Both A2780 human ovarian carcinoma and HCT116 colon carcinoma xenografts
were studied in female, athymic nude mice. The PD model consisted of a growth term which
slowed as the tumor volume increased; a bilinear kill term was added that decreased the
rate of proliferation in response to the presence of the drug as predicted by the PK model.
The cells exiting the proliferating phase in response to the drug entered subsequent damaged
cell compartments (three in series) eventually leading to the death of the cells. The authors
accurately predicted both untreated and treated tumor growth in animals. They further
presented this as a tool which could be used in preclinical and clinical trials.
The study of drug disposition (PK) and effects (PD) are common in the field of oncology
(over 19,000 results when searching for ‘cancer PK PD’ in pubmed) . These studies are
not generic; most focus on specific drug/tumor combinations. These combinations are
dealt with individually because the PK and PD can vary significantly depending on the
chemotherapeutic agent(s), tumor line, and host organism. Examples presented here dealt
specifically with camptothecin analogs. As suggested by Simeoni [14] and Gallo [43], PK
and PD models can be exploited to inform clinical decisions and to aid in the development
of dose schedules.
17
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Figure 6: Drug continuum for treatment efficacy and toxicity indicating the location of most
current anticancer agents (dashed region).
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1.5 CONTROL: DOSE SCHEDULING
Anticancer drugs can be conceptually thought to lie on the two continua shown in Figure 6.
One continuum characterizes the efficacy of the drug while the other describes toxicity.
Ideally, drugs would be found which reside in the upper left quadrant of Figure 6 (target).
However, existing drugs are more often located in the quadrant containing the dashed circle.
Consequently, the objective of a clinician in prescribing chemotherapy is to determine the
amount and frequency of drug administration that balance the competing drug effects of
efficacy and toxicity. The methods currently used to determine such schedules are well
established in the clinic, and they are also highly empirical. While these methods currently
yield positive results, it is appropriate to inquire if a more rigorous method could be applied,
not as a substitute for, but in tandem with, the current process.
1.5.1 Literature Approaches
The dose scheduling problem has been considered by several authors in the literature [12,
13, 16, 18, 38, 38, 44, 45, 46, 47, 48]. Like many problems in process control, this was
formulated as a constrained optimization. An objective function is constructed such that
the changes in the input which yield the minimum possible objective function value are
considered the optimum set of inputs. The objective is to minimize the number of cancerous
cells, or the volume of a tumor, at a final time. This is accomplished while satisfying the
dynamic constraints defined by the PK and PD of the drug [38, 45]. Also, inequality and
equality constraints could be included to limit toxicity and account for logistical concerns.
One of the first mathematical approaches applied to optimizing cancer chemotherapy was
described by Swan [13]. A logistic growth model was used to describe macroscopic tumor
proliferation, and chemotherapeutic effects were considered to be bilinear (proportional to
drug concentration and tumor size) and saturable with respect to drug concentration. The
objective was to achieve homeostasis by continuously delivering an intravenous drug. While
this type of treatment is possible, it can lead to toxicity and become prohibitively expensive.
Hence, most drugs are developed to be delivered intravenously over short periods of time (e.g.,
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one hour infusions) or more ideally to be administered orally. The methodology developed
in this document can readily deal with these constraints.
A chemotherapy dosing problem was posed in 1990 by Pereira et al. [16] where a cell–
cycle model was used to describe the proliferation of cancer in the presence of multi–drug
chemotherapy. The PK of the drugs were described generically as linear ODEs. An algorithm
utilizing a gradient based approach to solve the nonlinear programming problem for generic
drug/tumor combinations. This method of solution provides no guarantee of optimality and
ignores the fact that most drug/tumor combinations require specific consideration.
Panetta considered a similar theoretical problem using a simplified cell–cycle model [15],
represented by two populations of cells, resting and proliferating. The chemotherapeutic
effect occurred in the proliferation phase. The effects of pulsed chemotherapy were analyzed
to categorize the regimens between those that would and would not eliminate tumor masses.
Panetta identified the optimal treatment period and dose in the absence of constraints
addressing toxicity. By ignoring toxicity, Panetta ignores one of the primary concerns of
clinicians [49, 50] and thus a critical aspect of the dosing problem.
In 1990, Martin et al. studied an intravenously administered drug with first–order
elimination acting on a tumor undergoing Gompertzian growth [51]. In contrast to the
work by Swan, the drug here was considered to be administered weekly — a more relevant
treatment methodology based on current clinical practice. The objective was to determine
the amount of drug to administer on a weekly basis over a treatment horizon of one year to
minimize the final tumor volume without violating toxicity constraints. This is a topic
that Martin detailed in 1992 [45] and eventually expanded into a book with Teo [12].
The dosing problem was formulated as a utilized optimal control and used control vector
parameterization to determine the solutions. The “parameters” here refer to the magnitude
of the doses given weekly. The solutions developed by Martin were mathematically optimal,
however clinically irrelevant, as the algorithm suggested withholding treatment until the
last half of the treatment window for highly effective drugs. At this point, as much drug as
possible would be given such that toxicity constraints were not violated. Manipulation of the
manipulated variable at the end of the prediction horizon is a common characteristic found
in optimal control problems when optimizing states at the end of the horizon [52]. This
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type of solution completely ignores clinical practice where toxicity and efficacy are what
drive treatment. In the absence of further compelling evidence, it would be unethical for
a clinician to withhold treatment for six months based on the suggestion of an engineering
algorithm. One of the primary focuses of this dissertation is to develop methodologies which
can address clinical concerns.
Costa et al. considered a deviation of the final time problem previously mentioned [53].
PD models were altered to contain a population of both drug susceptible and a uniform
population of drug resistant cells. Drug effect was described by a bilinear kill term, and the
objective was a variant of the final time objective considered by Martin and Teo [12]. This
work utilized optimal control as a solution methodology and found optimal dosing profiles
when considering cells in the rapidly proliferating phase of growth. However, the dosing
profiles found by Costa et al. for cells at slower rates of proliferation were suboptimal.
Similar to the work by Costa et al. [53], Swierniak et al. also considered a PD model in
which cancer cells were segregated into both drug susceptible and drug resistant cells [46].
The drug resistant cells contained a range of drug resistances. A gradient–based approach
was utilized to find solutions dosing solutions The final time selected was short and solved
for successively to develop a periodic treatment. Toxicity was not explicitly considered. A
maximum value was placed on each dose and the total amount of drug administered was
included as a term in the objective function. While the solutions found were mathematically
suboptimal, their periodic nature is more realistic in a clinical sense.
Afenya considered a minimum time problem [47]; using an optimal control formulation.
This methodology places the control variable at one extreme (maximum possible dose) and
the objective is to determine the optimum time to switch to the other extreme (no drug
administered) such that the objective is achieved in the minimum possible time. The PD
model selected consisted of two cell populations: abnormal, or cancerous, tissues comprised
one population while healthy cells were modeled with the second. While the minimum time
analysis may apply to other engineering processes, it is an inherently poor choice for the
development of cancer chemotherapy schedules. It results in applying the maximum possible
dose of drug for an extended duration. In a clinical setting, this would likely lead to fatal
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drug–induced toxicity. Constraints to prevent this type of toxicity are easily implemented
using the framework discussed in this dissertation.
Ledzewicz and Scha¨ttler also approached cancer treatment as a final time problem
[38, 44]. A cell–cycle model of cancer proliferation was used in conjunction with cycle specific
drugs. The PK of the drug was ignored; it was assumed that drug administration directly
inhibited proliferation. In order to achieve solution optimality, bang-bang solutions were con-
sidered. This involves determining the times to switch between the maximum value of drug
input and the minimum amount of drug input. The objective consisted of two components:
the amount of diseased tissue at a final time and the total amount of drug administered.
Again, no explicit consideration of toxicity was made. These solutions are mathematically
optimal; however, they are myopic in that continuous infusion of chemotherapeutics at their
maximum tolerable level is not clinically realizable.
1.5.2 Toward Clinical Relevance
The clinical final treatment time (as employed by Martin and Teo) is not generally defined
a priori. Toxicity and efficacy drive treatment decisions [49, 50], and endpoints such as
disease remission are not easily predicted. High variability in patient response can make it
difficult for clinicians to predict treatment outcomes in terms of efficacy and toxicity. For this
reason, treatment is typically given in cycles which allow clinicians to evaluate the response
of patients and use information feedback to alter treatment accordingly.
The studies discussed in subsection 1.5.1 drug dosing for cancer treatment in the ab-
stract as a single problem with a generic drug/tumor combination. While there are many
situations in engineering where such abstraction is possible, the problem of determining
cancer chemotherapy dosing schedules does not allow such generalizations. Unlike many
chemical processes, biological systems are very complex. It is not uncommon for organisms
to exhibit significant variability in response to disease treatment [54]. As a result, drug/tumor
combinations may have to be treated independently from a modeling perspective and patient
specific parameters may have to be derived when trying to obtain an optimal treatment
schedule.
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1.6 DISSERTATION OVERVIEW
It should be possible to determine a clinically relevant chemotherapy schedule that optimizes
the trade-off between treatment efficacy and patient quality of life based on a prescribed ob-
jective and a mathematical characterization of drug pharmacokinetics, efficacy, and toxicity.
It is proposed that a method for developing optimal cancer chemotherapy schedules can be
accomplished in two steps: (1) model development and (2) control algorithm synthesis and
analysis.
Chapter 2 develops a linear PK model of 9-nitrocamptothecin (9NC), and its major active
metabolite 9-aminocamptothecin (9AC), in the plasma of severe combined immunodeficient
(SCID) mice at a single dose level. A revised model is then developed based on additional
PK data to describe the nonlinear plasma disposition of 9NC and 9AC over a range of dose
levels. The PK models are then used in chapter 3 to derive PD models that characterize
the effects of 9NC administration on HT29 human colon carcinoma xenografts implanted
subcutaneously in SCID mice. Two PK/PD models are presented: the first is driven by the
linear PK model and the second forced by the nonlinear PK model.
Chapter 4 focuses on step 2, the synthesis of model–based control algorithms. Instead
of employing optimal control techniques, this chapter addresses these control problems from
a mathematical programming perspective. Optimal dosing problems for the linearly driven
PK/PD model from chapters 2 and 3 and the system studied by Martin [12] are addressed.
These problems are transformed and the dosing profiles are determined by solving a mixed–
integer linear programming problems (MILP). The optimal dosing profile for the nonlinear
PK/PD system from Chapters 2 and 3 is also determined using an MILP. Finally, in Chapter
5, conclusions drawn from the modeling and treatment design studies, and recommendations
for extending and improving upon the results are provided.
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2.0 PHARMACOKINETIC MODELING
After administration, a drug will distribute throughout an organism. At different locations
within the organism, the drug can also be metabolized or eliminated. PK models are
utilized to describe these processes and provide researchers with an in silico means of
estimating physiological phenomena such as drug clearance and exposure. To facilitate model
construction of tools such as ADAPT II r© [25] and NONMEM r©[23] have been employed
by the medical and pharmacological communities. Novel model structures can also be
developed in simulation packages such as MATLAB ( c© 2005, The Mathworks, Nantick,
MA). In addition to describing drug concentrations as a function of time, PK models in this
work are used to drive the PD models developed in Chapter 3.
2.1 9-NITROCAMPTOTHECIN
The drug 9-nitrocamptothecin (9NC) is an orally administered camptothecin analog that is
being evaluated in clinical trials [55]. Preclinical PK data were obtained from SCID mice
(some bearing subcutaneously implanted human HT29 colon carcinoma xenografts) after oral
9NC administration. Following oral administration, 9NC is absorbed into the bloodstream
through the gastrointestinal tract. In plasma, 9NC quickly equilibrates between its active
lactone and inactive carboxylate forms [55]. Further, the nitro group on 9NC is readily
reduced to form the active primary metabolite 9-aminocamptothecin (9AC) [56]. 9AC also
exists in both the active lactone and inactive carboxylate forms [55] (see Figure 5). The
parent, 9NC, and metabolites then distribute to the tumor and normal tissues [40].
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←−−→
L−1{·}
L{·} GD(s)
k21 G21(s)
x1(t)
D(t)
k21
k12
k1e
x2(t)
v2v1
d(s)
(a) (b)
+
+ X1(s)
X2(s)
Figure 7: Two state compartmental model of intravenous drug disposition: (a) compartmen-
tal description, (b) equivalent Laplace domain representation. L{·} is the Laplace transform
operation and L−1 {·} is the inverse Laplace transform.
25
2.2 MODELING METHODOLOGIES
2.2.1 Compartmental Models
Figure 7(a) shows an example of a compartmental model which could be used to represent
the intravenous administration of a drug, D(t), to a central compartment (e.g. plasma) with
drug mass x1(t) and volume of distribution v1(t). This model assumes that the drug is being
eliminated from the central compartment at a rate k1e and can be distributed to and released
from a peripheral tissue at rates k12 and k21, respectively. The peripheral tissue contains
a mass of drug x2(t) distributed homogeneously throughout the volume v2(t). The system
shown in Figure 7(a) can be represented mathematically by performing mass balances over
each compartment:
x˙1(t) = D(t)− k12x1(t)− k1ex1(t) + k21x2(t)
x˙2(t) = k12x1(t)− k21x2(t)
C(t) = x1(t)
v1
(2.1)
Here C(t) is the concentration of the drug with respect to time and the dot operator (˙)
indicates a rate of change—the first derivative with respect to time.
2.2.2 Laplace Domain Representation
The system from equation (2.1) is referred to as a time domain representation. Another
common way to conceptualize this system is in the Laplace domain. The Laplace domain
provides a useful framework for dynamic analysis of linear systems. Equation (2.1) is
comprised of linear ODEs, and it is possible to transform equation (2.1) into the Laplace
domain. Assuming both the the initial concentration of the drug (x1(t = 0)) and that the
amount of drug administered before time zero (D(t = 0−)) are zero, the individual elements
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for the state equation describing x1 are transformed in the following way:
L{x˙1(t)} = sX1(s)
L{D(t)} = d(s)
L{−k12x1(t)} = −k12X1(s)
L{−k1ex1(t)} = −k1eX1(s)
L{k21x2(t)} = k21X2(s)
(2.2)
Where L{·} is the Laplace transform operator and the variable s is the independent variable
in the Laplace domain. For clarity, states in the Laplace domain are identified by capital
letters as a function of s with the exception of dose which is represented in the Laplace
domain by d(s). The state equations from (2.1) can be transformed and solved for their
respective states in the Laplace domain to yield:
X1(s) =
1
(k12+k1e)
1
(k12+k1e)
s+ 1
d(s) +
(k21)
(k12+k1e)
1
(k12+k1e)
s+ 1
X2(s) (2.3a)
= (d(s) + k21X2(s))
1
(k12+k1e)
1
(k12+k1e)
s+ 1︸ ︷︷ ︸
GD(s)
(2.3b)
X2(s) =
k12
k21
1
k21
s+ 1︸ ︷︷ ︸
G21(s)
X1(s) (2.3c)
The functions GD and G21 are first–order transfer functions. The term transfer function
is used because it translates, or transforms, effects of changes in one state or input onto
another. For example, G21 translates changes in X1 on to X2. The order of the transfer
function refers to the highest power of s in the denominator. A transfer function is said to
be in standard form when the coefficients of s0 are equal to one in both the numerator and
denominator. Transforming the system into the Laplace domain and placing it in standard
form provides a system of equations which are unique from an analysis standpoint. Consider
G21(s): the coefficient
k12
k21
is referred to as the system gain and the coefficient of s in the
denominator, 1
k21
, is the time constant of the system. These are typically referred to by
the symbols Ki and τi, respectively, and the index i is used to distinguish between transfer
functions. The gain translates the magnitude of changes in X1 in to proportional magnitude
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changes in X2, and the time constant determines the rate at which this occurs. This form is
unique because it effectively decouples steady–state and dynamic effects into two separate
parameters.
The system of equations from equation (2.3) can be represented in block diagram from
as shown in Figure 7(b). Arrows represent the values of the states and the blocks contain
the transfer functions. The operators shown in Figure 7, L{·} and L−1{·}, represent the
Laplace transform and inverse Laplace transform operations, respectively.
The method of transforming linear ODEs into the Laplace domain was shown in equa-
tion (2.2). This example encompasses some important concepts in discussing dynamic
systems. However, it does not address the concept of delayed systems. This issue was
introduced in subsection 1.4.3 when delayed PD effects were discussed. Delay systems are
common in both chemical processes and biological systems. Mathematically, delayed states
are represented by the Heaviside function, H(·), in the time domain. The Heaviside function
acts as a switch and is defined in the following way:
H(t) =
 0 t < 01 t ≥ 0
A state, x, delayed by 5 time units would be represented by x(t − 5)H(t − 5) in the time
domain. The Laplace domain representation would be given by:
L{x(t− 5)H(t− 5)} = X(s)e−5s
A natural question arises: if both domains (i.e., time and Laplace) describe the same
phenomenon, why should one be selected over the other? The distinction between the two
methods becomes important when trying to regress model parameters.
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2.2.3 Parameter Estimation
The objective of parameter estimation is to determine the set of parameters which will best
fit the data—this presupposes that a model structure has been selected. The parameter
estimation problem from a given model structure is formulated as an optimization problem
where values for the set of parameters, P , are determined such that the prediction error
— the difference between the actual values, Y(k), and the predicted values, Yˆ(k,P) — is
minimized. Mathematically, this is written as follows:
min
P
SSE =
ndata∑
k=1
Γ2Y(k, k)
(
Y(k)− Yˆ(k,P)
)2
=
∣∣∣∣∣∣ΓY (Y(k)− Yˆ(k,P)) ∣∣∣∣∣∣2
2
(2.4)
Equation (2.4) minimizes the sum squared error, SSE, between actual and predicted. This is
commonly referred to using the notation at the far right of equation 2.4, called the squared
two–norm. This increases the penalty for prediction errors as the deviation from experimental
data increases. One side effect of this optimization is that parameters which satisfy (2.4)
are assumed to be part of a Gaussian distribution [57]. The parameter, ΓY , is a weighting
parameter to increase or decrease the penalty associated with individual data points. One
possible weighting uses the inverse of the variability associated with individual measurement
points; this increases the importance of fitting data points associated with smaller standard
deviations.
All of the parameter estimation techniques previously mentioned require an optimization
of some kind. While the models may consist of linear ordinary differential equations (ODEs),
meaning they are linear in the states, x, the optimization may not be linear with respect to
the parameters. It can be advantageous to transform the system such that nonlinearities are
eliminated, the number of parameters are reduced, or nonlinear structures more amenable
to regression are used. However, it can be difficult to eliminate all of the nonlinearities and
parameter couplings when estimating parameters.
Hence, it is often necessary to solve nonlinear programming problems (NLP) [58, 59].
While efficient algorithms exist for specific types of nonlinearities [60], gradient-based meth-
ods provide a general technique for solving a NLP [59]. Gradient-based minimization utilizes
the partial derivatives of the objective function with respect to the parameters to determine
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the parameter adjustments necessary to minimize the objective function. This is an iterative
process that depends on initial guesses for parameter estimates; based on the quality of the
initial guess, the algorithm may converge to either a local or global minimum [58]. In order to
reduce the probability of finding a local minimum, the algorithm may be started at different
points in the parameter space. Parameter estimates in this work were determined using
the fmincon function from the optimization toolbox in MATLAB r© Release 14 ( c©2005, The
MathWorks, Natick, MA) on x86-based computers.
2.2.4 Selecting from Competing Model Structures
Situations arise where different model structures can be developed to describe the same
system. The intended use of a model may contribute to structure selection decisions (e.g.,
linear structures are typically more amenable to controller synthesis than nonlinear models).
When no a priori preference or justification for a particular model structure exists, other
metrics are considered. Since the purpose of a model is to act as a surrogate for an actual
system, it is necessary to determine which model structure best estimates the data. One
method of comparing different model structures is to employ Akaike’s Information Criterion
(AIC) [61]:
AIC = (number of points) ln
(
SSE
(number of points)
)
+ 2(number of parameters) (2.5)
The AIC is a metric that balances between adding parameters and improving model quality
(lowering SSE). The model structure which provides the lowest AIC is preferred based on
the parsimony principle.
2.3 LINEAR PK MODELING OF 9NC AND 9AC LACTONE
2.3.1 Five Compartment Model
The first step in modeling this system was to characterize the PK of 9NC. Since an orally
administered drug with a metabolite of interest was being considered, the compartmental
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x4
x2
C9NCL =
x1
v1
C9ACL =
x3
v3
x1
x3
k34
x0
k1e k13
k01
D
k43
k12
k21
k3e
Figure 8: Five compartment pharmacokinetic model for the disposition of 9NC and 9AC
lactone after oral dosing of 9NC.
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model shown in Figure 8 was used. Compartments x2 and x4 were included to capture
the dynamics (in this case slowed elimination) of 9NC and 9AC in compartments x1 and
x3 respectively. Parallels can be drawn between the underlying physiology and the model
structure, given in differential form in equation (2.6):
x˙0(t) = D(t)− k01x0(t) (2.6a)
x˙1(t) = k01x0(t) + k21x2(t)− (k12 + k13 + k1e)x1(t) (2.6b)
x˙2(t) = k12x1(t)− k21x2(t) (2.6c)
x˙3(t) = k13x1(t) + k43x4(t)− (k34 + k3e)x3(t) (2.6d)
x˙4(t) = k34x3(t)− k43x4(t) (2.6e)
C9NCL =
x1(t)
v1
(2.6f)
C9ACL =
x3(t)
v3
(2.6g)
Here the states are represented by xi and parameters are given by ki and vi. The mass of
the drug, D, enters the compartment x0 as a bolus. This compartment can be interpreted as
describing the kinetics of drug absorption and first-pass liver effects after oral administration.
The drug is absorbed from the gut into the plasma at a rate k01. Transport from the plasma
central compartment (x1) to the remote peripheral compartment (x2), and vice versa, takes
place at the respective rates k12 and k21. The lactone form of 9NC is either eliminated
from the plasma at a rate of k1e or metabolized to 9AC lactone at a rate of k13. Similar
interaction with the peripheral tissues (x4) is possible for 9AC lactone at the rates of k34
and k43, respectively. Lastly, 9AC lactone is eliminated at a rate of k3e.
Major shifts in the equilibrium between the active lactone and inactive carboxylate forms
of 9NC and 9AC occur in the presence of binding proteins [55, 62]. While these are commonly
found in humans, they do not affect 9NC or 9AC dynamics in mice (i.e., no human serum
albumin is present) [62]. It was assumed that equilibrium between lactone and carboxylate
forms of 9NC and 9AC in the plasma was achieved rapidly [55], and no attempt was made
to model equilibrium shifts because 9NC lactone was measured, albeit indirectly.
For parameter estimation purposes, the ten parameters for this model were all estimated
independently. Two sets of parameters were found for two separate sets of 9NC and 9AC
32
Table 1: Mean, standard deviation, and individual estimates for the compartmental model
parameters.
Mean Std. Dev. tumor–bearing non–tumor–bearing
k01 2.15× 10−2 6.97× 10−3 1.656 ×10−3 2.642 ×10−3 min−1
k12 3.11 3.01 0.984 5.242 min
−1
k13 0.643 8.22× 10−2 0.585 0.701 min−1
k1e 1.016 0.301 0.803 1.229 min
−1
k21 0.471 0.248 0.295 0.646 min
−1
k34 2.030 1.012 2.746 1.314 min
−1
k3e 2.575 1.023 1.856 3.298 min
−1
k43 0.966 0.227 0.806 1.127 min
−1
v1 3.888 0.169 3.768 4.008 ml
v3 9.639 0.462 9.966 9.313 ml
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Figure 9: Experimental 9NC lactone (top pane) and 9AC lactone (bottom pane) concentra-
tions from two studies: (—) - tumor-bearing animals and (›) - non-tumor-bearing animals.
Data shown ± are 1 standard deviation. Compartmental model predictions using the model
from Figure 8 (· · ·) and mean PK parameter values.
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plasma data: one experiment used tumor-bearing animals and the other using non-tumor-
bearing animals. These parameters are shown in Table 1. These parameters will be discussed
in detail in section 2.3.3. These data are shown in Figure 9 along with one standard deviation
in the measurement, for each experimental point in time—each datum point represents the
average value for three mice. From these data it can be seen that there is no statistical
difference between the two studies. The two sets of parameters were averaged and the
“average” model was simulated in response to the same 0.67 mg/kg dose to produce the
model prediction shown in Figure 9. The data shown in Figure 9 exhibit a quick increase in
9NC concentration followed by a slow decrease. Consider the 9NC lactone concentrations.
The compartmental model underestimates the peak concentration to better approximate
the data points which follow. In fact, this model does a poor job of capturing the dynamic
behavior seen in the data. This is particularly true between t = 15 min and t = 60 min.
2.3.2 Two Timescale Model
To better capture the dynamic response, an alternative PK model for 9NC and 9AC lactone
dynamics is shown in the Laplace domain in Figure 10. This model is referred to as a two
timescale model because the dynamics are governed by two distinctly different pathways.
This model is governed by the following equations:
x˙1(t) = H(t− θ)D(t− θ)β1
τ1
− x1(t)
τ1
(2.7a)
x˙2(t) =
α1
τ2
D(t)− x4(t)
τ4
(2.7b)
x˙3(t) =
x1(t) + x2(t)
τ3
− x2(t)
τ3
(2.7c)
x˙4(t) =
α2
τ4
x3(t)− x4(t)
τ4
(2.7d)
C9NCL = K1x3(t) (2.7e)
C9ACL = K2(x3(t) + x4(t)) (2.7f)
A fraction, α1, of the dose D enters the system as a mass through the right pathway in
Figure 10 and experiences the dynamics governed by G2. The remainder of the dose, β1,
takes the left pathway and is delayed by θ time units before passing through G1. The states
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e−θs
++
β1 α1
α2β2
C9NCL
G1(s) G2(s)
G3(s)
G4(s)
where:
Gi(s) =
1
τis+1
βi = 1− αi
0 ≤ αi ≤ 1
X1 X2 X4
X3
C9ACL
K2
K1
Dose d
Figure 10: Two timescale pharmacokinetic model for the disposition of 9NC and 9AC lactone
after oral dosing shown in the Laplace Domain. Transfer functions, Gi, have unity gain and
βi and αi are complementary fractions. The gains, K1 and K2, convert the respective signals
representing the masses of 9NC and 9AC lactone to concentrations, and θ is a time delay.
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Table 2: Mean, standard deviation, and individual estimates for the two time scale model
parameters.
Mean Std. Dev. tumor–bearing non–tumor–bearing
τ1 389 469.5 57.06 721.0 min
τ2 11.87 0.134 11.97 11.776 min
τ3 11.65 6.252× 10−2 11.70 11.609 min
τ4 38.07 44.97 6.275 69.865 min
K1 0.327 0.177 0.201 .45187e-01 ml
−1
K2 3.84× 10−2 2.33× 10−2 2.192×10−2 5.48 ×10−2 ml−1
α1 0.343 0.208 .489 .19581e-01 —
α2 0.442 0.166 .325 .55939e-01 —
θ 29.97 3.812× 10−3 29.98 29.97 min
x1 and x2 are combined to form the input into G3 whose output x3 represents the mass of
9NC lactone in the plasma. The two pathways can be biologically interpreted as different
areas of adsorption in the digestive tract of the mouse. A fraction, β2, of the 9NC lactone
in plasma is converted directly into 9AC, and the remaining 9NC, α2, is converted to 9AC
after passing through G4.
This model contains nine parameters, and these were regressed independently to the
tumor–bearing and non–tumor–bearing mouse data sets. For each dataset, parameters were
estimated by first finding the parameters describing 9NC dynamics. These parameters (α1,
θ, τ1, τ2, τ3, and K1) were fixed, and the parameters associated with 9AC (α2, τ4 and K2)
were regressed. The parameter estimates are given in Table 2 and will be discussed in
detail later. The mean parameter values for the two studies were used to develop the model
predictions shown in Figure 11. These model predictions are plotted along with those of the
compartmental model previously discussed. By comparing the two model predictions from
Figure 11, the two timescale model appears to be superior to the compartmental model.
The two timescale model is able to capture the rapid increase in 9NC plasma concentrations
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Table 3: AIC and SSE results for compartmental, and two timescale (indicated by the
subscripts c, and t, respectively) for both tumor–bearing and non-tumor-bearing animals.
Mean values represent AIC and SSE calculated by considering deviations of mean model
predictions from both datasets.
tumor-bearing non-tumor-bearing mean parameters
AICc 62.4 64.7 105.8
AICt 33.4 45.2 106.1
SSEc 225.9 262 529.7
SSEt 41.9 87.6 503.2
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Figure 11: Experimental 9NC lactone (top pane) and 9AC lactone (bottom pane)
concentrations from two studies: (—) - tumor–bearing animals and (›) - non–tumor–bearing
animals. Data shown are ± 1 standard deviation. Model predictions use the compartmental
from Figure 8 (· · ·) and the two timescale model from Figure 10 (-·-) with mean PK parameter
values.
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as well as the slowed elimination seen at later times. Similar dynamics are seen for 9AC
as well. To quantitatively compare the compartmental and two timescale model structures,
the AIC was calculated and is shown in Table 3. The AICs for the individual data sets are
significantly lower for the two timescale model. To determine an average AIC, sum-squared
errors were calculated based on the differences between the average model predictions and
the individual data points — this doubled the number of data points in the AIC calculation.
While the average AIC for the two timescale model is still lower, the effect is less dramatic.
The two timescale model provides better predictions for the individual data sets, but this
improvement is not as apparent when all of the data is considered simultaneously.
2.3.3 Recycle Model
An alternative PK model for 9NC and 9AC lactone dynamics is shown in the Laplace domain
in Figure 12 and has the following differential equation representation:
x˙0(t) = −x0(t)
τ0
+
D(t)
τ0
(2.8a)
x˙1(t) =
x0(t)
τ1
− x1(t)
τ1
+
x3(t)
τ1
(2.8b)
x˙2(t) =
β1α2
τ2
x1(t)− x2(t)
τ2
+
x4(t)
τ2
(2.8c)
x˙3(t) = H(t− θ)x1(t− θ)α1
τr
− x3(t)
τr
(2.8d)
x˙4(t) = H(t− θ)x2(t− θ)α1
τr
− x4(t)
τr
(2.8e)
C9NCL = β1Kpx1(t) (2.8f)
C9ACL = β1Kpx2(t) (2.8g)
The recycle structure model given by equation (2.8) also captures plateau dynamics observed
in the experimental PK data, around t = 35 min. The dose, D, enters as a bolus (in
mass units) and undergoes first-order dynamics described by equation (2.8a). This can be
physiologically interpreted as absorption from the gastrointestinal tract. Next, the rate of
appearance of 9NC lactone is dictated by equation (2.8b). A fraction, β1, of the mass of 9NC
lactone appears in the plasma with the remainder, α1, recycled. Recycling can be loosely
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e−θs
β1 β1
α1α1
α2
β2
where:
elimination
+ +
+ +
e−θs
X2
C9NCL C9ACL
G0(s)
G2(s)
Gr(s)
Kp
Gr(s)
Kp
X0
X1
X3 X4
G1(s)
Gi(s) =
1
τis+1
βi = 1 − αi
0 ≤ αi ≤ 1
Dose d
Figure 12: Recycle-based pharmacokinetic model for the disposition of 9NC lactone and
9AC lactone after oral dosing shown in the Laplace domain. The transfer functions, Gi,
have unity gain, β1 and α1 are complementary fractions, the gain, Kp, converts the signals
representing the masses of 9NC lactone and 9AC lactone to concentrations, and θ is a time
delay.
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Table 4: Mean, standard deviation, and individual estimates for the recycle model
parameters.
Mean Std. Dev. tumor–bearing non–tumor–bearing
τ0 11.4 0.465 11.05 11.71 min
τ1 12.5 1.49 13.52 11.42 min
τ2 0.492 0.681 1.0×10−2 0.974 min
τr 16.1 6.92 11.169 20.95 min
Kp 0.173 1.82× 10−2 0.186 0.160 ml−1
α1 0.447 1.74× 10−2 0.434 0.460 —
α2 0.157 3.76× 10−4 0.156 0.157 —
θ 28 8.81 21.76 34.22 min
interpreted as representing the sluggish dynamics associated with storage in a remote non-
plasma tissue, for eventual return to the plasma; this is similar in concept to Figure 8. The
recycled mass, α1x1, is then delayed by θ minutes and undergoes the dynamics described by
equation (2.8e) before being recombined with x0 (the mass leaving G0 from Figure 12). A
fraction, β2, of the 9NC lactone mass found in the plasma, β1x1, is eliminated; the remainder,
α2, appears as 9AC lactone. The dynamics of conversion of 9NC lactone to 9AC lactone are
described by equation (2.8c). A fraction of 9AC lactone, β1x2, appears immediately in the
plasma and the remainder, α1x2, is recycled in a manner similar to the 9NC lactone recycle
loop.
All eight parameters (τ0, τ1, τ2, τr, Kp, α1, α2, andθ) for the recycle model were estimated
simultaneously for each dataset: tumor–bearing and non–tumor–bearing and are given in
Table 4. Using the average parameters, the recycle model predictions shown in Figure 13
were simulated. The quick initial increase in plasma concentrations of 9NC lactone and 9AC
lactone, as well as the relatively slow elimination at later times are captured well by the
recycle model structure. The AIC and quality of fit criteria for all three linear PK models
are shown in Table 5. When the individual studies were modeled, the two timescale model
42
Table 5: AIC and SSE results for compartmental, two timescale, and recycle models
(indicated by the subscripts c, t, and r, respectively) for both tumor–bearing and non-
tumor-bearing animals. Mean values represent AIC and SSE calculated from deviations of
mean model predictions from both datasets combined.
tumor-bearing non-tumor-bearing mean
AICc 62.4 64.7 105.8
AICt 33.4 45.2 106.1
AICr 42.1 46.6 80.19
SSEc 225.9 262 529.7
SSEt 41.9 87.6 503.2
SSEr 81.5 108.3 237.84
had lower AIC values. However when the AIC was calculated using the data and the average
model predictions, the recycle model was shown to better represent the average behavior.
Parameter estimates for each model structure were obtained for each of the two studies,
and the average values of the parameters for the two model structures along with parameter
standard deviations, are shown in Table 6.
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Figure 13: Experimental 9NC lactone (top pane) and 9AC lactone (bottom pane)
concentrations from two studies: (—) - tumor–bearing animals and (›) - non–tumor–bearing
animals. Data shown are ± 1 standard deviation. Model predictions use the compartmental
from Figure 8 (· · ·), the two timescale model from Figure 10 (-·-), and the recycle model
from Figure 12 (—) with mean PK parameter values.
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Table 6: Average PK parameters for linear models.
5-Compartment Two Timescale Recycle
Mean Std. Dev. Mean Std. Dev. Mean Std. Dev.
k¯01 2.15× 10−2 6.97× 10−3 min−1 τ¯1 389 469.5 min τ¯0 11.4 0.465 min
k¯12 3.11 3.01 min
−1 τ¯2 11.87 0.134 min τ¯1 12.5 1.49 min
k¯13 0.643 8.22× 10−2 min−1 τ¯3 11.65 6.252× 10−2 min τ¯2 0.492 0.681 min
k¯1e 1.016 0.301 min
−1 τ¯4 38.07 44.97 min τ¯r 16.1 6.92 min
k¯21 0.471 0.248 min
−1 K¯1 0.327 0.177 ml−1 K¯p 0.173 1.82× 10−2 ml−1
k¯34 2.030 1.012 min
−1 K¯2 3.84× 10−2 2.33× 10−2 ml−1 α¯1 0.447 1.74× 10−2 —
k¯3e 2.575 1.023 min
−1 α¯1 0.343 0.208 — α¯2 0.157 3.76× 10−4 —
k¯43 0.966 0.227 min
−1 α¯2 0.442 0.166 — θ¯ 28 8.81 min
v¯1 3.888 0.169 ml θ¯ 29.97 3.812× 10−3 min
v¯3 9.639 0.462 ml
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To evaluate model confidence, the variability in the parameters was considered. A
lower overall variability in model parameters would indicate that the model structure is
more amenable to representing the experimental data. Many of the parameters in both
the compartmental and two timescale models exhibited significant variability (standard
deviations greater than half of the mean). Values such as k12 from the compartmental model
and τ1 and τ4 from the two timescale model would be cause for concern — τ1 and τ4 have
standard deviations greater than the mean. However, this is not so for the majority of the
recycle model parameters. There is significant variability (standard deviating greater than
the mean) for the parameter τ2 in the recycle model which is a direct result of the variability
observed in the mean values in the 9AC data. Referring specifically to the variance in the
mean values in the third and fourth time points for 9AC lactone in Figure 13, the parameter
τ2 is the only adjustable parameter which affects only the 9AC lactone concentration profile.
This would lead to an expectation of high variability in τ2.
Of the three models presented here, the recycle model provides the best fit of the
overall system response. The average AIC values are lower, and this is related to decreased
parametric variability. More robust model predictions can be made when the bounds on
parameter variability are tighter. The recycle model had fewer parameters than the other
two models; this reduces parameter identifiability problems which may be encountered in
the nonlinear optimization.
The model structures studied above assume that the PK of 9NC lactone and 9AC lactone
are linear with respect to dose. A series of experiments were carried out to determine the
disposition of 9NC and 9AC total (lactone + carboxylate) at 0.44, 0.67 and 1.0 mg/kg to
support or invalidate the claim of linear PK.
2.4 NONLINEAR PK MODEL OF TOTAL DRUG
The experiments investigating nonlinearity of 9NC and 9AC PK utilized the analysis method
described in subsection B.5 of Appendix B. Because all 9NC and 9AC present in plasma
was converted to their respective lactone forms prior to analysis only total 9NC and 9AC
46
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Figure 14: Total plasma concentrations measurements/model predictions of 9NC (top) and
9AC (bottom) in response to oral administration of 9NC at dose levels of 0.44 (A/· · ·),
0.67 (—/-·-), and 1.0 (›/—) mg/kg. Error bars indicate ± one standard deviation in the
measured data.
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levels were modeled. The plasma PK data after oral administration of 0.44, 0.67, and 1.0
mg/kg 9NC are shown in Figure 14. The data obtained after a dose of 0.44 mg/kg are
characteristically different than those data obtained in response to doses of 0.67 and 1.0
mg/kg. The peak plasma concentration after a 0.44 mg/kg dose occurs at the second time
point (5 min), whereas the peak plasma concentration for the higher dose levels appears to
occur at the third time point (15 min). In the context of linear systems, changing peak time
indicates a nonlinear in the time constant. Furthermore, the ratio of peak 9NC concentrations
after doses of 1.0 to 0.67 mg/kg is 1.24 whereas for a linear system it should be 1.49. This
violation of the scaling property of linear systems indicates a nonlinearity in the gain of the
system. The model structure shown in Figure 15 was developed to address these issues.
Because of the characteristic difference between plasm a concentration versus time profiles
after a low doses (0.44 mg/kg) and after higher doses (0.67 and 1.0 mg/kg), a two pathway
approach was considered. The drug mass below a threshold takes one pathway and the
mass of drug above that threshold takes another. The portion of the model in Figure 15
bounded by the dotted line was developed in order to characterize the response after a dose
of 0.44 mg/kg. The mass of 9NC administered below the Threshold, dl, pases through two
identical first order systems characterized by τl. A fraction, β1, of the mass in X3 is recycled
as an input to Gr. The remainder, α1, of X3 is present in the plasma. This portion of the
model is linear and characterized by four parameters (τl, α1, τr, and Kl). These parameters
were estimated and fixed, and the portion of the model bounded by the dashed line was
added. This additional model contribution characterized the disposition of 9NC after higher
doses (0.67 and 1.0 mg/kg). The mass of 9NC above the threshold, du, undergoes dynamics
governed by two first order systems in series. These systems, Gu, were characterized by
τu, and the mass X1 was converted into concentration using Ku. There was one nonlinear
component in this portion of the model — the inverse relationship between the gain, Ku,
and the most recent dose administered, Dlast. The nonlinear gain was defined as:
Knl =
Ku
Dlast
The two portions of the model discussed above represent the dynamics of 9NC. The
remainder of the model characterized the dynamics of 9AC. The total mass of 9NC, α1X3
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where:
Gi(s) =
1
τis+1
βi = 1− αi
0 ≤ αi ≤ 1
τnl =
τa
Dlast
Threshold
+
+
+
+
+
+
e−θ2s
C9NC
+
+
C9AC
X5
Gnl(s)
X1 X3
X4X2
Dose d
dldu
Gu(s) Gl(s)
Gu(s) Gl(s)
Gr(s)
X6
Knl =
Ku
Dlast
β1
α2
α1
Kl
Ka
Knl
β2
Figure 15: Nonlinear PK model for the total forms of 9NC and 9AC. Both the gain Knl and
time constant τnl are nonlinear in the most recent dose applied Dlast.
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and X1 resulting from dose masses below and above the threshold, respectively, is split into
two pathways. A fraction of 9NC, β2, is converted directly to 9AC. The remaining fraction,
α2, experienced a time delay of length θ2 and the dynamics Gnl before being converted to
9AC. The portion of the model which describes the conversion of 9NC to 9AC is linear with
the exception of the nonlinear time constant, τnl, which is inversely proportional to the dose.
This was done to account for the more rapid elimination of 9AC observed at higher doses
(Figure 14). The ODE representation of Figure 15 is given as:
x˙1(t) =
x2(t)
τu
− x1(t)
τu
(2.9a)
x˙2(t) =
Du(t)
τu
− x2(t)
τu
(2.9b)
x˙3(t) =
x4(t)
τl
− x3(t)
τl
(2.9c)
x˙4(t) =
Dl(t) + x5(t)
τl
− x4(t)
τl
(2.9d)
x˙5(t) = β1
x3(t)
τr
− x5(t)
τr
(2.9e)
x˙6(t) = α2(x1(t− θ2) + α1x3(t− θ2))H(t− θ2)Dlast
τnl
− x6(t)Dlast
τnl
(2.9f)
CNC = x1(t)
Ku
Dlast
+Klα1x3(t) (2.9g)
CAC = (x1(t) + x3(t)α1)β2Ka + x6(t)Ka (2.9h)
Here Dlast is the value of the last nonzero dose in mg/kg. The values of Dl(t) and Du(t) are
defined in terms of D(t) and the Threshold as follows:
Dl(t) =
 D(t) D(t) ≤ ThresholdThreshold D(t) > Threshold (2.10)
Du(t) =
 0 D(t) ≤ ThresholdD(t)− Threshold D(t) > Threshold (2.11)
Here D(t), Dl(t), Du(t) and Threshold are all defined in terms of drug mass. The parameters
for the model (2.9) are shown in Table 7. The predicted responses from the model are also
shown in Figure 14 for each of the three dose levels. The model captures the characteristic
shape of the 9NC responses well. The 9AC responses for 1.0 and 0.44 mg/kg are also also
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Table 7: PK parameters for the nonlinear model of the total forms of 9NC and 9AC.
Threshold 9.078 ×103 ng–9NC
τu 12.36 min
τl 1.482 min
τr 0.184 min
τnl 107.98 min
α1 0.64 —
α2 0.468 —
Knl 0.216 ml
−1
Kl 0.162 ml
−1
Ka 0.0491 ml
−1
θ2 49.20 min
described by the model. The 9AC data for 0.67 mg/kg at 15 and 30 min exhibit behavior
which this model structure is unable to capture. The key shortcoming of the nonlinear PK
model is its inability to capture the dynamics of the delayed peak in 9AC (15 ≤ t ≤ 30 min)
for a dose of 0.67 mg/kg. The analytical methods used to determine the total concentrations
of 9NC and 9AC in response to 0.44 and 1.0 mg/kg are considered to be more reliable.
Consequently, greater importance was placed on these data for modeling purposes. Given
the relative concentrations of 9NC and 9AC, however, the overall performance is quite good.
2.5 SUMMARY OF PK MODELS
In this chapter several different model structures were presented to describe the PK of
9NC in SCID mice. Linear models were developed using two datasets of plasma lactone
concentrations of 9NC and 9AC obtained from tumor–bearing and normal SCID mice after
oral administration of 0.67 mg/kg of 9NC. The compartmental model structure lacked
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predictive accuracy A two timescale model was developed which reduced the number of
parameters from ten to nine and improved the model fit of the individual datasets. A
recycle model was developed which further reduced the number of parameters to eight.
Although the two timescale model better represented the individual data sets, the recycle
model provided superior fit to the combined data as measured by AIC. Experimental data
were obtained for the total concentrations of 9NC and 9AC after oral administration of 9NC
at 0.44, 0.67 and 1.0 mg/kg. Analysis of the average response of these data showed the
existence of nonlinear behavior dependent on the dose levels. A nonlinear PK model was
developed to capture the nonlinear dynamics. Both the lactone and total PK models exhibit
novel structures. By developing these models in the Laplace domain, structures were selected
such that parameters were associated with specific behavior. Using this methodology, time
points associated with significant variability could be associated with specific parameters.
This was demonstrated in the description of the parametric variability of the recycle model.
The objective of this work is to utilize mathematical descriptions of cancer chemotherapy
to derive treatment schedules. The PK models developed in this chapter were constructed
to drive PD models of toxicity and efficacy. Much effort was made to accurately describe the
dynamic PK response under the assumption that model quality limits achievable controller
performance [8]. The structures were also selected with the objective of controller synthesis
in mind. Linear PK models were selected because control methodologies for linear systems
are well understood. Of the linear PK models presented, the recycle model structure was
found to be superior based on AIC values as well as being the model structure with the
fewest parameters. However, if the linear descriptions are unable to achieve desired results
(in a control sense), the nonlinear PK model can be utilized. The nonlinear PK model was
found to accurately describe the plasma concentrations of 9NC and 9AC total in response
to a range of doses. From a PK/PD modeling perspective, linear PK models will first be
considered and nonlinear models will be investigated for their ability to predict a broader
range of PK responses.
52
3.0 PHARMACODYNAMIC MODELING
Drugs are administered to elicit an effect; however, side effects are common. In cancer
chemotherapy, the desired effect is the reduction of tumor burden. Chemotherapy is a
systemic form of treatment with side effects including the reduction of the patient’s immune
system performance, neurotoxicity, and loss of body weight, among others. PD models
are mathematical representations of the various effects of the drug. In this chapter the
progression of the disease in the absence of treatment is characterized first. For the SCID
mouse case study, growth of the HT29 human colon carcinoma xenografts is modeled in the
absence of treatment. The untreated tumor growth model is then combined with an average
PK model and data from mice treated with 9NC is used to develop a PK/PD description of
drug effect. This combined PK/PD representation was further used to develop a model of
drug toxicity using body weight reductions as an indicator since mice receiving 9NC develop
diarrhea leading to loss of body weight.
3.1 TUMOR GROWTH MODELING
3.1.1 Cell–Cycle
Figure 2 in Chapter 1 shows the five phases of the cell–cycle with the rate of transition
between states given by the various ki parameters. The quiescent, or resting, state of a
cell is given by G0. When cells are actively proliferating, they readily move through the
other phases of the cell–cycle. The S and M phases represent the phases in which DNA is
synthesized and mitosis occurs, respectively, and they are separated by the growth phases
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G1 and G2 [2]. Most cells of healthy tissues in adults spend a majority of their time in the
quiescent G0 phase [2]. However, this is not so for cancer cells. Conceptually, cancerous cells
can be thought of to have a combination of higher values of k’s within the cell–cycle and
a higher ratio of kG01 to kG10 than normal tissues. Treating the phases of the cell–cycle as
compartments, the cell–cycle can be modeled in the following manner:
G˙0(t) = kG10G1(t)− kG01G0(t) (3.1a)
G˙1(t) = kG01G0(t)− kG10G1(t) +2kMM(t) − kG1G1(t) (3.1b)
S˙(t) = kG1G1(t)− kSS(t) (3.1c)
G˙2(t) = kSS(t)− kG2G2(t) (3.1d)
M˙(t) = kG2G2(t) −kMM(t) (3.1e)
N(t) = G0(t) +G1(t) + S(t) +G2(t) +M(t) (3.1f)
The total number of cancer cells is given by N . Tumor size can be either a volume
(as measured experimentally) or a total number of cancerous cells as mentioned above.
The volume of a tumor is considered to be proportional to the number of tumor cells. The
constant of proportionality is 1000pi µm3, which assumes cells of spherical shape and a radius
of 10 µm. The description in equation (3.1) is linear and mitotic proliferation is highlighted
by the boxed terms in (3.1b) and (3.1e) — for every cell leavingM two cells enter G1. While
the transition rates in (3.1) are written as constants, they can just as easily be functions of
time, average cell age, or the number of cells in a particular phase. Using transition rates
which are not constants will result in a set of nonlinear equations. A major drawback of
cell–cycle models is that identification of the parameters in (3.1) requires measurements of
the different phases of the cell–cycle at different points in time. At present this is not an
obtainable measurement for solid tumors in a clinical setting.
3.1.2 Macroscopic Growth Models
HT29 tumor growth data, like much experimental data, was macroscopic in nature. Detailed
tumor growth models, like the cell–cycle model above, become over–parameterized in the
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context of available preclinical data. Hence, lumped-parameter growth models were used in
this work.
3.1.3 Exponential Growth Model
Exponential growth is described in terms of a doubling time, τe, and the following first–order
linear ODE [63]:
N˙e =
ln(2)
τe
Ne (3.2)
Here Ne represents the size of the tumor. Well–nourished tumor cells will proliferate ex-
ponentially, and empirical evidence suggests that tumors initially undergo an exponential
growth phase [11].
3.1.4 Gompertz Growth Model
As tumor size increases, the tumor growth slows as the mass approaches a plateau population
[11]. This type of growth is normally described using the Gompertz equation [12, 32]:
N˙g =
1
τg
ln
[
ln(ρg/N0)
ln(ρg/2N0)
]
Ng ln
(
ρg
Ng
)
(3.3)
Here ρg is the plateau population, N0 is the initial number of tumor cells, and τg is the
doubling time of the tumor during exponential growth [12].
3.1.5 Switched Exponential Growth Model
To characterize the Gompertz equation (3.3), data from the plateau region of growth must
be obtained. However, many animals would succumb to the tumor burden and die before
entering this region of growth [32]. In the xenograft model evaluated here, the tumor-
bearing animals were euthanized for ethical reasons before their tumors approached the
plateau population. Hence, data from these animals encompasses the exponential phase of
growth and a portion of the transition from exponential to Gompertzian growth, but ρg is not
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uniquely identifiable. To fit the data in the transition between exponential and Gompertzian
growth, a modification was made to the exponential growth model (3.2):
N˙s =
ln 2
τe(Ns)
Ns (3.4a)
τe(Ns) =
 τe,f , Ns < Nthτe,s, Ns > Nth (3.4b)
Equation (3.4) is referred to as a switched exponential model, and it is a modification of the
model presented by Simeoni et al. which used a nonlinear continuous function to describe the
transition from exponential to Gompertzian growth [14]. In the present study, a piecewise
continuous function was used here because the discontinuity is more amenable to controller
design in a mixed–integer programming framework. The model in (3.4) is structurally similar
to the exponential model (3.2); however, τe is dependent on the current size of the tumor.
The cancerous mass increases at a rate τe,f until the tumor size reaches the threshold size,
Nth. At this point, the rate of proliferation slows to τe,s.
3.1.6 Model Comparison
The models from equations (3.2),(3.3), and (3.4) assume a homogeneous population of cells.
Each of these model structures are shown for comparison in Figure 16. All model predictions
are essentially identical for the first doubling time (τ time units). At this point the cells under
Gompertzian growth begin to proliferate less rapidly due to the nonlinear growth dynamics.
The switched exponential model is capable of tracking the Gompertzian growth curve over
a longer period of time when compared to the exponential model — approximately 3.5τ and
1τ , respectively. Hence, the switched exponential model is expected to provide a superior fit
to tumor growth data that grows sub–exponentially but cannot fully inform a Gompertzian
plateau population estimate.
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Figure 16: Normalized (N0 = 1) predictions for exponential (—), Gompertzian (−−), and
switched exponential (-·-) tumor growth models of untreated cancer growth. Here, τ is τe for
the exponential model, τg for the Gompertzian model, and τe,s for the switched exponential
model. Parameter values used: τe = τg = τe,f = 2, τe,s = 3.8, ρg = 17, and Nth = 3
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3.2 UNTREATED TUMOR GROWTH MODELING RESULTS
3.2.1 Exponential Growth Model
Untreated tumor growth was modeled for twenty control mice using equation (3.2). The
tumor doubling time, τe, was estimated for each of the twenty mice, and the average, τ¯e,
was taken to represent the population. The results are shown in Figure 17. These tumor
volumes were from separate two studies, and the symbols represent the mean values at each
time point normalized to the corresponding initial volumes. The model prediction shown is
for the average doubling time, τ¯e ≈ 11 days. One standard deviation in τe, approximately 2.3
days, characterizes the observed inter-subject variability in growth rate. The mean model
successfully captures the growth dynamics in the experimental data, although slight model
underprediction is observed early in the growth trajectory. The doubling time was held
constant at τ¯e for subsequent modeling of PD drug effect.
3.2.2 Switched Exponential Growth Model
To better characterize untreated tumor growth, the switched exponential model (3.4) was
used. Individual parameter estimates were obtained for the same twenty mice. The model
prediction is shown with the data from twenty mice in Figure 18. To calculate the lower
standard deviation and upper standard deviation used in Figure 18, the largest possible
bounds were used (N¯th − std., τ¯e,f + std., and τ¯e,s + std.) and (N¯th + std., τ¯e,f − std., and
τ¯e,s − std.), respectively. The parameter values and their standard deviations are shown in
Table 8.
3.2.3 Untreated Growth Model Comparison
To compare the exponential and switched exponential models, the AIC values for the indi-
vidual animals were calculated and are given in Table 9. The model with two distinct regions
of growth consistently outperforms the exponential model. To quantify the effects of using
mean parameter estimates, mean AIC values were calculated for each study and for both
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Figure 17: Mean exponential growth model prediction, (—), and one standard deviation
in growth rate, (−−), based on individual estimates of τe from twenty mice in two studies.
The average values of control mice from the first (—) and second (›) studies are also shown
normalized to their initial tumor volumes.
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Figure 18: Mean switched exponential growth model prediction, (—), and one standard
deviation in growth rate, (−−), based on individual estimates of Nth, τe,f , and τe,s from
twenty mice in two studies (markers connected by · · ·). Initial time points were shifted such
that the initial volumes (›) would lie on the average model prediction.
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Table 8: Mean parameter estimates for switched exponential model of tumor growth
calculated from twenty untreated mice.
Mean Std. Dev.
N¯th 477.36 183.10 mm
3
τ¯e,f 9.56 3.94 days
τ¯e,s 13.49 7.17 days
studies combined. To calculate the AIC for multiple data sets, sum squared error between all
of the data points in each study and the average model prediction were added together and
used as the SSE in the AIC calculation (2.5). All of the points used in the SSE calculation
were added together as the “number of points”. The “number of model parameters” were
one and three for the exponential and switched exponential models, respectively. The mean
values for each study are also shown in Table 9. For the first study, AIC values favor the
switched exponential model based on parameter estimates for both the individuals and the
mean. The mean parameters would suggest the exponential model is better at representing
the data in study two. These results are not surprising and can be explained by considering
Figure 17. The data for study two stop on day 30 because this efficacy trial was halted
due to toxicity. No information is available at later time points; hence, τe,s and Nth cannot
be adequately estimated. To better quantify this statement, consider N¯th from Table 8 and
Figure 18. The average model predicts N¯th to occur between 35 and 40 days (based on tumor
volume predictions), so only a small fraction of the data (10-14%) from study two occurs
during the portion of the model where τe,s would be active.
3.3 EFFECT MODELING
PD models relate the administration of drugs to observable effects. The effects considered
here focus primarily on reductions in both tumor volume (efficacy) and body weight (toxic-
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Table 9: AIC for the exponential (3.2) and switched exponential (3.4) models applied to two
studies of untreated tumor growth.
Mouse Exponential Switched Exponential
Study 1 Study 2 Study 1 Study 2
1 92.92 108.65 84.32 77.72
2 80.28 122.97 79.20 120.53
3 78.55 105.30 72.22 100.59
4 70.82 109.85 67.70 106.20
5 102.93 114.83 90.83 111.15
6 87.15 111.76 85.86 106.02
7 81.91 116.23 78.79 93.83
8 84.44 128.80 65.70 123.88
9 90.50 127.63 77.96 125.75
10 100.41 123.25 98.67 103.23
Mean 1036.55 1343.07 1030.06 1358.95
2401.07 2397.14
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ity). PD effect models can be a simple correlation between an amount of drug administered
and decreased mortality rates after a period of time (e.g., 6 months). Alternatively, a more
mechanistic approach can be used to relate the drug PK directly to the PD effects. The
tumor growth models developed in sections 3.1.3, 3.1.5, and 3.1.6 for the growth of HT29
xenografts in SCID mice establish a nominal description of tumor growth. The presence
of the drug, in this case 9NC and 9AC, can be considered a perturbation of this nominal
description.
The circulatory system is the primary method for transporting systemically delivered
drugs to cancerous tissues is. PK models which relate drug delivery to drug plasma concentra-
tion, which can be further coupled to PD effect. Plasma drug concentration predictions can
be used to approximate drug concentrations at the site of the tumor based on the rationale
that tumors have highly permeable capillaries and are well perfused. The therapeutic effect
of the drug on the tumor is then represented mathematically by adding a bilinear kill term
to the nominal tumor growth equation. The added nonlinear term is proportional to both
the current size of the tumor and the concentration of the drug [12]. The motivation for this
functionality is that larger tumors will have more susceptible cells, and higher drug plasma
concentrations will more effectively kill tumor cells. Because 9NC inhibits topoisomerase-
I, DNA synthesis cannot be completed and tumor cells are stopped in the S phase of the
cell–cycle. To incorporate this effect, equation (3.1c) would be modified in the following
manner:
S˙(t) = kG1G1(t)− kSS(t)− keffCeff (t)S(t) (3.5)
Here, Ceff (t) is the drug concentration at the site of action. This could be the plasma drug
concentration as predicted from a PK model; alternatively, additional functionality, such as
delays, nonlinear dynamics, etc., specific to the problem could be included. For example,
a drug with effects proportional to the amount of drug above a therapeutic concentration,
Cth, would define Ceff in terms of the plasma concentration of the drug, C(t), as:
Ceff (t) = (C(t)− Cth)H(C(t)− Cth)
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The proportionality constant for drug effectiveness is keff . The exponential and Gompertz
models can be augmented with similar PK/PD functionality as follows:
N˙e =
ln(2)
τe
Ne(t)− keffCeff (t)Ne(t) (3.6a)
N˙g =
1
τg
ln
[
ln(ρg/N0)
ln(ρg/2N0)
]
Ng(t) ln
[
ρg
Ng(t)
]
− keffCeff (t)Ng(t) (3.6b)
Since equations (3.6a) and (3.6b) are lumped approximations, they lack the cycle–specificity
of the cell–cycle model. Therefore, the effect term is proportional to the total tumor volume.
3.4 PD DRIVEN BY LINEAR PK MODEL
The complexity associated with control algorithm synthesis scales with the complexity of
the system models. For the models presented here, a PK/PD model can be derived by
combining linear PK with exponential tumor growth. To characterize the anticancer effects
of 9NC, the nominal tumor growth model (3.2), developed in section 3.2.1, was combined
with the recycle PK model of 9NC lactone and 9AC lactone (2.8) from subsection 2.3.3 in
the following manner:
N˙(t) =
ln(2)
τ¯e
N(t)− k
eff,NCLCeff,NCL(t)N(t)− keff,ACLCeff,ACL(t)N(t) (3.7a)
C
eff,NCL(t) = C¯NCL(t− θeff )H(t− θeff ) (3.7b)
C
eff,ACL(t) = C¯ACL(t− θeff )H(t− θeff ) (3.7c)
In the absence of treatment, the tumor proliferates according to the average exponential
growth rate, τ¯e. The average parameter values for the recycle model, found in Table 6,
are used to predict C¯NCL(t) and C¯ACL(t), the lactone concentrations of 9NC and 9AC,
respectively, after 9NC oral administration. The effect terms k
eff,NCL and keff,NCL rep-
resent the effectiveness of 9NC lactone and 9AC lactone, respectively. To improve the fit
to experimental observations, the drug concentrations were delayed by θeff time units. The
effective concentrations of 9NC lactone and 9AC lactone were then defined in terms of
C¯NCL(t), C¯ACL(t), and θeff by C¯eff,NCL(t), and C¯eff,ACL(t), respectively. This model
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Table 10: Mean PD parameters for the effect of the lactone forms of 9NC and 9AC.
k¯
eff,NCL
(
ml
day–ng9NC
)
k¯
eff,ACL
(
ml
day–ng9AC
)
θ¯eff (days)
Mean 2.42× 10−5 3.19× 10−5 0.7840
Std. Dev. 8.08× 10−6 2.54× 10−5 0.3778
was fit to the tumor growth data from the ten mice administered 0.67 mg/kg of 9NC
on a QD×5×2 schedule. The average values for the PD parameters are given in Table
10. The values of k¯
eff,NCL and k¯eff,ACL from Table 10 are similar given the observed
variability in k¯
eff,NCL. One interpretation would be that the two compounds have similar
activity. This is consistent with in vitro studies [64]. Further analysis is complicated by the
drug concentration differences (9NC lactone concentration is an order of magnitude higher
than 9AC lactone). Furthermore, parameter variances indicate that a significant statement
about the relative efficacy of 9NC and 9AC cannot be made. Finally, from a mathematical
perspective, reducing kac while simultaneously increasing knc might result in essentially the
same PD model prediction; hence a categorical statement of parent/metabolite activity (9NC
versus 9AC) based on present data would be premature. Model fit to ten individual mice
are shown in Figure 19. While the intersubject variability seen in the data cannot be fully
captured by a model of mean behavior, the model was capable of predicting decreases in
tumor volume in response to treatment, which is necessary for developing useful treatment
algorithms.
By combining a linear PK model (2.8) with a linear growth model (3.2) a PD structure
(3.7) has been developed which will be shown to be quite amenable to control algorithm
synthesis in Chapter 4. However, this efficacy model was developed using data obtained at
a single dose level. To improve the predictive capacity of the PK/PD model over a range of
dose levels, a more complex structure was investigated.
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Figure 19: PK/PD model response using average PK predictions from the linear recycle
model (2.8) with the PD model shown in equation (3.7). Tumor volume measurements are
given by (·) with the drug administered at 0.67 mg/kg on days indicated by (+), and the
model prediction is represented by (—).
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3.5 PD DRIVEN BY NONLINEAR PK MODEL
To characterize the PD effect over a range of doses, the nonlinear PK model given in equation
(2.9) was combined with the switched exponential growth model for untreated cancer (3.4)
to provide the following PK/PD model:
N˙s(t) =
ln(2)
τ¯e(Ns(t))
Ns(t)− keffCeff (t)Ns(t) (3.8a)
τ¯e(Ns(t)) =
 τ¯e,f , Ns(t) < N¯thτ¯e,s, Ns(t) > N¯th (3.8b)
Ceff (t) = CNC(t) + CAC(t) (3.8c)
The rate of proliferation is governed by the switched exponential growth model in the absence
of drug. When drug is administered, proliferation decreases at a rate proportional to the size
of the tumor and Ceff (t). The total plasma concentration of 9NC and 9AC was used here
based on the rationale that they have similar activities [64]. The concentrations of 9NC and
9AC total, CNC and CAC, respectively, were calculated using the parameters from Table 7.
To describe nominal tumor growth, the average values for the switched exponential model
parameters given in Table 8 were used. The PK/PD model has a single free parameter, keff ,
which was fit individually to thirty mice — three sets of ten mice administered 0.44, 0.67
and 1.0 mg/kg of 9NC QD×5×2. The results for the three different dose levels are shown in
Figures 20, 21, and 22, respectively. There are instances where the proposed model structure
does not accurately fit the data (e.g. Figure 20(i)). In general, however, the model structure
(3.8) captures the tumor growth response to 9NC treatment at the three different dose levels.
At higher dose levels (Figure 22), the model predicts tumor volume decreases consistent with
the experimental data. This ability to predict responses across dose levels is important for
the development of treatment algorithms. Figure 23 presents the parameter distribution
for keff . he average value of keff for the 0.44 mg/kg dose of 9NC was slightly higher than
keff for 9NC doses of 0.67 and 1.0 mg/kg. However, given the parameter distributions at
each dose level, the parameter values are not statistically different between dose levels. The
time profiles for the product of keff and the sum of camptothecin concentration and the
67
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Figure 20: PK/PD model response using predictions from the nonlinear PK model (2.9)
with the PD model shown in equation (3.8). Tumor volume measurements are given by (·).
Drug was administered at 0.44 mg/kg QD×5×2 on days indicated by (+), and the model
prediction is represented by (—). Data for mouse (i) after day 42 lies outside of the plot
range.
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Figure 21: PK/PD model response using predictions from the nonlinear PK model (2.9)
with the PD model shown in equation (3.8). Tumor volume measurements are given by (·).
Drug was administered at 0.67 mg/kg QD×5×2 on days indicated by (+), and the model
prediction is represented by (—).
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Figure 22: PK/PD model using predictions from the nonlinear PK model (2.9) with the PD
model shown in equation (3.8). Tumor volume measurements are given by (·). Drug was
administered at 1.0 mg/kg QD×5×2 on days indicated by (+), and the model prediction is
represented by (—).
70
  

 
 	























 


 














ff
fi
fl
ffi

 
 

 
 	








 

ff
fi
!
fi
"

#

$
%
&
%
'
(
)
ff
fi
*
+,-. /0-1
2 3
.,-. /0-1
4
5,6. /0-1
2 37
,08 /0-1
4
7
,95 /0-
1
2
3
0,9: /0-
1
2
;<
==
;<>
? @
; A
;
@
;; @A
; B
;;
B
A
;
;<
==
;<>
?
@
B
=
>
C D
@
;E
F
;
@
B
G
=
;<
B
;<G
;<
=
;<
A
;<>
;<
?
;<C
Figure 23: PD parameter analysis — PK/PD parameter distribution (mean ± one standard
deviation) for 0.44, 0.67, and 1.0 mg/kg administration of 9NC QD×5×2 (bottom pane);
product of keff and sum of camptothecin concentrations (middle pane), and AUC of
kd(CNC + CAC) versus time curve (top pane).71
area under the concentration versus time curve (AUC) — calculated based on the simulated
concentrations using trapezoidal rule — of this product are given in the middle and top
panes of Figure 23, respectively. The latter would indicate that the exposure (as measured
by AUC) predicted by the nonlinear PK model is approximately linear with dose.
3.5.1 Toxicity Modeling
A common toxicity constraint is an upper bound on drug exposure [12]. Because of inter–
patient, or in this case inter–mouse, variability, large variations can occur across a population,
and consequently average exposure as a metric for approximating toxicity may provide little
utility. As a more quantitative and experimentally accessible metric for assessing toxicity,
reductions in body weight were considered. By modeling body weight, a constraint specifying
the minimum allowable body weight can be included in the control algorithm formulation.
The experimental protocol specifies that animals with body weight below a prescribed value
will have treatment withheld until the animal recovers. Therefore, it is advantageous to
quantify the effects of 9NC administration on bodyweight. The body weight, B, of a mouse
undergoing treatment with 9NC was modeled in the following manner:
B˙(t) = kgB(t)− kc(CNC(t) + CAC(t)) (3.9)
Here CNC and CAC are the total plasma plasma concentrations from the nonlinear PK
model using the parameters from Table 7 for 9NC and 9AC, respectively. The body mass is
assumed to grow at a rate kg, and the rate of decrease in body mass is first order with respect
to the total concentration of camptothecins (CNC and CAC) with a rate constant kc. The
parameters for this model were regressed using PD data for mice which were administered
1.0 mg/kg of 9NC QD×5×2. The mean body weights of ten animals after normalization
to their initial conditions are shown in Figure 24 along with the average model prediction.
The model is capable of qualitatively capturing body weight reductions in response to drug
administration and the subsequent increases at the end of treatment cycles. However, the
model does not quantitatively capture the body weight dynamics observed. Furthermore, the
bodyweight predicted by the model will continue to increase exponentially when no drug is
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Figure 24: Average normalized body weights of ten animals given 1.0 mg/kg of 9NC p.o.
QD×5×2 every four weeks.
73
administered; this is not seen in the control group. This can be accounted for by reinitializing
the bodyweight model as measurements become available or at the end of treatment cycles.
Another option would be to use standardized growth curves to bound normal body weight
changes over the course of the experiment.
The body weight, B, is the total mass of the animal which includes the mass of the tumor.
The body weight for toxicity purposes, Btox, is calculated using the following equation:
Btox(t) = B(t)− N(t)
1000
This corrects (reduces) body weight as the tumor burden changes by removing the mass from
that of the animal. The tumor volume, N , is divided by 1000 to convert the volume into
a mass — this assumes the density of a tumor is approximately that of water. To provide
conservative estimates, a slow body growth rate and a high value of kc could be used.
3.6 SUMMARY
Two different models were presented to describe untreated growth of HT29 human colon
carcinoma xenografts implanted subcutaneously in SCID mice: an exponential model and
a switched exponential model. The exponential model was coupled with the linear recycle
model of 9NC PK to provide a model of drug efficacy at a dose level of 0.67 mg/kg adminis-
tered QD×5×2. The PK/PD model driven by linear PK provided the least complex of the
two PK/PD representations presented here. The linear PK modeling also indicated which
time points (around 30 min) would be important for further development of a dynamic model.
To better describe the range of possible doses, a second PK/PD model was constructed. This
model combined the nominal growth described by the switched exponential model with the
nonlinear model of 9NC PK. By calculating the PK/PD response over a range of doses, it
was found that the exposure, as measured by AUC, was linear with respect to dose. A PD
model of body weight reductions in response to 9NC administration was also developed using
predictions from the nonlinear PK model of 9NC. By constructing a model of body weight
changes in response to treatment, a means for determining the recovery time in response to
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treatment was developed. The next chapter will focus on (the synthesis of chemotherapy
treatment schedules) using the PK/PD models developed in this chapter.
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4.0 CLINICALLY–RELEVANT DESIGN OF CANCER CHEMOTHERAPY
SCHEDULES
The ultimate objective of chemotherapy is to extend the life of the cancer patient. For
clinicians, chemotherapy represents a set of competing objectives: maximize treatment
efficacy while maintaining tolerable levels of drug–induced toxicity. Oncologists administer
chemotherapeutic drugs following standard regimens; often these are cycles of 21 or 28
days in length. Toxicity is evaluated formally after the first cycle. Based on the toxicity
encountered by the patient during the first cycle, the drug dose may be altered or treatment
my be withheld until the patient recovers from the effect of the first cycle. Following a
second cycle of treatment, the patient is evaluated for efficacy in addition to toxicity. Several
cycles of treatment may be given if the patient shows some form of clinical response. When
treatment is no longer effecting the tumor burden, or unacceptable toxicity occurs, dosing is
terminated.
The drug schedules administered by clinicians are obtained from empirical evidence
resulting from preclinical and clinical trials. Engineers have attempted to provide more
rigorous methods for determining drug schedules [12, 38, 46, 53]. However, there is a
disconnect between recommended engineering approaches and clinical implementation. In
order to help bridge this gap, this chapter focuses on the development of solution techniques
for clinically applicable problems. These solution methodologies will be shown to solve
problems as they are currently posed in the engineering literature. Furthermore, problem
extensions that provide dose schedules of greater clinical relevance are formulated and solved.
The term clinical relevance refers to the fact that toxicity and efficacy are the primary drivers
of treatment, and clinical objectives must be considered. In addition clinicians administer
drugs in cycles, so the problem formulation and underlying mathematical models must
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incorporate periodic and discrete effects. Finally, the information gained from the periodic
evaluation of efficacy and toxicity should be able to be used to update treatment.
4.1 GENERAL PROBLEM FORMULATION
Control of cancer chemotherapy systems with linear PK and macroscopic PD descriptions
having bilinear nonlinearities has been considered by several authors [38, 45, 65]. The most
common approach has been to consider the fixed final time problem:
min
D(t)
J = FJ(x(tf ,D(t))) (4.1a)
s.t. x˙ = Ft(x(t),D(t))) (4.1b)
Fi(x(t),D(t)) ≤ 0 (4.1c)
Fe(x(t),D(t)) = 0 (4.1d)
The functions FJ , Ft, Fi, and Fe, represent arbitrary functions of their respective arguments
which may or may not contain nonlinearities. The internal states and dose levels are given by
x(t) and D(t), respectively. The objective is to minimize a function, J , typically the number
of cancerous cells or the volume of a tumor, at a final time, t = tf . This is accomplished
while satisfying the dynamic constraints (4.1b) defined by the PK and PD of the drug
[38, 45]. Also, inequality (4.1c) and equality (4.1d) constraints can be included to limit
toxicity and account for logistical concerns. Due to the dynamic constraints, optimal control
theory provides a convenient solution structure, and it has been applied previously by several
groups [12, 13, 16, 18, 38, 38, 44, 45, 46, 47, 48].
When considering the objectives and constraints clinicians face, the above formulation
(4.1) and its solution may not provide practically applicable results — mathematically
optimal may not be the same as clinically optimal (or even clinically relevant). It is possible to
formulate mathematical problems which can provide clinically relevant results [66]. Model–
based controllers for the continuous infusion of insulin have been developed which provide
implementable results. The ability to implement cancer chemotherapy schedules predicted
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by dosing algorithms is dependent on the formulation used. The remainder of this chapter
will focus on the analysis of case studies which are representative of the class of scheduled
chemotherapy problems. The objective is to determine optimal, but clinically relevant, drug
administration schedules for anticancer drugs described by macroscopic PK and PD models.
Before addressing the specific case studies, the complexity of the problem will be reduced
with a variable transformation, and the types of constraints considered will be motivated
and formulated based on clinical and mathematical grounds.
4.1.1 Continuous–Time Constraint Formulation
The constraints from the general problem statement (4.1) come from a variety of sources.
The dynamic constraints (4.1b) represent the PK/PD models of drug distribution and
host response. The inequality and equality constraints, (4.1c) and (4.1d), respectively, are
derived primarily from three areas of concern: financial limitations, logistical restrictions,
and toxicity constraints. Foregoing such restrictions, an algorithm to determine the optimal
dosing regimen would deliver as much drug as possible as frequently as possible, thereby
leading to tumor eradication. Toxicity and logistics will be considered explicitly below;
financial considerations are not addressed in the course of this dissertation.
Logistical constraints can be thought of as restrictions associated with managing treat-
ment. For example, inconsistent drug administration times may lead to a patients who forget
to take their medication [67]; likewise, varying dose levels in a non periodic manner may lead
to patients taking the wrong dose. Treatment requiring the direct attention of hospital staff,
e.g. intravenous infusions, are fundamentally limited by the working schedules of the medical
professionals. Similarly, drugs delivered in pill form are administered in discrete amounts —
e.g., three pills every other day. Problem formulation and solution methodologies should be
able to account for the discrete nature and limitations imposed by logistical constraints (e.g.,
bounding administration times based on work schedules, selecting from discrete treatment
options, etc.). Let a set of l drug levels, 1 ≤ l ≤ ml, represent the treatment options at a
given time t (e.g., one pill, two pills, etc.). This constraint would be formulated as a discrete
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variable:
D(t) = Qdose(1), or Qdose(2), · · · , Qdose(ml) (4.2)
Here, Qdose(l) is the vector of possible dosing values.
Toxicity constraints vary widely by drug class and are physically manifested as reductions
in the patient’s immune system function, fatigue, nausea, loss of body weight, and pain
experienced by the patient, among other factors. It is common to characterize toxicity
constraints in terms of both the drug PK and measurable PD effects [12]. Some PK–derived
constraints are illustrated in Figure 25. Placing a limit on exposure is a common toxicity
constraint. Total exposure, AUCexp, is commonly calculated by integrating drug plasma
concentration over the treatment interval:
AUCexp =
∫ tf
0
C(t)dt ≤ Ccum (4.3)
Equation (4.3) limits the cumulative toxicity of the drug, as measured by the total area
under the solid line in Figure 25, which cannot exceed Ccum. Alternatively, drugs may not
become effective until a therapeutic plasma concentration is reached (Cth). Once Cth has
been reached, the effective drug concentration (Ceff ) is that concentration above Cth. For
such drugs, the effective exposure, AUCeff , is represented by the shaded region of the PK
profile in Figure 25. An effective drug concentration (Ceff ) can then be defined in terms of
the therapeutic drug concentration (Cth) in a piecewise fashion:
Ceff (t) =
 0 C(t) ≤ CthC(t)− Cth C(t) > Cth (4.4)
Therefore, drug administration which does not increase the plasma concentration to at least
Cth is ineffective and undesirable. The dose applied at time t3 shown in Figure 25 contributes
to the total exposure but not the effective exposure; this may add to toxicity via (4.3), but
will not contribute to treatment effect. Acute toxicity is reached when the drug plasma
concentration exceeds some maximum, Cmax. This is a state constraint given by:
C(t) ≤ Cmax ∀t ∈ [0, tf ] (4.5)
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Figure 25: Plasma PK profile for a drug delivered intravenously as a bolus having first
order elimination illustrating the minimum therapeutic drug concentration, Cth (−−), the
maximum tolerable drug concentration, Cmax (· · ·), and the exposure (total exposure: area
under the concentration versus time curve, AUCexp; effective exposure: shaded area, AUCeff )
over the dosing interval, (t0 ≤ ti ≤ tf , ∀i ∈ I+ ≤ f).
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Since this is an intravenously administered drug, Cmax can be defined in terms of Dmax. In
Figure 25, this constraint is violated by the dose at t1. Depending on the drug, this could
result in death or some form of irreversible harm. Non-intravenously administered drugs,
those delivered orally for example, will have peak values described by their PK. In this case,
relationships between Cmax and Dmax can be constructed using the PK model.
It is also possible to restrict the amount of drug which can be administered at any given
point in time. This can be a result of discrete dosing quantities (e.g., pills) or because the
drug was found to be effective only over a particular range of doses. In the latter case,
considered here, a semicontinuous variable is encountered at each dosing opportunity, as
follows:
Dlb ≤ D(ti) ≤ Dmax
or D(ti) = 0 ∀i ∈ [1, · · · ,mq] (4.6)
Here Dlb and Dmax are the lower and upper bounds of the continuous portion of the
therapeutic dosing range, respectively, and mq is the final dosing point. The upper bound is
typically based on the MTD, or the amount of drug which will produce chronic side effects.
The lowest amount of drug which can be administered and have an observable effect defines
the lower bound. Also, q is the set of all possible times in which drugs may be administered
during treatment, thereby making ti the i
th dosing time for the set of values in mq. For an
intravenously administered drug, Cmax may relate directly to Dmax.
4.1.2 Discrete–Time Constraint Formulation
In order to cast the problem in the mixed–integer programming framework, the constraints
must be discretized. For the discrete formulations, k will denote the current time step with
a system step size of h. Hence k exists on the range [1,mk], and the final time point, mk,
is defined as mk =
tf
h
. The subscript d will be used to indicate the discrete variants of
continuous variables. For example, continuous states, x(t), and outputs such as plasma drug
concentration, C(t), or logarithmically transformed tumor size, P (t), would have the discrete
variable counterparts xd(k), Cd(k) and Pd(k), respectively.
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Given systems with PK described by linear ODEs, the state equations relating to drug
PK can be written in matrix form:
x˙(t) = Ax(t) +B u(t) (4.7)
Where A is the state transition matrix and B is the input coefficient matrix. The PK
equations can then be discretized exactly for any step size h yielding [68]:
xd(k + 1) = Ad xd(k) +Bd ud(k) (4.8)
The coefficients A
d
and B
d
are the discrete–time forms of the state transition and input
coefficient matrices, respectively, and can be written in terms of their continuous counterparts
[68]:
A
d
= eAh, B
d
= A−1(A
d
− I)B (4.9)
To force a system to choose from a discrete set of possibilities, such as the magnitude of
a dose from a set of possible doses, Qdose(l), as shown in (4.2), the binary variable bd,dose(q, l)
is introduced. The constraint (4.2) is replaced in discrete–time with:
Dd(q) =
ml∑
i=1
bd,dose(q, i)Qdose(i) ∀q ∈ [1,mq] (4.10a)
1 =
ml∑
i=1
bd,dose(q, i) ∀q ∈ [1,mq] (4.10b)
At each dosing opportunity, q, equation (4.10b) ensures that only one dosing value is selected.
The cumulative toxicity constraint (4.3) contains an integral term which can be approx-
imated using the trapezoidal rule [69]:
AUCd,exp =
h
2
Cd(1) + h
mk−1∑
j=2
Cd(j) +
h
2
Cd(mk) ≤ Ccum (4.11)
This yields the discretized total exposure AUCd,exp.
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Discrete counterparts of linear state inequality constraints, such as the acute toxicity
constraint found in (4.5), are formulated by replacing the continuous variables with their
discrete counterparts. Therefore, (4.5) can be replaced with:
Cd(k) ≤ Cmax ∀k ∈ [1,mk] (4.12)
One issue which can arise from discretization is that the plasma concentration might be
greater than Cmax between discretization points. This is not a problem for intravenously
administered drugs described by first order kinetics when administered as either a bolus or
a rectangular wave in which the initial and final dosing times lie on time steps. In this
situation the peak associated with any given drug administration occurs during the time
of administration, and on a discretization point. In general, however, the maximum of a
continuous system in response to an input may occur between discretization points. This
can be overcome by choosing suitably small values for h, knowing the time of a peak, or by
mapping a dose level to a peak drug concentration (e.g., through an existing PK model).
The requirement that the effective drug concentration is nonzero only when the plasma
concentration is greater than the therapeutic concentration creates a semicontinuous variable.
This is written in a piecewise fashion in equation (4.4). In discrete time this can be written as
linear inequalities by introducing the binary variable bd,th(k) at each time step, and requiring
that the following inequalities be satisfied [70]:
Cd(k)− Cth ≤ (Cmax − Cth)(1− bd,th(k)) (4.13a)
0 ≤ Cd,eff (k) (4.13b)
(Cmax − Cth)(1− bd,th(k)) ≥ Cd,eff (k) (4.13c)
Cth − Cd(k) ≤ Cthbd,th(k) (4.13d)
0 ≤ Cd,eff (k)− (Cd(k)− Cth) (4.13e)
Cthbd,th(k) ≥ Cd,eff (k)− (Cd(k)− Cth) (4.13f)
Consider the situation when the drug plasma concentration is below the therapeutic value
(Cd(k) ≤ Cth). In this case, the left hand side of (4.13d) will be greater than zero which
requires bd,th(k) to be one. This forces the left hand side of (4.13c) to be zero, resulting in
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Cd,eff (k) being zero also. The left hand side of (4.13a) will be negative, so this constraint
will be satisfied. The right hand side of constraints (4.13e) and (4.13f) will be positive on
the range [0, Cth], so these constraints will also be satisfied.
Alternatively, consider the case where the drug is having an effect (Cd(k) > Cth). This
forces bd,th(k) to be zero for the constraint (4.13a) to be satisfied. Thus, Cd,eff (k) will be
forced to take on the value Cd(k)−Cth because the left hand side of constraints (4.13e) and
(4.13f) will be zero. Furthermore Cd,eff (k) will exist on the range [0, (Cmax−Cth)] satisfying
the constraints (4.13b) and (4.13c). Finally the the constraint (4.13d) will always be satisfied
because the left hand side will have a maximum value of zero.
Similarly, the constraint requires that drugs only be administered in the therapeutic
range (4.6) can also be transformed into a set of linear inequalities by the introduction of a
binary variable.
Dlbbd,u(k) ≤ D(k) ≤ Dmaxbd,u(k) ∀k ∈ [1,mk] (4.14)
When bd,u(k) is zero, D(k) must be zero. When the drug is to be administered, bd,u(k) must
be one, and D(k) must lie between Dlb and Dmax.
4.2 CASE STUDY I: INTRAVENOUSLY ADMINISTERED DRUG WITH
GOMPERTZIAN PROLIFERATION
The first case study considered was taken from the engineering literature. This system,
originally studied by Martin and Teo, consists of a tumor proliferating in a Gompertzian
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fashion (3.3) and an intravenously administered drug [12]. The following system was analyzed
using optimal control and control vector parameterization techniques [12]:
C˙(t) = D(t)− γC(t) (4.15a)
N˙g(t) =
1
τg
ln
[
ln(ρg/N0)
ln(ρg/2N0)
]
Ng(t) ln
[
ρg
Ng(t)
]
− keffCeff (t)Ng(t) (4.15b)
Ceff (t) = (C(t)− Cth)H(C(t)− Cth) (4.15c)
C(0) = C0 (4.15d)
Ng(0) = N0 (4.15e)
The PK of the drug is described by equation (4.15a) where the plasma drug concentration,
C(t), increases with intravenous infusions of the drug, D(t), and decreases according to
first–order elimination kinetics at a rate γ. The change in the number of cancer cells is
described by equation (4.15b). The cancerous cells proliferate in a Gompertzian fashion
described by τg, ρg, and N0, as discussed in section 3.1. The drug effect is proportional,
with constant of proportionality keff , to the number of cancer cells, Ng(t), and the effective
drug plasma concentration, Ceff ; Ceff (t) is the drug concentration above the minimum
therapeutic concentration, Cth. The initial drug concentration and number of cancer cells
are given by C0 and N0, respectively.
The parameters considered for this case study [12] are provided in Table 11, and a time
step of h = 1 day was used. The rate of elimination for the drug, D, is slow enough that a
timestep of one day will not lead to a significant loss of information. Three values of keff
were considered representing different levels of drug efficacy [12]. Highly effective, marginally
effective, and ineffective drugs were represented by keff,1, keff,2 and keff,3, respectively.
4.2.1 Constraint Formulation
It was assumed that the drug could be administered weekly with a final time, tf , of 52
weeks [12]. The maximum allowable plasma concentration was Cmax; this bounded the
amount of drug that could be administered at any point in time leading to the constraint [12]:
C(t) ≤ Cmax ∀t ≤ tf (4.16)
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A cumulative toxicity constraint (4.17) was placed on the system for the treatment period
[12], as follows:
∫ tf
0
C(t)dt ≤ Ccum (4.17)
The final constraint placed on the system dealt with efficacy. Since it was undesirable for
the status of a patient to decrease (e.g., tumor burden to increase), the number of cancer
cells was not allowed to increase to a number larger than the initial condition.
Ng(t) ≤ N0 ∀ t (4.18)
4.2.2 Optimal Control Problem
The optimal control problem considered by Martin and Teo [12] was given as:
minD(t) Ng(tf ) (4.19)
s.t. (4.15), (4.17), (4.16), (4.18)
The objective here is to minimize the tumor volume at a final time while satisfying the
dynamic constraints (4.15), the cumulative toxicity constraints (4.17), the maximum plasma
drug concentration (4.16) and the efficacy constraint (4.18) This equation had nonlinear
growth and death terms as well as the discontinuity associated with the therapeutic drug
concentration (Cth).
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4.3 MILP PROBLEM REFORMULATION
4.3.1 PD Variable Transform
Because of the bilinear term from the drug PD (either (3.6a) or (3.6b)), the optimization
from (4.1) is a nonlinear programming (NLP) problem. Nonlinear optimizations can possess
local minima, and efforts to eliminate nonlinearities can improve the likelihood of achieving
the global optimum. The effect of the bilinear kill term can be included, and the explicit
nonlinearity removed, by performing the following logarithmic transformation [47]:
P (t) = ln(N(t))⇔ N(t) = eP (t) ⇔ N˙(t) = P˙ (t)eP (t) (4.20)
Notice that ln(N(t)) increases monotonically with N(t) such that the value of drug admin-
istration which minimizes N(tf ) will also minimize P (tf ). The transform in (4.20) can be
applied to cancerous masses under both exponential and Gompertzian growth resulting in:
P˙ (t) =
ln(2)
τe
− keffCeff (t) (4.21a)
P˙ (t) =
1
τg
ln
[
ln(ρg/N0)
ln(ρg/2N0)
]
(ln ρg − P (t))− keffCeff (t) (4.21b)
By logarithmically transforming the PD equations (3.6a) and (3.6b), cancer proliferating
exponentially can be described by an ODE (4.21a) which is linear in effective drug concen-
tration (Ceff (t)). Also, PD models with bilinear kill terms in which cancer proliferates in
a Gompertzian fashion can be reduced to an ODE (4.21b) which is linear in both effective
drug concentration (Ceff (t)) and transformed tumor size (P (t)). Each transformed model
has a positive constant term which accounts for proliferation and a negative term accounting
for the presence of the drug.
The first step in the reformulation involved the logarithmic transformation from equation
(4.20). By performing this transformation on the PD equation (4.15b) the nonlinear growth
and bilinear kill nonlinearities were eliminated yielding:
P˙ (t) =
1
τg
ln
[
ln(ρg/N0)
ln(ρg/2N0)
]
(ln ρg − P (t))− keff (C(t)− Cth)H(C(t)− Cth) (4.22)
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The discontinuous drug effect was accounted for during discretization. In discretizing the
system, the dynamic constraints were converted into algebraic constraints. The plasma drug
concentration was discretized at a time step h [68] and resulted in a piecewise continuous
function (4.23):
Cd(k + 1) =
 − 1γ
(
e−γh − 1) u(q)
h
+ e−γhCd(k) when k = hq
e−γhCd(k) otherwise
(4.23)
The input is present along with a decay term at time steps which coincide with drug
administration times. When no drug can be administered, the plasma concentration simply
decays at the rate γ. The discontinuous effective drug concentration, Ceff (t), from equation
(4.15c) was accounted for using the methodology discussed in section 4.1.2. By applying
the binary variable bd,th(k), and enforcing the constraints found in equation (4.13) at each
timestep, k, the discontinuous effective drug concentration was reduced to linear inequalities.
The logarithmically transformed PD (4.22) was discretized using Euler’s method [69]:
Pd(k + 1) = Pd(k) + hFd(Pd(k), Cd,eff (k)) (4.24)
Fd(k) =
1
τg
ln
[
ln(ρg/N0)
ln(ρg/2N0)
]
(ln ρg − P (t))
−keff (C(t)− Cth)H(C(t)− Cth) (4.25)
Note that Fd is the discretized right hand side of equation (4.22). The discrete–time form of
the acute toxicity constraint (4.16) was represented with the following state constraint:
Cd(k) ≤ Cmax ∀k ∈ [1,mk] (4.26)
Cumulative toxicity for this system (4.17) was replaced with equation (4.11), the trapezoidal
rule approximation of the integration (4.17). The efficacy constraint (4.18) was incorporated
in the following manner:
Pd(k) ≤ ln(N0); ∀k ∈ [3,mk] (4.27)
It is important to notice that the efficacy constraint was not enforced for the first two time
steps. The nature of discrete–time systems without direct feedthrough dictates that the
effects of an input change on states not manifest until subsequent time steps. In this case,
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manipulated variable changes at time step one induce plasma drug concentration changes
at time step two. These manipulated variable changes then indirectly affect the number of
cancer cells at time step three. Since the cells are continuously proliferating, the continuous–
time efficacy constraint cannot be satisfied until the third time step.
Based on the discretization results above, the continuous problem (4.19) was recast as
the following MILP:
minDd(q) Pd(mk) (4.28)
s.t. (4.11), (4.13), (4.23), (4.24), (4.26), (4.27)
4.3.2 MILP Results
Solutions for each value of keff case were found using the optimization software CPLEX in
the General Algebraic Modeling System (GAMS) and are shown in Figure 26. The objective
function values (N(tf )) for both the MILP and optimal control solutions are shown for each
value of keff in Table 12. Problem formulations contained approximately 4106 equations,
1873 continuous variables and 364 discrete variables, and solution required less than a second
to solve on a dual AMD Athlon 1.8 GHz machine with one GB of RAM.
The solutions shown in Figure 26 are qualitatively similar to those presented by Martin
and Teo [12]. An initial dose was administered at the first time step in all instances. This
was done to accommodate the efficacy constraint (4.27) and drives the number of cancer cells
down initially. As the cancer population approached the initial number of cells, more drug
was administered to satisfy the efficacy constraint. This was most evident for drug efficacies
keff,3 and keff,2. At the end of the treatment cycle, the drug was administered in large
amounts to reduce the final time tumor volume (the objective) such that the cumulative
toxicity constraint (4.11) was met and the acute toxicity constraint (4.26) was not violated.
When considering the highly effective drug, (keff,1), the optimal control solution found
by Martin [12] and MILP solution achieved essentially the same result. For the moderately
effective drug (keff,2) the MILP solution was clinically indistinguishable (within measure-
ment error) from the optimal control solution. However, there were quantifiable differences
between the two methodologies when considering the ineffective drug (keff,3). This can be
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Table 11: PK/PD parameters taken from the Martin and Teo case study [12]. Here [D] are
the units of drug concentration/mass of drug delivered.
parameter value units
τg 150 days
ρg 10
12 cells
N0 10
10 cells
keff,1 2.7×10−2 1days·[D]
keff,2 8.4×10−3 1days·[D]
keff,3 1.5×10−3 1days·[D]
γ .27 1
days
Cth 10 [D]
Cmax 50 [D]
Ccum 4.1×103 [D]·days
tf 364 days
Table 12: Objective function values, N(tf ), for the MILP and optimal control (OC) solutions
[12].
keff,1 keff,2 keff,3
MILP < 1 333 1.9× 109
OC < 1 1.2× 103 1.8× 109
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Figure 26: Case study I response to treatment. Top pane: tumor volume predictions for the
three drug types: keff,1 (—), keff,2 (-·-) and keff,3 (· · ·). Remaining panes: dose schedule
(bar/shaded region) and concentration (—) for drugs keff,1 (2
nd pane), keff,2 (3
rd pane) and
keff,3 (bottom pane); Cth (−−) and Cmax (· · ·) in panes 2-4.
91
resolved by decreasing the stepsize, h. However, there is a compromise. Extremely small
values for h leads to more mathematical operations. Consequently, roundoff errors associated
with floating point mathematics begin to dominate. On the other end of the continuum,
extremely large values for h lead to discretization error. Hence, the value for h must be
selected to balance these effects. A more accurate discretization scheme, such as Runga–
Kutta, could be employed, but this leads to a significant increase in the number of algebraic
constraints associated with the PK/PD model.
4.3.3 Clinical Relevance
Clinicians make use of periodic feedback to evaluate the efficacy of treatment and to adjust
treatment as necessary to mitigate side effects. To approach the cancer chemotherapy
dosing problem from a more practical perspective, the problem from equation (4.28) was
reformulated as a receding horizon problem:
minDd(q)
mp∑
i=1
(Pd(i)− Td(i))2 + Γu
mq∑
i=1
Dd(i) (4.29)
s.t. (4.11), (4.13), (4.23), (4.24), (4.26), (4.27)
This mixed–integer quadratic programming problem (MIQP) minimizes the deviations be-
tween the transformed tumor volume, Pd(i), and a specified target, Td(i), over a horizon of
wp points (two weeks per point). The input penalty term, weighted by Γu, was added to
penalize small drug doses. This formulation assumes the patient returns every eight weeks
for evaluation and the prediction horizon (wp) for optimization purposes is initially 26 (one
trajectory point every two weeks), and decreases by 4 times the number of treatment periods
preceding the current period (a receding horizon formulation [71, 72]).
The problem in (4.29) was modeled in GAMS and solved using CPLEX. This resulted in
a series of 6 optimizations. Each optimization contained approximately 1894 equations, 865
continuous variables, 168 discrete variables and the solution was found in less than a second.
The calculations were performed on a dual AMD Athlon 1.8 GHz machine with one GB of
memory.
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Figure 27: Case study I receding horizon solution for keff,1. Top pane: predicted tumor
response profile, Pd, and desired response, Td, (×) for Γu = 0 (—) and Γu = 1 (· · ·). Other
panes: drug administration levels (bar/shaded region) and plasma concentrations (—) for
Γu = 0 (middle pane) and Γu = 1 (bottom pane); Cth (−−) and Cmax (· · ·) in the middle
and bottom panes.
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Table 13: Total exposure, AUCexp, and effective exposure, AUCeff , for solutions to (4.29)
and the given input weights, Γu.
Γu = 0 Γu = 1 units
AUCexp 3438 2069 [d]·days
AUCeff 1110 1061 [d]·days
AUCeff
AUCexp
0.32 0.54 —
The results for the most efficacious drug, keff,1, are shown in Figure 27. The trajectory
specified in Figure 27 represents the desire to decrease the tumor burden as quickly as
possible. For the two cases presented here, a large amount of drug is administered during the
first cycle. This rapidly eliminates a large number of the cancerous cells. With Γu = 0, the
focus was on adhering to the trajectory and resulted in many small doses being administered.
While dose levels were predicted which led to immediate plasma levels at or below the
therapeutic level, Cth, these administrations did combine with subsequent administrations
to increase the effective exposure.
While this result is mathematically optimal, it is suboptimal from a clinical perspective.
A significant amount of drug was being administered at variable small doses that contributed
to the cumulative exposure, without contributing significantly to the efficacy of the treat-
ment. Furthermore, the use of variable small doses is a dose preparation concern in the
clinic. By increasing the penalty for drug administration to Γu = 1, the administration
profile in the bottom pane of Figure 27 was obtained. This tracked the trajectory well, as
indicated by the dotted line in the top pane of Figure 27, with a greater fraction of the drug
exposure above Cth. Table 13 contains the total exposure, AUCexp, the effective exposure,
AUCCeff , and the ratio of the effective to total exposure. By changing Γu from zero to one
the fraction of the effective drug exposure increases from a third to over one half. This is
desirable because all drug administered contributes to toxicity but not necessarily efficacy.
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4.4 CASE STUDY II: LINEAR PK/BILINEAR PD EFFECT
The second case study considers the effects of the lactone forms of 9NC and 9AC modeled
in equation (3.7). The tumor volume increases exponentially, and bilinear kill terms employ
PK concentration predictions after oral administration. The state and output equations are
as follows:
x˙0(t) = − x0(t)
τ0
+
D(t)
τ0
(4.30a)
x˙1(t) =
x0(t)
τ1
− x1(t)
τ1
+
x3(t)
τ1
(4.30b)
x˙2(t) =
β1α2
τ2
x1(t)− x2(t)
τ2
+
x4(t)
τ2
(4.30c)
x˙3(t) = H(t− θ)x1(t− θ)α1
τr
− x3(t)
τr
(4.30d)
x˙4(t) = H(t− θ)x2(t− θ)α1
τr
− x4(t)
τr
(4.30e)
x˙5(t) =
ln(2)
τe
x5(t)− keff,NCLCeff,NCL(t)x5(t)− keff,ACLCeff,ACL(t)x5(t)
(4.30f)
CNCL(t) = β1kpx1(t) (4.30g)
C
eff,NCL(t) = CNCL(t− θeff )H(t− θeff ) (4.30h)
CACL(t) = β1kpx2(t) (4.30i)
C
eff,ACL(t) = CACL(t− θeff )H(t− θeff ) (4.30j)
Ne(t) = x5(t) (4.30k)
The details of this model, including parametric descriptions, were discussed in Chapters 2 and
3. Briefly, equations (4.30a)-(4.30e) represent the PK of the lactone forms of 9NC and 9AC.
The concentrations of 9NC and 9AC in the plasma are given by the outputs CNCL(t) and
CACL(t), respectively. Equation (4.30f) accounts for the drug PD, and the tumor volume
is given by Ne(t). The effective concentrations of the drug and metabolite are the plasma
concentrations delayed by θeff . The initial state of the system is x(0) = [0, 0, 0, 0, 0, N0]
>,
where no drug is present and the tumor volume is initially N0.
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4.4.1 Continuous Constraint Formulation
Based on the mathematical representation in equation (4.30), the optimal dosing regimen
was determined for a treatment interval of four weeks (tf = 33600 minutes). For this system,
logistical constraints associated with drug dosing were considered as well. Based on work
schedules, drugs could be administered no more often than once every weekday (i.e., no
weekends). For a cycle of treatment, four weeks in this case, there were twenty possible
dosing times q.
To bound the amount of drug that can be administered, a cumulative exposure constraint
was placed on the system for each treatment period. Currently, 9NC is administered once
daily, Monday–Friday, at 0.67 mg/kg, for two weeks, followed by two weeks with no drug
being administered (QD×5×2) [55]. This schedule is then repeated at four week intervals.
It was assumed that the cumulative toxicity should not exceed that encountered when
administering 9NC using the current standard of practice (0.67 mg/kg QD×5×2 = 6.7
mg/kg, per four weeks). Typically this would be a bound on the integrated drug plasma
concentration versus time curve; however, the result of this integral for systems modeled by
linear PK is proportional to the amount of drug administered. As such, a limit was placed
on the total mass of drug delivered:
∫ tf
0
D(t) ≤ 6.7mg
kg
(4.31)
After administration of 9NC, the plasma levels are below the detectable limit by the end of
a day. Since the period between administrations is at least a day, there are no combinatorial
effects between doses. The amount of drug delivered on any given day was bounded above
by the MTD of 1 mg/kg and bounded below by the minimum effective dose of 0.44 mg/kg:
0.44
mg
kg
≤ D(ti) ≤ 1.0mg
kg
or D(ti) = 0 ∀i ∈ [1, · · · ,mq] (4.32)
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4.4.2 Continuous Problem Formulation
With an understanding of the constraints imposed on the system, the continuous problem
was formulated as:
minD(q) Ne(tf ) (4.33)
s.t. (4.30), (4.31), (4.32)
The discontinuities in the manipulated variable D(t) and the bilinear kill term from equation
(4.30f) indicate that this is a nonlinear programming problem (NLP) with dynamic con-
straints. Solutions to this optimization would include local minima. Martin has shown that
control vector parameterization can be used to guarantee a global optimum for this problem
is found [12]. However, including alternate constraints or altering the current constraints
could supplant the ability of optimal control theory to determine the global optimum (i.e. the
introduction of path or state constraints). To guarantee optimality, options were explored
to eliminate nonlinearities and restate the problem such that a global optimum could be
guaranteed in the current form and the problem could be easily extended as well.
4.4.3 MILP Problem Reformulation
By substituting the values from equation (4.20) into equation (4.30f), the tumor growth
equation becomes:
P˙ (t) =
ln(2)
τe
− k
eff,NCLCeff,NCL(t)− keff,ACLCeff,ACL(t) (4.34)
The discontinuity in the range of drug administration was reformulated as in (4.14), thereby
introducing the binary decision variable bd,u(q). The constraints in equation (4.32) were
replaced with:
0.44bd,u(q)
mg
kg
≤ Dd(q) ≤ 1.0bd,u(q)mgkg bd,u(q) ∈ {0, 1}∀d (4.35)
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When bd,u(q) is zero, then Dd(q) must be zero, and when bd,u(q) is one then Dd(q) must lie
within the therapeutic range. The cumulative toxicity limit (4.31) was replaced with the
following summation:
20∑
q=1
Dd(q) ≤ 6.7 (4.36)
Finally, the PK equations (4.30a) through (4.30e) were written in the matrix form:
x˙0
x˙1
x˙2
x˙3
x˙4

︸ ︷︷ ︸
x˙(t)
=

− 1
τ0
1
τ1
− 1
τ1
− 1
τ1
−α2β1
τ1
− 1
τ2
1
τ2
− 1
τr
− 1
τr

︸ ︷︷ ︸
A

x0
x1
x2
x3
x4

︸ ︷︷ ︸
x(t)
+

1 0 0
0 0 0
0 0 0
0 α1
τr
0
0 0 α1
τr

︸ ︷︷ ︸
B

D(t)
x1(t− θ)H(t− θ)
x2(t− θ)H(t− θ)

︸ ︷︷ ︸
u(t)
(4.37)
The delayed states in equations (4.30d) and (4.30e) have been transformed into inputs u1(t)
and u2(t), respectively, to facilitate simulation. The state equations from (4.37) can be
discretized for any step size h in terms of A and B as shown in equations (4.8) and (4.9).
The logarithmically transformed PD from equation (4.34) was also discretized using Euler’s
method [69]. The continuous dynamic constraints from equations (4.30) and (4.34) were
recast in discrete–time form as follows:
xd(k + 1) = Adxd(k) +Bdud(k) (4.38a)
Pd(k + 1) = Pd(k) + h
( ln 2
τe
− k
eff,NCLCd,eff,NCL(k)− keff,ACLCd,eff,ACL(k)
)
(4.38b)
C
d,NCL(k) = β1kpx1,d(k) (4.38c)
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C
d,eff,NCL = Cd,NCL(k − θd,eff )H(k − θd,eff ) (4.38d)
C
d,ACL(k) = β1kpx2,d(k) (4.38e)
C
d,eff,ACL = Cd,ACL(k − θd,eff )H(k − θd,eff ) (4.38f)
xd(1) = [0, 0, 0, 0, 0, ln(N0)]
> (4.38g)
Where θd,eff = bθeff/hc, or θeff/h rounded down to the nearest integer. By utilizing the
binary variables introduced in equation (4.35), the nonlinear transform from (4.20), and the
discretization (4.38), the dose regimen determination problem can be restated as follows:
minDd(q) Pd(mk) (4.39)
s.t. (4.35), (4.36), (4.38)
The resulting optimization is a MILP which can be solved to optimality given a reasonable
step size h, which is selected such that the fastest dynamics are adequately captured.
defined by the fastest dynamic equation.
4.4.4 MILP Results
The parameters used in this case study were given in Table 6. The initial tumor volume was
assumed to be N0 = 40 mm
3 and a discretization step size of h = 20 min was used. The
system was modeled in the General Algebraic Modeling System (GAMS) using the bdmlp
solver. For a four week treatment window, the resulting problem had m = 2016 steps,
20202 equations, 20201 continuous variables and 20 discrete variables. The optimal solution
was found in 109 seconds and is shown in Figure 28 along with the current standard of
preclinical practice. In this case study, the final tumor volumes using both dosing regimens
are not experimentally differentiable. While the MILP–derived regimen is mathematically
optimal (the final tumor volume from the QD×5×2 was −3.2× 10−9 mm3 larger than that
found using the optimal dosing regimen), the results suggest that an exponentially growing
tumor affected in a bilinear fashion by a drug with linear PK has a final tumor volume
determined solely by the amount of drug administered and is independent of the dosing
schedule.
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Figure 28: Case study II response to treatment. Top pane: optimal dosing profile (—), as
suggested by the MILP (4.39), and current standard of practice (›). Bottom pane: tumor
volume in response to the optimal dosing profile (—) and the current standard of practice
(−−).
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The independence of outcome to dose schedule can be shown using a simple example.
Consider the following simple model of exponential growth in response to an intravenously
administered drug:
PK: x˙0(t) = −x0(t)τ0 +
u(t)
τ0
PD: x˙1(t) = − ln(2)τe x1(t)− keffx1(t)x0(t)
N(t) = x1(t)
(4.40)
Let the input be a bolus, u(t) = Mδ(t), occurring at some time (t = ti). The objective
is to evaluate the effect of this input on tumor size, x1(t), at some final time (t = tf ).
The transformation in equation (4.20) was carried out and applied to (4.40) to provide the
following dynamic linear system:
x˙0(t) = −x0(t)τ0 +
u(t)
τ0
x0(0) = 0
x˙t(t) =
ln(2)
τe
− keffx0(t) xt(0) = ln(x1(0)) = K
Nt(t) = xt(t)
(4.41)
Now consider the input profile u(t) = Mδ(t− θ)H(t− θ) — a bolus of magnitude M applied
at an arbitrary time θ. Based on this input, equation (4.41) can be transformed into the
Laplace domain and solved analytically to provide the following time domain representation
for Nt(t):
Nt(t) =
ln(2)
τe
1
K
(
eKt − 1)︸ ︷︷ ︸
growth
− keffM
(
1
τ0K + 1
eK(t−θ) − 1
τ0
1
1
τ0
+K
e
− (t−θ)
τ0
)
H(t− θ)︸ ︷︷ ︸
death
(4.42)
The time domain result (4.42) can be segregated into growth and death terms as shown.
In the absence of drug administration, the tumor will continue to increase exponentially.
The presence of an input will decrease the tumor volume according to the death term. By
increasing or decreasing θ the dynamic response will change. However, the point of interest
for final time problems is the state of the system after the influence of drug administration
has passed. For a first order linear system this occurs approximately at the time tf > θ+5τ0
[26]. At tf , the overall decrease in tumor size (i.e., Nt(tf )) will be the same regardless of when
the drug is administered provided it is not given within 5τ0 of tf . This is a straightforward
application of the superposition principle [68].
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4.5 CASE STUDY III: NONLINEAR PK/SWITCHED EXPONENTIAL
GROWTH
The final case study considered utilizes the nonlinear PK/PD model of 9NC and 9AC efficacy,
(2.9), and the linear model of toxicity (3.9). The state and output equations are given by:
x˙1(t) =
x2(t)
τu
− x1(t)
τu
(4.43a)
x˙2(t) =
Du(t)
τu
− x2(t)
τu
(4.43b)
x˙3(t) =
x4(t)
τl
− x3(t)
τl
(4.43c)
x˙4(t) =
Dl(t) + x5(t)
τl
− x4(t)
τl
(4.43d)
x˙5(t) = β1
x3(t)
τr
− x5(t)
τr
(4.43e)
x˙6(t) = α2(x1(t− θ2) + α1x3(t− θ2))H(t− θ2)Dlast
τnl
− x6(t)Dlast
τnl
(4.43f)
x˙7(t) =
ln(2)
τ¯e(x7(t))
x7(t)− keffCeff (t)x7(t) (4.43g)
x˙8(t) = kgx9(t)− kcCeff (t) (4.43h)
Ceff (t) = CNC(t) + CAC(t) (4.43i)
CNC(t) = x1(t)
Ku
Dlast
+Klα1x3(t) (4.43j)
CAC(t) = (x1(t) + x3(t)α1)β2Ka + x6(t)Ka (4.43k)
Ns(t) = x7(t) (4.43l)
B(t) = x8(t) (4.43m)
Btox(t) = x8(t)− x7(t)
1000
(4.43n)
τ¯e(x7(t)) =
 τ¯e,f , x7(t) < N¯thτ¯e,s, x7(t) > N¯th (4.43o)
The methodology behind the construction of this model was covered in Chapters 2 and 3.
Equations (4.43a) through (4.43f) represent the PK of 9NC and 9AC after oral adminis-
tration of 9NC. Tumor proliferation and PD response (efficacy) to 9NC administration is
characterized by equation (4.43g). Toxicity, in terms of body weight reduction, is described
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by equation (4.43h). The outputs CNC(t) and CAC(t) represent the plasma concentrations
of 9NC and 9AC total, respectively. Tumor volume, mouse body weight and the corrected
body weight are given by the outputs Ns, B, and Btox, respectively. The initial state of the
system is x(0) = [0, 0, 0, 0, 0, 0, N0, B0]
>, where no drug is present, the tumor volume is
initially N0, and the initial body weight is B0.
4.5.1 Continuous Constraint Formulation
Based on the mathematical representation in equation (4.30), the optimal dosing regimen was
determined for a treatment interval ofNweeks (tf = Nweeks×7(days/week)×1440(minutes/day)).
The same logistical constraints apply as those from section 4.4. Work schedules dictate
that drugs could only be delivered once each weekday. For Nweeks of treatment, there are
q = Nweeks × 5 possible dosing times.
The semicontinuous dosing constraint from section 4.4, equation (4.32), is still valid. The
amount of drug administered at any dosing opportunity is either zero or must lie somewhere
between an upper and lower bound, 1.0 and 0.44 mg/kg, respectively. In section 4.4, a
toxicity bound was placed on total exposure. In this case study, a lower bound on Btox is
considered:
Btox(t) ≥ Bmin (4.44)
4.5.2 Continuous Problem Formulation
The continuous problem can be formulated as
minD(q) Ns(tf ) (4.45)
s.t. (4.32), (4.43), (4.44)
The optimization in (4.32) is a NLP because of the nonlinear PK, discontinuities in D(t),
and the bilinear kill term. This problem can be reformulated as a MILP which can be solved
to global optimality.
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4.5.3 MILP Problem Reformulation
4.5.3.1 Parameterized PK Nonlinearities such as those found in the nonlinear 9NC
PK model (4.43a)–(4.43f) can make optimizations quite complicated. To eliminate these
nonlinearities, we make use of the fact that both 9NC and 9AC are cleared at a rate such
that any drug from a dose on a given day is below the level of detection by the following
day. While the range of doses is continuous (0.44 – 1.0 mg/kg), realistically there are a set
of doses, l = [1,ml], which can be distinguished from each other. For each of these doses, a
PK profile can be calculated a priori such that 9NC and 9AC concentrations at all the times
after a given dose are parameterized by dose magnitude. The set of steps per day is given
by z = [1,mz]. The algorithm then selects from the set of profiles each dosing opportunity.
This is achieved by introducing the binary variable bd,dose(q, l) at each dosing opportunity for
each possible dose level. The dynamic PK equations can then be replaced with the following
constraints:
C
d,NC(k) =

∑ml
i=1 bd,dose(q, i)QNC(j, i), k = Qmap(q)− 1 + j, ∀j ∈ [1, · · · ,mz]
0, otherwise
(4.46a)
C
d,AC(k) =

∑ml
i=1 bd,dose(q, i)QAC(j, i), k = Qmap(q)− 1 + j, ∀j ∈ [1, · · · ,mz]
0, otherwise
(4.46b)
1 =
l∑
i=m1
bd,dose(j, i) ∀j ∈ [1, · · · ,mq] (4.46c)
Cd,eff (k) = Cd,AC(k) + Cd,NC(k) (4.46d)
Where QNC(z, l) and QAC(z, l) are matrices of precalculated concentrations of 9NC and
9AC, respectively. The parameter Qmap(q) is a map between the dosing opportunity (q) and
the timestep (k) in which it occurs. For example, the second dosing opportunity, q = 2, with
a time step of one minute occurs at k = 2881, so Qmap(2) = 2881. The constraint (4.46c)
ensures that only one dose level is selected at any given dosing opportunity.
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4.5.3.2 PD Variable Transform The tumor growth equation (4.43g) is transformed
using the method found in (4.20) such that the tumor growth model becomes:
P˙ (t) = Fs(P (t))− keffCeff (t) (4.47a)
Fs(P (t)) =

ln(2)
τ¯e,f
, P (t) < ln
(
N¯th
)
ln(2)
τ¯e,s
, P (t) > ln
(
N¯th
) (4.47b)
The discontinuity in the rate of proliferation is a piecewise continuous function of P (t).
As shown in equation (4.13), this behavior can be accounted for by adding a binary variable
bd,P (k) and replacing (4.47) with the following constraints [70]:
Pd(k)− ln N¯th ≤ (ln(Nmax)− ln(N¯th))(1− bd,P (k)) (4.48a)
(1− bd,P (k))
(
ln(2)
τ¯e,s
− ln(2)
τ¯e,f
)
≤ Fd,s(k)− ln(2)
τ¯e,f
(4.48b)
(1− bd,P (k))
(
ln(2)
τ¯e,s
− ln(2)
τ¯e,f
)
≥ Fd,s(k)− ln(2)
τ¯e,f
(4.48c)
ln N¯th − Pd(k) ≤ ln(N¯th)bd,P (k) (4.48d)
bd,P (k)
(
ln(2)
τ¯e,f
− ln(2)
τ¯e,s
)
≤ Fd,s(k)− ln(2)
τ¯e,s
(4.48e)
bd,P (k)
(
ln(2)
τ¯e,f
− ln(2)
τ¯e,s
)
≥ Fd,s(k)− ln(2)
τ¯e,s
(4.48f)
Where Fd,s(k) is the discrete–time form of Fs(P (t)). The values Nmin and Nmax are smallest
and largest possible tumor volume, respectively. The lower bound is represented by zero,
and the upper bound is represented at each timestep by the predicted size of the tumor at
that timestep in the absence of treatment.
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4.5.3.3 Effect of Transform on Body Weight Calculations By performing the PD
transform (4.20) as employed in (4.47), the body weight calculation becomes:
Bd,tox(k) = Bd(k)− e
Pd(k)
1000
To avoid the nonlinearity associated with the exponential term, a conservative estimate was
made. The transformed tumor volume, Pd(k), was replaced with the value it would take if
no drug were administered, QPnom(k):
Bd,tox(k) = Bd(k)− e
QPnom(k)
1000
(4.49)
And the bound on body weight is given by:
Btox(t) ≥ Bmin (4.50)
It is possible for the tumor size to increase at the nominal rate which would yield large values
of QPnom at the end of treatment cycles. This could lead to conservative dose schedules being
returned by the controller for the cycle. Two options that address this problem are: (i) a less
conservative value for Bmin could be used, or (ii) the duration of treatment cycles could be
reduced to allow the clinician more frequent feedback and model correction. Shorter cycles
would be preferred from the perspective of patient safety.
4.5.3.4 Dynamic Equations The remaining dynamic equations (4.43h) and (4.47b)
can now be discretized for a stepsize h using the Euler’s method [69]:
Pd(k + 1) = Pd(k) + h (Fd,s(k)− keffCd,eff (k)) (4.51a)
Bd(k + 1) = Bd(k) + h (kgBd(k)− kcCd,eff (k)) (4.51b)
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Table 14: Parameters used in Case Study III.
parameter value units
B0 20 g
Bmin 0.98B0 g
N0 40 mm
3
h 5 min
tf 8 weeks
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Figure 29: Mesh plot of concentration profiles of 9NC (top pane) and 9AC (bottom pane)
total for dose levels ranging from 0.44 to 1.0 mg/kg 9NC in 0.01 mg/kg increments.
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until the latter portion of treatment when a maximum amount of drug was administered
such that the toxicity constraint (4.50) was not violated.
4.5.5 MILP Results: Shrinking Horizon Problem
As before, a more clinically relevant reference trajectory for the tumor volumes to follow was
specified. This was done by minimizing the tumor volumes at the end of each week. This
can be stated mathematically as:
minbd,dose(q,l)
mp∑
i
Pd(i) ∀i ∈ [2016, 4032, 6048, · · · , 16128] (4.53)
s.t. (4.46), (4.48), (4.49), (4.50), (4.51),
Here i is the index corresponding to 1 week (1 week = 100080 min/h min). The same set
of parameters and possible dose levels used in the final time problem, Table 14 (section ??),
were used here. The problem (4.53) was modeled in GAMS and solved using CPLEX. The
same number of equations and variables were generated, and the optimal solution was found
in approximately 11 hours. The dosing profile and corresponding body weights and tumor
volumes are shown in Figure 31. By modifying the objective function, a more clinically
relevant treatment regimen was developed. The body weight satisfied the constraint while
the tumor volume was gradually reduced over the treatment window.
Next the amount of drug administered was constrained to be either the maximum possible
value (1.0 mg/kg) or none at all. This is similar to the clinical case where a pill will either
be administered or not at each dosing opportunity. All of the parameters from (4.53) were
the same with the exception of the possible dose levels, which were 0 and 1.0 mg/kg. Once
formulated, this problem hadmk = 16, 128 time steps, 193,575 equations, 112,977 continuous
variables, 16,208 discrete variables, and a solution time of 22 minutes. The solution is shown
in Figure 32. When considering the solutions provided in Figures 31 or 32, the first four weeks
of drug administration would be implemented. At the end of four weeks, measurements of
body weight and tumor volume would be made. New dosing profiles would then be calculated
for the next eight weeks and the first four weeks implemented. This process would then be
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repeated until tumor progression occurred, unacceptable toxicity resulted, or clinical response
was obtained.
To place the controller results into perspective, they will be compared to the current
standard of practice, QD×5×2 every four weeks, shown in Figure 33. Table 15 summarizes
the results presented in this section. Minimizing tumor volumes at a final time has already
been established to be of little clinical relevance. The results presented in Figure 31 de-
livered a total of 25.76 mg/kg of 9NC and have minimum and maximum tumor volumes
of 7.9 and 42.1 mm3 respectively. The solution to the more constrained problem shown in
Figure 32 delivered slightly more drug, 27 mg/kg of 9NC. The binary dosing option also had
a wider range of tumor volumes 6.7 and 44.2 mm3 for the minimum and maximum values,
respectively. Both of the solutions had body weight values above the 98% level specified.
The finely graded dosing option had a minimum normalized corrected body weight of 0.982,
while the the binary dosing option had a minimum normalized corrected body weight of
0.98, both satisfying the toxicity constraint. The standard of practice delivers 20 mg/kg
over the eight week window with a minimum normalized corrected body weight of 0.972.
The maximum tumor volume is lower than the two solutions previously discussed at 40 mm3
while the minimum tumor volume is higher at 10.5 mm3.
Each of the dosing profiles have their positives aspects. Considering the clinically relevant
aspects of the problem, the solution to the trajectory tracking problem which constrained
the dosing to be either 0 or 1.0 mg/kg, shown in Figure 32, would be considered optimal.
While allowing the controller to select from more possible doses yields a more mathematically
optimal solution, clinicians would find little difference between the two trajectory tracking
solutions in terms of efficacy. However, the binary dosing option is preferred for two reasons.
The first is that it eventually becomes periodic. Regular, or periodic, administration is
preferred over the more erratic schedule shown in Figure 31. The chance for error is
significantly reduced by constraining the dose levels to fixed discrete values. This is highly
relevant when considering oral drugs prescribed in pill form.
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Table 15: Summary of relevant statistic for different dosing profiles: (i) minimizing tumor
volume at a final time, (ii) trajectory tracking using a near continuous dosing profile, (iii)
trajectory tracking allowing dose levels of 0 or 1.0 mg/kg of 9NC, and (iv) the current
standard of practice (QD×5×2 every four weeks).
Dosing Profile: max(N(t)) min(N(t)) min
(
Btox(t)
B0
) ∑mq
i=1D(q)
(mm3) (mm3) (–) (mg/kg)
(i) Minimize N(tf ), Figure 30 86.5 5.2 0.980 28.48
(ii) Trajectory, Figure 31 42.1 7.9 0.982 25.76
(iii) Trajectory, Figure 32 44.3 6.7 0.981 27.0
(iv) QD×5×2, Figure 33 40.0 10.5 0.972 20.0
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Figure 30: Case study III response to treatment — Minimizing tumor burden at a final time
(eight weeks). Top pane: optimal dosing profile (—), as suggested by the MILP (??). Middle
pane: corrected body weight (—) and lower bound on corrected body weight (−−). Bottom
pane: tumor volume in response to the optimal dosing profile (—).
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Figure 31: Case study III response to treatment — Trajectory tracking of zero tumor volume
every week. Top pane: optimal dosing profile (—), as suggested by the MILP (4.53). Middle
pane: corrected body weight (—) and lower bound on corrected body weight (−−). Bottom
pane: tumor volume in response to the optimal dosing profile (—) and desired trajectory
(×). Possible dose levels 0 to 1.0 mg/kg in 0.01 mg/kg increments
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Figure 32: Case study III response to treatment — Trajectory tracking of zero tumor volume
every week. Top pane: optimal dosing profile (—), as suggested by the MILP (4.53). Middle
pane: corrected body weight (—) and lower bound on corrected body weight (−−). Bottom
pane: tumor volume in response to the optimal dosing profile (—) and desired trajectory
(×). Possible dose values: 0 and 1.0 mg/kg
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Figure 33: Case study III response to treatment — standard of practice dosing. Top pane:
QD×5×2 every four weeks (—), representing the current standard of practice (4.53). Middle
pane: corrected body weight (—) and lower bound on corrected body weight (-·-). Bottom
pane: tumor volume in response to the dosing profile (—) and desired trajectory (×).
Possible dose values: 0 and 1.0 mg/kg
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4.6 SUMMARY
In this chapter three case studies in chemotherapy control were presented. The first, studied
previously by Martin and Teo [12], was reformulated as a MILP and a solution similar to
that of the original authors was calculated. This resulted in treatment being withheld for a
significant period of time and large amounts of drug being administered over the last half of
the treatment cycle. This mathematically optimal solution would be ethically questionable
for a clinician to implement due to the long window in which no treatment would be delivered.
It is neither intuitive nor desirable from a clinical perspective to withhold treatment for long
periods of time when no complications due to toxicity or other extenuating circumstances
have been encountered. In an effort to develop a more pragmatic solution, a shrinking tumor
objective was considered. A trajectory specifying a rapid reduction in tumor volumes over
time was used as the objective, and the result was a more clinically acceptable treatment
regimen.
The remaining two case studies focused on the 9NC treatment of SCID mice bearing
HT29 human colon carcinoma xenografts as modeled in chapters 2 and 3. The second case
study considered exponentially growing tumors with PD driven by linear PK and cumulative
toxicity constraints. Cumulative toxicity constraints were shown to be inadequate because
tumors under exponential growth with bilinear PD driven by linear PK gain no benefit by
altering the dosing schedule due to the principle of superposition. The third case study
consisted of a switched exponential tumor model coupled with a nonlinear PK model and a
model of body weight reductions in response to treatment. When attempting to minimize
the final tumor volume, a solution which applied as much drug as possible at the end of the
treatment cycle was obtained. As in case study I, the objective function was modified to yield
a more clinically amenable treatment strategy. The receding horizon framework makes use of
periodic feedback and addresses the fact that endpoints are not clearly defined. In the event
that measurements vary significantly from the predictions, new parameter estimates could
be obtained and the dosing schedule recalculated (although the parameter update step was
not address in the present work). In theory, treatment would continue along this path until
116
the subject no longer responded to treatment or the tumor volume fell below measurable
levels.
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5.0 CONCLUSIONS AND RECOMMENDATIONS
5.1 CONTRIBUTIONS
The work discussed here has focused on modeling and control of cancer chemotherapy with a
primary focus on developing control methodologies that could be clinically applicable. The
methodologies used are based on those used to optimize and control industrial processes.
Novel modeling and control approaches to cancer therapy problems were developed which
provide a basis for the design of clinically relevant drug schedules.
5.1.1 PK/PD Modeling
The models developed here are empirical data–driven models of drug PK and PD. Two novel
models were introduced to describe the PK of 9NC. A linear model of the plasma disposition
of 9NC lactone and 9AC lactone in response to oral administration of 9NC at 0.67 mg/kg to
SCID mice was developed. Based on experimental data for total concentrations of 9NC and
9AC at 9NC dosing levels of 0.44, 0.67, and 1.0 mg/kg, a nonlinear PK model was developed
to capture the observed nonlinear dynamics.
Untreated tumor growth was characterized for twenty mice using two different macro-
scopic models. A simple model characterized the exponential growth of the implanted
tumors. A more complicated model structure was investigated which segregated tumor
growth into two regimes. Initially the tumor grew quickly, and after reaching a threshold
size, the rate of proliferation decreased. This was referred to as a switched exponential model
and was capable of accurately predicting tumor volumes over a wider range of times and
eliminated the underpredictions found in the exponential model at early time points.
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Based on the PK and untreated tumor growth models, two PK–driven PD models were
developed. The first PK/PD model coupled the linear PK of 9NC lactone and 9AC lactone
with the exponential growth model. This resulted in a description of drug distribution and
efficacy having a single nonlinear (bilinear) term. An alternative structure combined the
nonlinear PK model with the switched exponential growth model to develop a more complex
PK/PD model that captured treatment response across a range of dose levels. The nonlinear
PK model was also used to drive a toxicity model which predicted body weight changes in
response to drug administration.
The models developed here were designed to balance predictive accuracy with model
complexity. Predictive accuracy is important because model accuracy limits the theoretically
achievable performance of a controller [8]. The importance of model complexity can be seen
when trying to develop control algorithms. As the number of states and nonlinearities
increase and the nonlinear character becomes more complicated [73, 74, 75, 76, 77], control
algorithm synthesis may become markedly harder. More information could be used to
improve the accuracy of the model. Since 9NC and 9AC are cycle–specific compounds,
a model capable of predicting the population of cells in the cell–cycle would lead to a better
predictions of exposure. More complicated models, such as PBPK models, will provide
more information about specific tissues. Model reduction techniques may be necessary when
implementing these models in control algorithms.
5.1.2 Cancer Control
Engineering approaches to chemotherapy dose scheduling have typically focused on elegant
mathematical solutions using optimal control theory. While these solutions are appealing in
theory, they are not generally relevant in the clinic. A different approach was developed in
this work, where tools common to plant scheduling and operations research were utilized.
Any chemotherapy scheduling algorithms should embrace the concept that toxicity and
efficacy are the primary drives of treatment. In mathematical terms, a dose scheduling
algorithm should meet clinically relevant objectives in terms of efficacy, without violating
toxicity constraints.
119
A mixed–integer programming methodology was employed because it is flexible when
considering constraints, especially those encountered in the clinic. Constraints such as semi-
continuous or discrete dosing ranges, therapeutic thresholds, and categorical classification
of toxicities lend themselves well to (mixed–)integer programming representations. Different
variants of the final time problem — minimizing tumor volume at some final time — have
been considered by engineers [12, 44, 53, 46]. However, final times in a clinical setting are
not well defined a priori. The goal of a clinician is to eliminate the tumor burden while
maintaining patient quality of life; speed of elimination is a secondary objective. This can
be stated mathematically as a trajectory tracking problem. While trajectory tracking can
be encumbering from an optimal control perspective, it is easily implemented by posing the
problem as a MIQP.
To demonstrate the utility of this methodology, a theoretical drug/tumor system pre-
viously studied by Martin and Teo was considered [12]. By reformulating the problem
and eliminating certain nonlinearities by variable transformation, a MILP solution strategy
was developed that solved the problem as originally posed. The solution to minimizing
the tumor burden at a final time yielded results which postponed treatment until the end
of the treatment interval. From a treatment perspective, it would be unethical to withhold
treatment for such an extended period of time. The theoretical system was then considered in
a more clinically relevant framework. By altering the objective function in the reformulation,
it was specified that the tumor burden be eliminated rapidly by establishing a trajectory
of small tumor volumes for treatment to follow. While this resulted in a numerically larger
tumor population at the end of the treatment horizon, the final tumor populations were less
than one for both the optimal control and the MINLP solutions. The rapid elimination led to
a more clinically acceptable method of treatment. The suggested dosing schedule delivered
a large amount of drug initially which drove the tumor volume down, and the remainder of
treatment consisted of a maintenance doses which tracked the trajectory well.
Next a preclinical system was considered. The effects of 9NC on HT29 tumor–bearing
SCID mice was studied. Two different case studies were developed around this system. The
first consisted of an exponential tumor growth PD model driven by a linear PK model of
9NC lactone and 9AC lactone. This was the least complicated model constructed from this
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system. To constrain the toxicity of this system, cumulative drug exposure was used. The
maximum allowable exposure was set to that experienced under the current standard of
practice (0.67 mg/kg QD×5×2). Because linear PK results in a direct link between drug
administration and exposure (AUC), an upper bound was placed on the total amount of
drug which could be administered. A mathematical analysis found that the overall effect
of drug administration on a tumor burden — described with linear PK, exponential tumor
growth, and a bilinear kill term — was the same provided the effect of all doses was observed
by the end of treatment.
The same preclinical system was reconsidered except this time it was described by
nonlinear PK, a switched exponential tumor growth model, and toxicity quantified in terms
of body weight. This problem was treated similarly to the Martin and Teo problem. To
account for the nonlinear PK, concentrations of 9NC and 9AC total were precalculated
for a range of dose levels. The algorithm was then allowed to select from this range of
precalculated dose levels. This eliminated the nonlinearity associated with the 9NC PK. A
lower bound was placed on the corrected body weight to bound the toxic effects of treatment.
The objective was specified to reduce tumor volumes over an eight week period. Solutions
were found to lie on toxicity boundaries and a cyclical treatment methodology eventually
evolved. This resulted in a treatment schedule with consistent reductions in tumor volumes
along a trajectory which was better, in terms of efficacy, than the standard QD×5×2 every
four weeks.
5.2 FUTURE WORK
Clinical oncologists and pharmacologists design experiments to answer specific questions. It
is possible for engineers and mathematicians to pick through the literature and find data
to drive their modeling and control efforts. However, to truly make an impact on the field
of oncology, strong interdisciplinary collaboration is required. All of the modeling work
discussed above will require additional experimental data to validate, and model and control
studies will drive new experiments. This will be a cyclical process where experiments drive
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models and modeling results drive experiments may bring new treatment methodologies to
the clinic that would otherwise be unavailable due to the data on theoretical shortcomings.
5.2.1 Detailed Modeling
Under the premise that model accuracy limits achievable controller performance [8], a better
understanding of tumor progression, drug distribution, and PD effects would enhance the
ability of control algorithms to aid clinicians in their dosing decisions. While detailed models
can lead to difficulties in controller synthesis, they can provide insight into the underlying
mechanisms of cancer progression and treatment. This insight could then be used to inform
more control–relevant models in an iterative fashion.
5.2.1.1 Cancer Progression Models There are several different areas in which mod-
eling of cancer progression could be improved. Many chemotherapeutics are cycle specific,
and they have their greatest effect on cells in certain phases of the cell–cycle. The models
presented in this work treated cancer as a lumped mass, and no distinction was made between
cancer cells. Population models are one method which can account for the heterogeneity
found between the states of cancer cells. Cell–cycle dynamics have been addressed by
considering purely theoretical systems [15, 16]. More recently, cell–cycle representations have
been applied actual experimental systems to characterize to characterize the transition rates
between the different phases of the cell–cycle [78, 79, 80]. These can lead to improvements
in chemotherapy scheduling by determining the population of cells susceptible to treatment
and how chemotherapy effects these phase transition rates (i.e. when cells will defensively
enter the quiescent phase to avoid treatment effects).
Proliferation can also be considered on a more detailed level. Cells communicate and
regulate their own intracellular process through complicated chemical signals. In the last
decade much effort has been devoted to mapping out and isolating these pathways [81, 82, 83,
84]. Often, research focuses on correlating the presence or absence of chemical signals with
specific cellular events [85, 86, 87]. Cellular dynamics are robust and result in redundant
pathways [88]. Isolated identification of signal pathways ignores these redundancies. A
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systemic approach is required to identify the interactions between the different signaling
mechanisms.
5.2.1.2 Detailed PK Models The PK models presented in this work attempted only
to account for plasma drug concentrations. Chemotherapy is a systemic form of treatment,
and drugs distribute throughout an organism after administration. Understanding where
the drug distributes may provide more accurate information for PD modeling. By obtaining
local tissue concentrations, a more direct relationship between drug administration and the
amount of exposure experienced by diseased tissues can be found. Drug disposition also
provides a metric for bounding exposure to both diseased and healthy tissues. This can be
accomplished with the development of PB/PK models [21] and using such models to drive
PD models.
5.2.1.3 Constraint Formulation Most constrained optimization routines result in so-
lutions which lie on the boundary of constraints. With the understanding that efficacy and
toxicity drive treatment, the predominate toxicities associated with any given chemother-
apeutic drug needs to be quantified and modeled. Two primary complications arise here:
available measurements and mechanisms of action. A drug known to have neurotoxicity can
be difficult or impossible to measure at the site of toxicity, the brain. The specific mechanism
of action (e.g. duration of exposure, cumulative exposure, etc.) which results in toxicity will
guide treatment. In the absence of direct measurements and a clear understanding of toxicity
mechanics, indirect measurements may need to be developed to inform models which can
predict toxicity within a reasonable range.
5.2.2 Multi-drug Chemotherapy
The focus of this work has been to study the effects of a single compound on a solid tumor
in an animal model. Methods for assessing the effects of combining drugs to better treat
cancer are currently under development [89, 90, 91, 92, 93]. Considering efficacy, there
are three different outcomes which can result from combining drugs. The combination can
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create a synergistic effect and enhance the overall effectiveness of treatment. It could be that
combining drugs decreases the effectiveness of treatment and creates an antagonistic effect.
Finally, the effects of the individual compounds may simply combine in an additive manner.
The efficacy of combined chemotherapy may be affected by the order in which drugs are
administered ??. Consider two drugs, A and B, which attack the S and M phases of the
cell–cycle, respectively. These drugs should be administered such that A is administered
when cells are most likely to be in the synthesis phase. Similarly, when most cells are in
the mitosis phase, drug B should be administered. Administering large amounts of B could
eliminate the population of cells in M . One response might be that more nutrients are
now available and cells in the quiescent G0 phase may enter the proliferating portion of
the cell–cycle. Drug A could then be administered as more cells enter the S phase. An
alternative response to large amounts of B being administered might be that many cells
enter the quiescent phase in response to the toxicity of their micro–environment. In this
case, most treatment would be ineffective because quiescent cells are not affected by most
chemotherapeutics. An accurate model of cell–cycle dynamics would provide more insight
into the problem and aid in scheduling combination chemotherapy.
5.2.3 Patient Variability
It is common for patients to respond quite differently to anticancer drugs [94]. Response
variations could be attributed to different rates of drug elimination, reduced liver function,
variations in body weight, the presence or absence of specific genes, etc [94]. Because of
the toxic nature of chemotherapy, it is important to account for such variability. From a
model–based control perspective, this can be characterized by estimating patient–specific
parameters.
Models can be developed initially in animals, and then adapted to humans based on
data from clinical trials. Clinical trials can provide a population mean behavior. Population
averages provide a starting point for treatment. For well–tolerated compounds, population
means can be used to design the first cycle of treatment. For particularly toxic substances,
conservative estimates for model parameters could be used to schedule the first cycle of
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treatment. After the first cycle of treatment has been delivered and responses collected,
deviations from the expected response can be used to reestimate patient specific parameters.
This update is not limited to the first cycle; at any point where a patient response deviates
significantly from the expected, a parameter update could be performed. Reestimation of
parameters would start with the current set of parameters as the initial guess and least
squares estimate would then be performed to obtain the new set of parameters. If data
suggests the PK parameters are incorrect (e.g. blood samples suggest reduced liver function
which may be reducing the rate of drug metabolism), then it may be necessary to obtain
another set of PK data to reestimate the PK parameters.
This seems very straightforward, however there are complicating factors. Detailed animal
models can be developed because different tissue measurements are more readily available.
This may not be the case in humans. Consider obtaining patient–specific parameters for drug
disposition in the kidney. Direct measurement of drug concentration in the kidney may not
be clinically feasible. In this regard, it may be necessary to develop indirect measurements
based in part on the concentration of the drug in the urine. Also, heuristics may be used
when indirect measures are not available. These methodologies would be most useful for
drugs which are know to have toxic effects on specific organs.
5.3 IMPLEMENTATION
The focus of this work was the development of treatment schedules in mice. However, the
ultimate goal is to apply these methodologies in a clinical setting. To implement these
concepts clinically, PK/PD models are necessary. Ideally, an individual specializing in
modeling would work in tandem with clinicians and animal pharmacologists during the drug
discovery process. Models for specific drug/tumor combinations could then be developed and
modified as more information becomes available. This process is ideal because the modeler
can help inform experiments. As new compounds enter clinical trials, model parameters
representing the most conservative estimates can be used initially in humans. Parameters
can be reestimated as human data becomes available. The data from clinical trials can be
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used to create population estimates for model parameters. Eventually, drugs approved for
clinical use could then have patient specific schedules developed. A patient would enter the
clinic and be given a drug. Blood would be draw at specified times based on the PK model
structure and the dynamics of the drug. This would provide patient specific PK parameters.
Conservative estimates of population PD parameters would then be used to predict schedules
for the first two cycles of treatment. This would then provide data for patient specific PD
parameters. These parameters could then be updated at the end of each treatment cycle.
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APPENDIX A
NOMENCLATURE
Abbreviations
AIC Akaike’s information criterion
AUC area under the curve
9NC 9-nitrocamptothecin
9AC 9-aminocamptothecin
DLT dose limiting toxicity
GAMS general algebraic modeling system
LD lethal dose
PK pharmacokinetic (s)
PB/PK physiologically–based pharmacokinetic(s)
PD pharmacodynamic (s)
MAP murine antibody profile
MILP mixed–integer linear programming problem
MINLP mixed–integer nonlinear programming problem
MIQP mixed–integer quadratic programming problem
MTD maximum tolerated dose
NLP nonlinear programming problem
NONMEM nonlinear mixed–effects modeling
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OC optimal control
ODE ordinary differential equation(s)
QD×5×2 five days/week for two weeks every four weeks
SCID severe combined immunodeficient
SSE sum squared error
Std. Dev. standard deviation
Notation
A state transition matrix
b binary decision variable
bth(k) binary variable used to switch the therapeutic drug level on and
off
bu binary variable used to enable semicontinuous dose ranges
bdose binary variable used to switch between acceptable dose levels
B body weight
B input coefficient matrix
B0 initial body weight
Bmin lower bound on Btox
Btox body weight corrected for tumor volume (B −N/1000)
C, C(t) drug concentration
Cmax maximum allowable plasma drug concentration
Cth minimum plasma drug concentration for therapeutic effect
D amount of drug administered (total mass)
Dlast the most recent amount of drug delivered (concentration in
mg/kg)
Dl the amount of drug given which falls below Threshold
Dlb minimum effective dose
Du the amount of drug given which falls above Threshold
128
Dmax maximum tolerable dose
F (·) generic function of (·)
Gi number of cells in i
th phase of the cell cycle
G, G(s) Laplace domain transfer function
h stepsize for discrete systems
i index variable
j index variable
d subscript indicating the current variable is in the discrete time
J objective function
K process gain
k discrete timestep
ki & kij rate constants
keff efficacy proportionality constant
l set of possible dosing levels
` length of a tumor during measurement
M number of cells in the mitosis phase of the cell cycle
m final element in a set
mk final time step
ml final dosing level
mp final trajectory point
mq final dosing opportunity
mz final timestep in a day
N0 initial tumor volume
N tumor size (number of cells or volume)
Ne tumor size described by exponential growth
Ng tumor size described by Gompertzian growth
Ns tumor size described by switched exponential growth
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Nth threshold tumor size for switching between fast (τe,f ) and slow
(τe,s) growth rates in the switched exponential model
Nweeks treatment window in weeks/treatment horizon
p set of points in the trajectory tracking problems
Q parameters (vector or matrix) which are constants for optimiza-
tion purposes
Qdose(l) matrix of drug concentrations at different dose levels, l
QAC(z, l) matrix of 9NC concentrations at different timesteps of the day,
z,for different dose levels, l
QNC(z, l) matrix of 9NC concentrations at different timesteps of the day,
z,for different dose levels, l
Qmap(q) mapping dosing opportunities q to their corresponding timesteps
k
QPnom(k) vector of nominal tumor growth in the absence of treatment
S number of cells in the DNA synthesis of the cell cycle
p prediction horizon used in the receding horizon problem
P log transformed tumor growth
q discrete dosing opportunities
s Laplace domain variable
S number of cells in the DNA synthesis phase of the cell–cycle
t time
tf final time of treatment window
u input to a system
v compartmental volume
w width of a tumor during measurement or week in which a
measurement is taken
x internal state variable
X internal state variable in the Laplace domain
130
y outputs
z set of timesteps in a day
Threshold switch used in nonlinear PK model of 9NC representing the
maximum amount of 9NC which will take a particular pathway
Greek Letters
α fraction of a state
β complementary fraction of a state (β = 1− α)
Γ weight of the importance of a term in the objective function
γ rate of elimination of drug in Martin and Teo case study [12]
ρg plateau population in Gompertzian growth
τ system time constant, unless specified otherwise
τe doubling time for tumor volumes in exponential growth
τe,s doubling time active during larger tumor volumes in the
switched exponential model
τe,f doubling time active during smaller tumor volumes in the
switched exponential model
τg doubling time for tumor volumes in exponential growth phase
of Gompertzian growth
θ time delays
θeff delay between plasma concentration and drug effect on tumor
Calligraphic Letters
F(·) used to describe generic functions of (·)
D(t) generic drug dose
H(·) Heaviside/step function
L{·} Laplace transform operator
P generic model parameters
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Y(t) generic system outputs
Yˆ(t) generic model predictions of system outputs
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APPENDIX B
EXPERIMENTAL METHODS
B.1 PK EXPERIMENTAL METHODS
All experimental data presented here (PK and PD) were obtained from studies carried out by
our collaborators at the University of Pittsburgh Cancer Institute. The analytical methods
used in the present work are based on the experiments conducted by Zamboni and coworkers
[95]. In order to eliminate redundancies, only differences between the present methods and
those presented in [95] will be highlighted.
B.1.1 Reagents
All chemicals for HPLC analysis were HPLC grade and purchased from Fisher Scientific
(Pittsburgh, PA). N,N-Dimethylacetamide (DMA) was purchased from Sigma-Aldrich (Mil-
waukee, WI); polyethylene glycol 400, liquid (PEG 400) was purchased from Baker (Phillips-
burg, NJ). Camptothecin, N,N-dimethylformamide and carbonyl iron (pentacarbonyl iron)
were purchased from Sigma-Aldrich, (St. Louis, MO). 9NC and 9AC were provided by
SuperGen (Dublin, CA). 5-fluorouracil was purchased as the clinical formulation, Adrucil
(Pharmacia & Upjohn, Kalamazoo, MI)
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B.1.2 Drug Formulations
9NC was prepared at concentrations of 0.1, 0.067 or 0.044 mg/ml in vehicle (2% DMA in 1
mM phosphoric acid:PEG 400(49:51, v/v)). 9NC doses and vehicle were administered orally
(p.o.) at a volume of 0.01 ml/g body weight using a 20-gauge oral gavage needle and 1 ml
syringe. Two different PK studies were conducted. In the first, a single dose of 0.67 mg/kg
9NC was administered, and doses of either 0.44, 0.67, or 1.0 mg/kg were administered in the
second study.
B.1.3 Mice
Female C.B-17 SCID mice (4-6 weeks of age, specific-pathogen-free) were obtained from
the National Cancer Institute (NCI) Animal Production Program (Frederick, MD) and
were allowed to acclimate to the University of Pittsburgh Central Animal Facility for 1
week prior to initiation of study. Mice were housed in autoclaved microisolator caging and
were given Prolab ISOPRO RMH 3000 Irradiated Lab Diet (PMI Nutrition International,
Brentwood, MO) and autoclaved water ad libitum. Animal rooms were maintained on a
12-hour light/dark cycle with at least 12 air changes/hour, and temperature was maintained
at 72 ± 2 ◦F. All animals were handled in accordance with the Guide to the Care and Use
of Laboratory Animals [96] and on a protocol approved by the Institutional Animal Care
and Use Committee of the University of Pittsburgh. Analysis of sentinel mice housed in 1/5
dirty bedding every three months confirmed that the study mice remained MAP (murine
antibody profile) test-negative throughout the study.
B.2 TUMOR LINE, IMPLANTATION, MEASUREMENTS, AND
CALCULATIONS
HT29 human colon xenografts were obtained from the NCI Tumor Repository (Frederick,
MD) and were MAP test-negative. HT29 tumors were passaged in C.B-17 SCID female
mice as approximately 25 mg fragments implanted subcutaneously on the right flank by
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aseptic techniques. Fragments of tumor (approximately 25 mg) harvested from passage
mice were subsequently implanted subcutaneously into study mice. Mice were observed
twice daily. Both tumor volumes and body weights were recorded twice weekly. Tumor
volumes were measured using a digital caliper. Tumor volumes, V , were calculated from
the formula: V = `×w
2
2
where ` was the longest tumor diameter, and w was the shortest
diameter perpendicular to the direction of `.
B.3 PHARMACOKINETIC STUDIES
Pharmacokinetic studies were performed in non-tumor-bearing female C.B-17 SCID mice
and in female C.B-17 SCID mice bearing HT29 tumors at 27 days post tumor implantation.
Mice were stratified into groups of three such that the mean and median body weight and
tumor volumes in the tumor-bearing cohorts were similar across groups. Animals were fasted
overnight prior to dosing, and a dose of 0.44, 0.67 or 1.0 mg/kg 9NC was administered by oral
gavage to the mice as a single bolus based on fasted body weight. After 9NC administration,
groups of three mice were euthanized by CO2 inhalation, and blood was collected by cardiac
puncture, using heparinized syringes and needles, at each of the following times: 5, 15, 30,
60, 90, 120, 240, 360, 420, 960, 1440 and 2880 min. Three additional mice were euthanized
at five minutes after dosing with vehicle. Blood was transferred to microcentrifuge tubes
and stored on ice for less than three minutes before plasma was obtained by centrifugation
of whole blood at 13,000×g for 4 minutes.
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B.4 DETERMINATION OF 9NC AND 9AC LACTONE
CONCENTRATIONS
B.4.1 Plasma Sample Preparation for HPLC Analysis
The sample preparation methods were modified from those developed for human trials
[95]. Deionized, distilled water was used for conditioning the solid phase extraction (SPE)
cartridges. Mouse plasma sample volumes of 200 µl were used instead of the 1 ml volumes
used in the human studies.
The plasma for the determination of both 9NC and 9AC lactone forms was processed as
soon as it was obtained. Plasma samples (200 µl) were mixed with 2.5 µl of internal standard
(2 µg/ml camptothecin in acetone) and loaded onto preconditioned solid phase extraction
(SPE) cartridges (Waters OASISTM HLB 1 ml, 30 mg, Waters Associates, Millford, MA)
conditioned with 1 ml of methanol and equilibrated with 1 ml of distilled deionized water.
After application of the plasma, the cartridges were washed with 1 ml of 5% methanol in
water, which eluted the carboxylate forms of the camptothecins from the column. The
lactone forms of 9NC, 9AC, and camptothecin were eluted from the columns with 0.5 ml of
methanol and these aliquots were stored frozen at -70 ◦C until analysis. Thus these SPE
eluates contained only the lactone forms of the compounds of interest. This method was
evaluated in the laboratory of our collaborators for 9NC to demonstrate that only the lactone
form is retained on the SPE column and the carboxylate form is not retained. This method
has previously been published for 9AC lactone by Takimoto and coworkers [39].
B.4.2 HPLC Analysis
The HPLC analysis used in the present study was also used in the human studies presented
in [95], with adjustments as follows. For the reduction, 12 µl of the reducing reagent (25
mg reduced pentacarbonyl iron/ml H2O) and 6 µl of 12 N HCl were added to 120 µl of
each eluate or methanolic plasma supernatant. These samples were vortexed for 1 min
and sonicated for 30 min at 70 ◦C. The samples were then centrifuged (10,000×g for 4
min). Reduction of 9NC to 9AC by reduced pentacarbonyl iron is 54% efficient. Prior to
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placing these supernatants in siliconized (3% surfasil in toluene) HPLC autosampler vials,
the reduced methanolic supernatants (150 µl) were mixed with 75 µl of 0.5 M ammonium
acetate in water, pH 5.5, while the supernatants from the reduced eluates (150 µl) were
diluted with 100 µl of 0.5 M ammonium acetate in water, pH 5.5. The mobile phase used
here was isocratic (9% methanol, 23% acetonitrile and 68% 0.1M ammonium acetate, pH
5.5), at a flowrate of 1.0 ml/min.
B.5 DETERMINATION OF 9NC AND 9AC TOTAL CONCENTRATIONS
In order to more directly quantify the concentration of 9NC and 9AC in plasma, a more direct
analytical method was used. While the method above provided lactone concentrations of
9NC and 9AC, this method only provides the total concentrations of each substance because
all 9AC and 9NC in plasma were converted to lactone forms. A liquid chromatography-
quadrupole mass spectrometer (LC-MS/MS) was first used to obtain the total concentration
of 9AC in the plasma samples (CAC). The plasma samples were then reduced to convert
all of the 9NC to 9AC. After reduction, the plasma samples were analyzed again with the
LC-MS/MS to determine the total concentration of 9AC (CAC+NC). The original total
concentration of 9NC was then calculated by subtracting CAC from CAC+NC.
B.6 PD EXPERIMENTAL METHODS
Tumor implantation was described in section B.2. Mice bearing HT29 tumors were stratified
to treatment groups of 10 mice on day 19 post implantation (three days prior to treatment)
such that mean and median body weight and tumor volumes for the groups of mice were not
statistically different. Tumor volumes on day 19 were between 26 and 71 mm3. Treatment
groups were as follows: control; vehicle-treated control; positive control (5-fluorouracil, 20
mg/kg); 9NC 1.0 mg/kg/day; 9NC 0.67 mg/kg/day; and 9NC 0.44 mg/kg/day. Treatment
began on day 21, and this was defined as study day zero. Mice on the efficacy study received
137
daily doses by oral gavage for 5 days/week for two weeks followed by a two week period
of no treatment before the treatment regimen was repeated (QD×5×2) every four weeks.
The positive control group received doses intraperitoneally (i.p.) on the same schedule. At
the completion of the efficacy study, mice were euthanized, and complete necropsies were
performed.
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APPENDIX C
GENERATING DOSING PROFILES
Several files are utilized when generating the optimal dosing profile. As an example, the
trajectory tracking problem with only two dosing options (0 and 1.0 mg/kg) will be discussed.
The file gen minlp results.m is called and sets the optimization specific parameters and calls
the file run gams nonlinear.m. The file, run gams nonlinear.m, then generates the following
input files:
• input-dose to acconc.inc
• input-dose to ncconc.inc
• input-objective function.inc
• input-parameters.inc
• input-sets.inc
These correspond to the parameterized concentrations of 9AC, the parameterized concen-
trations of 9NC, the objective function, model parameters, and the sets used in tams. After
dumping these input files, run gams nonlinear.m executes the gams optimal dose profile.gms.
When executing optimal dose profile.gms, the input files a previously listed and the following
files are generated:
• output-dose levels-min max.txt
• output-state values-min max.txt
The first file contains three columns. The first column corresponds to the index of the
dosing opportunity, the second column corresponds to the time step, and the third column
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corresponds to the the dosing level in mg/kg. The second output file contains relevant states
of the system. The first column corresponds to the time in minutes, the second and third
columns correspond to the concentrations of 9NC and 9AC, respectively. The tumor volume,
body weight, and corrected body weight are given by the fourth, fifth, and sixth columns,
respectively. The second output file (state values) contains several thousand rows, and was
truncated to accommodate inclusion into this document.
C.1 SOURCECODE FILES
Begin file: gen minlp results.m
f unc t i on [ ] = g en m in l p r e s u l t s ( )
c f g . a n a l y s i s . t imestep = 5 ; % minutes
c f g . a n a l y s i s . f i na lweek = 8 ; % pr ed i c t i on hor izon
c f g . a n a l y s i s . s tepsperday = f l o o r (1440/ c f g . a n a l y s i s . t imestep ) ;
c f g . a n a l y s i s . dose2mass = 10ˆ6/1000∗20 .75 ;
c f g . a n a l y s i s . f i n a l t im e s t e p = . . .
c f g . a n a l y s i s . s tepsperday ∗7∗ c f g . a n a l y s i s . f i na lweek ;
c f g . a n a l y s i s . s im s t ep s i z e = 0 . 1 ;
c f g . a n a l y s i s . e f f e c t i v e i n f = 80∗1440; % in minutes
c f g . a n a l y s i s .N0 = 40 ; % i n i t i a l tumor vo l mm3
c fg . a n a l y s i s . B0 = 20 ; % i n i t i a l body weight g
%−− beg inning o f treatment
c f g . a n a l y s i s .B0CYCLE = 20 ; % i n i t i a l body weight g
%−− beg inning o f c y c l e
c f g . a n a l y s i s .BMIN = .98;% bound body weight
%( f r a c t i o n o f body weight
% which must remain a f t e r
% treatment
c f g . a n a l y s i s .DLB = 0 . 4 4 ;
c f g . a n a l y s i s .DUB = 1 . 0 ;
c f g . a n a l y s i s .DMIN = 0 . 0 0 ;
c f g . a n a l y s i s .DMAX = 1 . 0 ;
c f g . a n a l y s i s . p lo t range = [0 1 4 40 ] ;
c f g . a n a l y s i s . dose range = . 4 4 : . 0 1 : 1 . 0 ;
c f g . a n a l y s i s . s imonly = 0 ;
c f g . a n a l y s i s . rungams = 1;% 1 −−− execute the
% opt imiza t i on
% 0 −−− read old r e s u l t s
c f g . a n a l y s i s . g ams f i l e = ’ o p t ima l d o s e p r o f i l e . gms ’ ;
c f g . g en e r i c . gams binary = ’/misc/opt/bin /gams ’ ;
c f g . g en e r i c . gams d i rec tory = s p r i n t f ( ’% s /GAMS/MINLP’ , pwd ) ;
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% days to minimize tumor volume
c f g . a n a l y s i s . Ntimes = ( 1 : 1 : 8 ) ∗ 7 ;
% vecto r o f p o s s i b l e doses
c f g . a n a l y s i s . dose range = [ 1 . 0 ] ;
% p r e f i x used f o r wr i t i ng parameters
c f g . a n a l y s i s . p r e f i x = ’min max ’ ;
r e s u l t s . min max = run gams nonl inear ( c f g ) ;
End file: gen minlp results.m
Begin file: run gams nonlinear.m
f unc t i on [ r e s u l t s ]= run gams nonl inear ( c f g )
% func t i on [ ]= run gams nonl inear ( c f g )
%
% c fg −− c on f i g u r a t i on var i ab l e , a s t r u c tu r e r e a l l y .
%
% the ana l y s i s f i e l d i s used to s p e c i f y d i f f e r e n t
% parameters o f the ana l y s i s
%
%
%c fg . a n a l y s i s . t imestep = 5 ; % minutes
%c fg . a n a l y s i s . f i na lweek = 12 ; % pr ed i c t i on hor izon
%c fg . a n a l y s i s . s tepsperday = . . .
% f l o o r (1440/ c f g . a n a l y s i s . t imestep ) ;
%c f g . a n a l y s i s . dose2mass = 10ˆ6/1000∗20 .75 ;
% ng o f drug ;
%c fg . a n a l y s i s . f i n a l t im e s t e p = . . .
% c f g . a n a l y s i s . s tepsperday ∗7∗ c f g . a n a l y s i s . f i na lweek ;
%c fg . a n a l y s i s . s im s t ep s i z e = 0 . 1 ;
%c fg . a n a l y s i s . e f f e c t i v e i n f = 80∗1440; % in minutes
% i n i t i a l tumor volume in cubic mm
%c fg . a n a l y s i s .N0 = 40 ;
% i n i t i a l uncorrec ted body weight in grams
% −− beg inning o f treatment
% i n i t i a l uncorrec ted body weight in grams
% −− beg inning o f c y c l e
%c fg . a n a l y s i s . B0 = 20 ;
%c fg . a n a l y s i s .B0CYCLE = 20 ;
% bound body weight ( f r a c t i o n o f body weight which
% must remain a f t e r treatment )
%c fg . a n a l y s i s .BMIN = . 9 7 ;
% days to minimize tumor volume
%c fg . a n a l y s i s . Ntimes = ( 1 : 1 : 8 ) ∗ 7 ;
% days to minimize tumor volume
%c fg . a n a l y s i s . Ntimes = 7∗ c f g . a n a l y s i s . f i na lweek ;
%c fg . a n a l y s i s .DLB = 0 . 4 4 ;
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%cfg . a n a l y s i s .DUB = 1 . 0 ;
%c fg . a n a l y s i s .DMIN = 0 . 0 0 ;
%c fg . a n a l y s i s .DMAX = 1 . 0 ;
%c fg . a n a l y s i s . p l o t range = [0 1 440 ] ;
%c f g . a n a l y s i s . dose range = [ 0 . 4 4 0 .67 1 . 0 ] ;
%c f g . a n a l y s i s . dose range = . 4 4 : . 0 1 : 1 . 0 ;
% 1 −−− execute the opt imiza t i on
% 0 −−− read old r e s u l t s
%c fg . a n a l y s i s . rungams = 1 ;
%
% p r e f i x used f o r wr i t i ng parameters
%c fg . a n a l y s i s . p r e f i x = ’ f i n a l t ime ’ ;
%c f g . a n a l y s i s . g ams f i l e = ’ o p t ima l d o s e p r o f i l e . gms ’ ;
%c f g . g en e r i c . gams binary = ’/misc/opt/bin /gams ’ ;
%c f g . g en e r i c . gams d i rec tory = s p r i n t f ( ’% s /GAMS/MINLP 002 ’ , pwd ) ;
% 1 − only run s imu la t i on f o r dose l e v e l s ;
%c f g . a n a l y s i s . s imonly = 0 ;
%
% i n i t i a l i z i n g the re turn va r i ab l e
%
r e s u l t s = [ ] ;
%
% cr e a t i ng dose t imes vec to r
%
c fg . a n a l y s i s . dose t imes = [ ] ;
cnt r = 1 ;
f o r week=0:( c f g . a n a l y s i s . f i na lweek − 1)
f o r day=0:6
% only dos in monday−−f r i d ay
i f day <5
c f g . a n a l y s i s . dose t imes = . . .
[ c f g . a n a l y s i s . dose t imes
cntr week∗7+day ] ;
cnt r = cntr +1;
end
end
end
c f g . a n a l y s i s . dose t imes ( : , 2 )= . . .
c f g . a n a l y s i s . dose t imes ( : , 2 ) ∗ c f g . a n a l y s i s . s tepsperday + 1 ;
%
% i n i t i a l i n g c f g va r i ab l e
%
%c fg . g en e r i c = i n i t c o n f i g ;
%
% load ing var i ous parameters (PK, tumor growth , PD)
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%% tumor growth parameters
c f g . params . tumor growth = fetch parameters tumor growth ;
% conver t ing tumor growth parameters from days to minutes :
c f g . params . tumor growth . average . t aue f = . . .
c f g . params . tumor growth . average . taues ∗1440 ;
c f g . params . tumor growth . average . taues = . . .
c f g . params . tumor growth . average . taues ∗1440 ;
% load ing non l in ea r pk parameters
c f g . params . non l inea r pk = f e t ch pa ramet e r s non l i n ea r pk ;
% load ing non l in ea r pd parameters
c f g . params . non l inear pd = fe t ch pa ramet e r s pd non l i n ea r ;
% load ing non l in ea r t o x i c i t y parameters
c f g . params . body weight = fe tch paramete r s body we ight ;
%
% genera t ing pk p r o f i l e s f o r p o s s i b l e dos ing l e v e l s
%
%i f c f g . a n a l y s i s . rungams
di sp ( ’ c a l c u l a t i n g pk p r o f i l e s ’ ) ;
c f g . a n a l y s i s . p r o f i l e s . t ime range = . . .
0 : c f g . a n a l y s i s . t imestep : 1 4 4 0 ;
f o r i =1:max( s i z e ( c f g . a n a l y s i s . dose range ) )
d l e v e l s = [ 0 , c f g . a n a l y s i s . dose range ( i ) ] ;
[ t , x , y ] = runsim ( cfg , d l e v e l s ) ;
% resampl ing at time s t ep s
c f g . a n a l y s i s . p r o f i l e s . nc ( : , i ) = . . .
resample data ( c f g . a n a l y s i s . p r o f i l e s . t ime range , t , y ( : , 9 ) ) ;
c f g . a n a l y s i s . p r o f i l e s . ac ( : , i ) = . . .
resample data ( c f g . a n a l y s i s . p r o f i l e s . t ime range , t , y ( : , 1 0 ) ) ;
end
d i sp ( ’ c a l c u l a t i n g va r i ab l e bounds ’ ) ;
c f g . bounds = fetch bounds ( c f g ) ;
%end
%
% dumping the in fo rmat ion f o r gams
%
i f c f g . a n a l y s i s . rungams
dump gams( c f g )
end
%
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% execut ing gams
%
i f c f g . a n a l y s i s . rungams
exec gams ( c f g ) ;
end
%
% read ing r e s u l t s
%
[ r e s u l t s ] = r ead gams r e su l t s ( c f g ) ;
f unc t i on [ bounds ]= fetch bounds ( c f g ) ;
% c a l c u l a t i n g the bounds on PK s t a t e s
bounds = [ ] ;
d l e v e l s = [ 0 , c f g . a n a l y s i s .DUB] ;
c f g . a n a l y s i s . p lo t range = [0 2∗1440 ] ;
% running s imu la t i on in re sponse to maximum
% al l owab l e dose
[ t , x , y ] = runsim ( cfg , d l e v e l s ) ;
% upper bound here
y = max(y , [ ] , 1 ) ;
% lower bounds are a l l z e ro
bounds . x1 . ub = y ( 1 ) ; bounds . x1 . lb = 0 ;
bounds . x2 . ub = y ( 2 ) ; bounds . x2 . lb = 0 ;
bounds . x3 . ub = y ( 3 ) ; bounds . x3 . lb = 0 ;
bounds . x4 . ub = y ( 4 ) ; bounds . x4 . lb = 0 ;
bounds . x5 . ub = y ( 5 ) ; bounds . x5 . lb = 0 ;
bounds . x6 . ub = y ( 6 ) ; bounds . x6 . lb = 0 ;
bounds .CNC. ub = y ( 9 ) ; bounds .CNC. lb = 0 ;
bounds .CAC. ub = y ( 1 0 ) ; bounds .CAC. lb = 0 ;
func t i on [ t , x , y]=runsim ( cfg , d l e v e l s ) ;
%
% the f i r s t 7 outputs are the s t a t e s
% the next two are the concent ra t i on
% of 9nc and 9ac r e s p e c t i v e l y
%
% i n i t i a l i z i n g v a r i a b l e s
t = 0 ; x = 0 ; y = 0 ;
de l t a = c fg . a n a l y s i s . s im s t ep s i z e ∗5 ;
drug = [0 0 ] ;
l a s t d o s e = [0 0 ] ;
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[ ndoses , tmp ] = s i z e ( d l e v e l s ) ;
f o r i =1: ndoses
drug = [ drug
d l e v e l s ( i , 1 ) 0
d l e v e l s ( i ,1)+ de l t a d l e v e l s ( i , 2 ) / ( 2∗ de l t a )
d l e v e l s ( i ,1)+2∗ de l t a d l e v e l s ( i , 2 ) / ( 2∗ de l t a )
d l e v e l s ( i ,1)+3∗ de l t a 0 ] ;
l a s t d o s e = [ l a s t d o s e
d l e v e l s ( i , 1 ) d l e v e l s ( i , 2 )
d l e v e l s ( i ,1)+1440− de l t a d l e v e l s ( i , 2 ) ] ;
end
drug = [ drug
c f g . a n a l y s i s . e f f e c t i v e i n f 0 ] ;
i n l cond = [0 0 0 0 0 0 0 c f g . a n a l y s i s .N0 c f g . a n a l y s i s . B0 ] ;
opt ions = s imset ( . . .
’ I n i t i a l S t a t e ’ , in lcond , . . .
’ s o l v e r ’ , ’ ode4 ’ , . . .
’ FixedStep ’ , c f g . a n a l y s i s . s ims t ep s i z e , . . .
’ SrcWorkspace ’ , ’ current ’ . . .
) ;
warning o f f ;
[ t , x , y ] = sim ( ’ pkpd non l i n e a r f u l l ’ , . . .
c f g . a n a l y s i s . p lotrange , . . .
opt ions ) ;
warning on ;
%
% dumping the in fo rmat ion f o r gams
%
func t i on [ ]=dump gams( c f g )
%
% dumping s e t s
%
[ numdoses , tmp]= s i z e ( c f g . a n a l y s i s . dose t imes ) ;
[ doseopts . nt imesteps , doseopts . ndoses ] = . . .
s i z e ( c f g . a n a l y s i s . p r o f i l e s . nc ) ;
FID = fopen ( s p r i n t f ( ’% s / input−s e t s . inc ’ , . . .
c f g . g en e r i c . gams d i rec tory ) , ’W’ ) ;
f p r i n t f (FID , ’ k d i s c r e t e time /1∗%d/ \n ’ , . . .
c f g . a n a l y s i s . f i n a l t im e s t e p ) ;
f p r i n t f (FID , ’ q dos ing time /1∗%d/ \n ’ , . . .
numdoses ) ;
f p r i n t f (FID , ’ spd s t ep s per day /1∗%d/\n ’ , . . .
doseopts . nt imesteps ) ;
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f p r i n t f (FID , . . .
’ d l v l s number o f p o s s i b l e dose l e v e l s /1∗%d/\n ’ , . . .
doseopts . ndoses + 1 ) ;
f c l o s e (FID ) ;
%
% dumping s c a l a r s
%
FID = fopen ( s p r i n t f ( ’% s / input−parameters . inc ’ , . . .
c f g . g en e r i c . gams d i rec tory ) , ’W’ ) ;
d i s c r e t e t h e t a = . . .
f l o o r ( c f g . params . non l inea r pk . theta / c f g . a n a l y s i s . t imestep ) ;
f p r i n t f (FID , ’∗ \n ’ ) ;
f p r i n t f (FID , ’∗ ana l y s i s s p e c i f i c \n ’ ) ;
f p r i n t f (FID , ’∗ \n ’ ) ;
f p r i n t f (FID , ’ t imestep d i s c r e t i z a t o i n s tep s i z e /%.8e/\n ’ , . . .
c f g . a n a l y s i s . t imestep ) ;
f p r i n t f (FID , ’ numsteps number o f time s t ep s /%d/ \n ’ , . . .
c f g . a n a l y s i s . f i n a l t im e s t e p ) ;
f p r i n t f (FID , ’∗ \n ’ ) ;
f p r i n t f (FID , ’∗ tumor growth parameters \n ’ ) ;
f p r i n t f (FID , ’∗ \n ’ ) ;
f p r i n t f (FID , ’ t aue f f a s t growth ra t e /%.8e /\n ’ , . . .
c f g . params . tumor growth . average . t aue f ) ;
f p r i n t f (FID , ’ taues slow growth ra t e /%.8e /\n ’ , . . .
c f g . params . tumor growth . average . taues ) ;
f p r i n t f (FID , ’ nth sw i tch ing s i z e /%.8e/\n ’ , . . .
c f g . params . tumor growth . average . nth ) ;
f p r i n t f (FID , ’∗ \n ’ ) ;
f p r i n t f (FID , ’∗ non l inea r pd parameters \n ’ ) ;
f p r i n t f (FID , ’∗ \n ’ ) ;
f p r i n t f (FID , ’ k e f f r a t e o f c e l l k i l l /%.8e /\n ’ , . . .
c f g . params . non l inear pd . summary . average ) ;
f p r i n t f (FID , ’∗ \n ’ ) ;
f p r i n t f (FID , ’∗ body weight model parameters \n ’ ) ;
f p r i n t f (FID , ’∗ \n ’ ) ;
f p r i n t f (FID , ’ tauw ra t e o f mouse doubl ing /%.8e/\n ’ , . .
c f g . params . body weight . d10 . nave . tauw ) ;
f p r i n t f (FID , ’ kd e f f e c t o f drug on bodyweight /%.8e/\n ’ , . . .
c f g . params . body weight . d10 . nave . kd ) ;
f p r i n t f (FID , ’∗ \n ’ ) ;
f p r i n t f (FID , ’∗ misca l l eneous parameters \n ’ ) ;
f p r i n t f (FID , ’∗ \n ’ ) ;
f p r i n t f (FID , ’N0 i n i t i a l cond i t i on /%.8e /\n ’ , . . .
c f g . a n a l y s i s .N0 ) ;
f p r i n t f (FID , ’B0 i n i t i a l body weight ( treatment ) /%.8e /\n ’ , . . .
c f g . a n a l y s i s . B0 ) ;
f p r i n t f (FID , ’B0CYCLE i n i t i a l body weight ( c y c l e ) /%.8e /\n ’ , . . .
c f g . a n a l y s i s .B0CYCLE) ;
f p r i n t f (FID , ’BMIN minimum body weight ( f r a c t i o n ) /%.8e /\n ’ , . . .
c f g . a n a l y s i s .BMIN) ;
f p r i n t f (FID , ’ dose t imes (q ) p o s s i b l e dose t imes /\n ’ ) ;
f o r i =1:numdoses
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f p r i n t f (FID , ’ %2d %5d \n ’ , . . .
c f g . a n a l y s i s . dose t imes ( i , 1 ) , . . .
c f g . a n a l y s i s . dose t imes ( i , 2 ) ) ;
end
f p r i n t f (FID , ’ / \n ’ ) ;
f p r i n t f (FID , ’ d o s e l e v e l s ( d l v l s ) p o s s i b l e dose l e v e l s /\n ’ ) ;
f o r i =1:max( s i z e ( c f g . a n a l y s i s . dose range ) )
f p r i n t f (FID , ’ %2d %5e \n ’ , i , . . .
c f g . a n a l y s i s . dose range ( i ) ) ;
end
f p r i n t f (FID , ’ / \n ’ ) ;
f c l o s e (FID ) ;
%
% dumping ob j e c t i v e func t i on
%
FID = fopen ( s p r i n t f ( ’% s / input−ob j e c t i v e f u n c t i o n . inc ’ , . . .
c f g . g en e r i c . gams d i rec tory ) , ’W’ ) ;
f p r i n t f (FID , ’ obj . . z =e= ’ ) ;
f o r i =1:max( s i z e ( c f g . a n a l y s i s . Ntimes ) )
% igno r i ng anything a f t e r the f i n a l week
i f c f g . a n a l y s i s . Ntimes ( i ) >= c fg . a n a l y s i s . f i na lweek
i f i > 1
f p r i n t f (FID , ’ + ’ ) ;
end
f p r i n t f (FID , ’ TUMOR( ’ ’%d ’ ’ ) ’ , . . .
c f g . a n a l y s i s . Ntimes ( i )∗ c f g . a n a l y s i s . s tepsperday ) ;
end
end
f p r i n t f (FID , ’ ; \n ’ , c f g . a n a l y s i s . f i n a l t im e s t e p ) ;
f c l o s e (FID ) ;
%
% dumping pk p r o f i l e s
%
FIDNC = fopen ( s p r i n t f ( ’% s / input−dose to ncconc . inc ’ , . . .
c f g . g en e r i c . gams d i rec tory ) , ’W’ ) ;
FIDAC = fopen ( s p r i n t f ( ’% s / input−dose to acconc . inc ’ , . . .
c f g . g en e r i c . gams d i rec tory ) , ’W’ ) ;
%
% pr i n t i ng headers
%
f p r i n t f (FIDNC, . . .
’ TABLE ALLNCCONC( spd , d l v l s ) ”Concentrat ions o f
9NC at d i f f e r e n t dose l e v e l s ”\n ’ ) ;
f p r i n t f (FIDAC, . . .
’ TABLE ALLACCONC( spd , d l v l s ) ”Concentrat ions
o f 9AC at d i f f e r e n t dose l e v e l s ”\n ’ ) ;
%
% pr i n t i ng the column headings
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%
f p r i n t f (FIDNC, ’ ’ ) ;
f p r i n t f (FIDAC, ’ ’ ) ;
f o r j =1: doseopts . ndoses + 1 % gotta get the zero column
f p r i n t f (FIDNC, ’%15d ’ , j ) ;
f p r i n t f (FIDAC, ’%15d ’ , j ) ;
end
f p r i n t f (FIDNC, ’\n ’ ) ;
f p r i n t f (FIDAC, ’\n ’ ) ;
f o r i =1: doseopts . nt imesteps
f p r i n t f (FIDNC, ’ %7d ’ , i ) ;
f p r i n t f (FIDNC, ’%15.4 e ’ , 0 ) ;
f p r i n t f (FIDAC, ’ %7d ’ , i ) ;
f p r i n t f (FIDAC, ’%15.4 e ’ , 0 ) ;
f o r j =1: doseopts . ndoses
f p r i n t f (FIDNC, ’%15.4 e ’ , c f g . a n a l y s i s . p r o f i l e s . nc ( i , j ) ) ;
f p r i n t f (FIDAC, ’%15.4 e ’ , c f g . a n a l y s i s . p r o f i l e s . ac ( i , j ) ) ;
end
i f i==doseopts . nt imesteps
f p r i n t f (FIDNC, ’ ;\n ’ ) ;
f p r i n t f (FIDAC, ’ ;\n ’ ) ;
end
f p r i n t f (FIDNC, ’\n ’ ) ;
f p r i n t f (FIDAC, ’\n ’ ) ;
end
f c l o s e (FIDNC) ;
f c l o s e (FIDAC) ;
%
%
% dumping user de f ined s o l u t i o n
%
%
i f c f g . a n a l y s i s . s imonly
i f (max( s i z e ( c f g . a n a l y s i s . s p e c i f i e d d o s e l e v e l s ) ) . . .
== numdoses )
FID = fopen ( s p r i n t f ( ’% s / input−s p e c i f i e d d o s e l e v e l s . inc ’ , . . .
c f g . g en e r i c . gams d i rec tory ) , ’W’ ) ;
f p r i n t f (FID , . . .
’ s p e c i f i e d d o s e l e v e l s ( q ) user s p e c i f i e d dose l e v e l s /\n ’ ) ;
f o r i =1:numdoses
f p r i n t f (FID , ’ %2d %d \n ’ , i , . . .
c f g . a n a l y s i s . s p e c i f i e d d o s e l e v e l s ( i ) ) ;
end
f p r i n t f (FID , ’ / \n ’ ) ;
f c l o s e (FID ) ;
e l s e
end
end
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f unc t i on [ g en e r i c ]= i n i t c o n f i g ;
g en e r i c . gams binary = ’/misc/opt/bin /gams ’ ;
g en e r i c . gams d i rec tory = s p r i n t f ( ’% s /GAMS/MINLP 002 ’ , pwd ) ;
%−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
%−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
f unc t i on [ ]= exec gams ( c f g ) ;
% a s s i gn i ng d i r e c t o r i e s
wd . matlab = pwd ;
wd . gams = c fg . g en e r i c . gams d i rec tory ;
% execut ing gams
e x e c s t r i n g = s p r i n t f ( ’% s %s ’ , . . .
c f g . g en e r i c . gams binary , . . .
c f g . a n a l y s i s . g ams f i l e ) ;
cd (wd . gams ) ;
d i sp ( s p r i n t f ( ’GAMS working d i r e c t o r y : %s ’ , pwd) )
%save /tmp/goat . mat ;
system ( e x e c s t r i n g ) ;
% backing up the s o l u t i o n s
e x e c s t r i n g = . . .
s p r i n t f ( . . .
’ cp output−d o s e l e v e l s . txt output−do s e l e v e l s−%s . txt ’ , . . .
c f g . a n a l y s i s . p r e f i x ) ;
system ( e x e c s t r i n g ) ;
e x e c s t r i n g = s p r i n t f ( . . .
’ cp output−s t a t e v a l u e s . txt output−s t a t e va l u e s−%s . txt ’ , . . .
c f g . a n a l y s i s . p r e f i x ) ;
system ( e x e c s t r i n g ) ;
% r e tu r i n g to the matlab d i r e c t o r y
cd (wd . matlab ) ;
%−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
%−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
f unc t i on [ r e s u l t s ]= r ead gams r e su l t s ( c f g ) ;
r e s u l t s = [ ] ;
l o a d s t r = s p r i n t f ( ’ load %s/output−do s e l e v e l s−%s . txt ’ , . . .
c f g . g en e r i c . gams directory , . . .
c f g . a n a l y s i s . p r e f i x ) ;
eva l ( l o a d s t r ) ;
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l o a d s t r = s p r i n t f ( ’ load %s/output−s t a t e va l u e s−%s . txt ’ , . . .
c f g . g en e r i c . gams directory , . . .
c f g . a n a l y s i s . p r e f i x ) ;
eva l ( l o a d s t r ) ;
tmp str = s p r i n t f ( ’ d l = ou t pu t d o s e l e v e l s %s ; ’ , . . .
c f g . a n a l y s i s . p r e f i x ) ;
eva l ( tmp str ) ;
tmp str = s p r i n t f ( ’ sv = ou tpu t s t a t e v a l u e s %s ; ’ , . . .
c f g . a n a l y s i s . p r e f i x ) ;
eva l ( tmp str ) ;
r e s u l t s . doses . dose t ime = dl ( : , 2 ) ;
r e s u l t s . doses . d o s e l e v e l = dl ( : , 3 ) ;
r e s u l t s . s t a t e s . s im time = sv ( : , 1 ) ;
r e s u l t s . s t a t e s .CNC = sv ( : , 2 ) ;
r e s u l t s . s t a t e s .CAC = sv ( : , 3 ) ;
r e s u l t s . s t a t e s .TUMOR = sv ( : , 4 ) ;
r e s u l t s . s t a t e s .BW = sv ( : , 5 ) ;
r e s u l t s . s t a t e s .BWc = sv ( : , 6 ) ;
r e s u l t s . p r o f i l e s = c f g . a n a l y s i s . p r o f i l e s ;
%−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
End file: run gams nonlinear.m
Begin file: input-dose to acconc.inc
TABLE ALLACCONC( spd , d l v l s ) ”Concentrat ions o f 9AC”
1 2
1 0 .0000 e+00 0.0000 e+00
2 0 .0000 e+00 1.0515 e+01
3 0 .0000 e+00 1.2084 e+01
4 0 .0000 e+00 1.1757 e+01
5 0 .0000 e+00 1.0598 e+01
6 0 .0000 e+00 9.1688 e+00
7 0 .0000 e+00 7.7520 e+00
8 0 .0000 e+00 6.4745 e+00
9 0 .0000 e+00 5.3796 e+00
10 0.0000 e+00 4.4685 e+00
11 0.0000 e+00 3.7260 e+00
12 0.0000 e+00 3.4499 e+00
13 0.0000 e+00 3.4149 e+00
14 0.0000 e+00 3.4610 e+00
15 0.0000 e+00 3.5240 e+00
16 0.0000 e+00 3.5737 e+00
17 0.0000 e+00 3.5980 e+00
18 0.0000 e+00 3.5946 e+00
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19 0 .0000 e+00 3.5658 e+00
20 0.0000 e+00 3.5156 e+00
21 0.0000 e+00 3.4484 e+00
22 0.0000 e+00 3.3683 e+00
23 0.0000 e+00 3.2790 e+00
24 0.0000 e+00 3.1832 e+00
25 0.0000 e+00 3.0834 e+00
26 0.0000 e+00 2.9814 e+00
27 0.0000 e+00 2.8785 e+00
28 0.0000 e+00 2.7759 e+00
29 0.0000 e+00 2.6742 e+00
30 0.0000 e+00 2.5741 e+00
31 0.0000 e+00 2.4760 e+00
32 0.0000 e+00 2.3801 e+00
33 0.0000 e+00 2.2868 e+00
34 0.0000 e+00 2.1961 e+00
35 0.0000 e+00 2.1081 e+00
36 0.0000 e+00 2.0229 e+00
37 0.0000 e+00 1.9405 e+00
38 0.0000 e+00 1.8608 e+00
39 0.0000 e+00 1.7840 e+00
40 0.0000 e+00 1.7098 e+00
41 0.0000 e+00 1.6384 e+00
42 0.0000 e+00 1.5696 e+00
43 0.0000 e+00 1.5034 e+00
44 0.0000 e+00 1.4397 e+00
45 0.0000 e+00 1.3784 e+00
46 0.0000 e+00 1.3196 e+00
47 0.0000 e+00 1.2630 e+00
48 0.0000 e+00 1.2087 e+00
49 0.0000 e+00 1.1566 e+00
50 0.0000 e+00 1.1066 e+00
51 0.0000 e+00 1.0586 e+00
52 0.0000 e+00 1.0126 e+00
53 0.0000 e+00 9.6846 e−01
54 0 .0000 e+00 9.2617 e−01
55 0 .0000 e+00 8.8564 e−01
56 0 .0000 e+00 8.4681 e−01
57 0 .0000 e+00 8.0961 e−01
58 0 .0000 e+00 7.7398 e−01
59 0 .0000 e+00 7.3987 e−01
60 0 .0000 e+00 7.0721 e−01
61 0 .0000 e+00 6.7595 e−01
62 0 .0000 e+00 6.4603 e−01
63 0 .0000 e+00 6.1740 e−01
64 0 .0000 e+00 5.9001 e−01
65 0 .0000 e+00 5.6380 e−01
66 0 .0000 e+00 5.3873 e−01
67 0 .0000 e+00 5.1475 e−01
68 0 .0000 e+00 4.9181 e−01
69 0 .0000 e+00 4.6988 e−01
70 0 .0000 e+00 4.4891 e−01
71 0 .0000 e+00 4.2886 e−01
72 0 .0000 e+00 4.0969 e−01
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73 0 .0000 e+00 3.9137 e−01
74 0 .0000 e+00 3.7385 e−01
75 0 .0000 e+00 3.5711 e−01
76 0 .0000 e+00 3.4110 e−01
77 0 .0000 e+00 3.2581 e−01
78 0 .0000 e+00 3.1119 e−01
79 0 .0000 e+00 2.9723 e−01
80 0 .0000 e+00 2.8388 e−01
81 0 .0000 e+00 2.7113 e−01
82 0 .0000 e+00 2.5894 e−01
83 0 .0000 e+00 2.4730 e−01
84 0 .0000 e+00 2.3618 e−01
85 0 .0000 e+00 2.2555 e−01
86 0 .0000 e+00 2.1540 e−01
87 0 .0000 e+00 2.0571 e−01
88 0 .0000 e+00 1.9644 e−01
89 0 .0000 e+00 1.8759 e−01
90 0 .0000 e+00 1.7914 e−01
91 0 .0000 e+00 1.7107 e−01
92 0 .0000 e+00 1.6336 e−01
93 0 .0000 e+00 1.5599 e−01
94 0 .0000 e+00 1.4896 e−01
95 0 .0000 e+00 1.4224 e−01
96 0 .0000 e+00 1.3582 e−01
97 0 .0000 e+00 1.2969 e−01
98 0 .0000 e+00 1.2384 e−01
99 0 .0000 e+00 1.1825 e−01
100 0 .0000 e+00 1.1291 e−01
101 0 .0000 e+00 1.0782 e−01
102 0 .0000 e+00 1.0295 e−01
103 0 .0000 e+00 9.8299 e−02
104 0 .0000 e+00 9.3860 e−02
105 0 .0000 e+00 8.9620 e−02
106 0 .0000 e+00 8.5572 e−02
107 0 .0000 e+00 8.1706 e−02
108 0 .0000 e+00 7.8015 e−02
109 0 .0000 e+00 7.4489 e−02
110 0 .0000 e+00 7.1123 e−02
111 0 .0000 e+00 6.7909 e−02
112 0 .0000 e+00 6.4840 e−02
113 0 .0000 e+00 6.1909 e−02
114 0 .0000 e+00 5.9111 e−02
115 0 .0000 e+00 5.6439 e−02
116 0 .0000 e+00 5.3888 e−02
117 0 .0000 e+00 5.1451 e−02
118 0 .0000 e+00 4.9125 e−02
119 0 .0000 e+00 4.6904 e−02
120 0 .0000 e+00 4.4783 e−02
121 0 .0000 e+00 4.2758 e−02
122 0 .0000 e+00 4.0825 e−02
123 0 .0000 e+00 3.8979 e−02
124 0 .0000 e+00 3.7216 e−02
125 0 .0000 e+00 3.5533 e−02
126 0 .0000 e+00 3.3926 e−02
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127 0 .0000 e+00 3.2391 e−02
128 0 .0000 e+00 3.0926 e−02
129 0 .0000 e+00 2.9528 e−02
130 0 .0000 e+00 2.8192 e−02
131 0 .0000 e+00 2.6917 e−02
132 0 .0000 e+00 2.5699 e−02
133 0 .0000 e+00 2.4537 e−02
134 0 .0000 e+00 2.3427 e−02
135 0 .0000 e+00 2.2367 e−02
136 0 .0000 e+00 2.1355 e−02
137 0 .0000 e+00 2.0389 e−02
138 0 .0000 e+00 1.9467 e−02
139 0 .0000 e+00 1.8586 e−02
140 0 .0000 e+00 1.7745 e−02
141 0 .0000 e+00 1.6943 e−02
142 0 .0000 e+00 1.6176 e−02
143 0 .0000 e+00 1.5444 e−02
144 0 .0000 e+00 1.4746 e−02
145 0 .0000 e+00 1.4078 e−02
146 0 .0000 e+00 1.3442 e−02
147 0 .0000 e+00 1.2833 e−02
148 0 .0000 e+00 1.2253 e−02
149 0 .0000 e+00 1.1698 e−02
150 0 .0000 e+00 1.1169 e−02
151 0 .0000 e+00 1.0664 e−02
152 0 .0000 e+00 1.0181 e−02
153 0 .0000 e+00 9.7206 e−03
154 0 .0000 e+00 9.2808 e−03
155 0 .0000 e+00 8.8609 e−03
156 0 .0000 e+00 8.4600 e−03
157 0 .0000 e+00 8.0772 e−03
158 0 .0000 e+00 7.7117 e−03
159 0 .0000 e+00 7.3628 e−03
160 0 .0000 e+00 7.0297 e−03
161 0 .0000 e+00 6.7116 e−03
162 0 .0000 e+00 6.4079 e−03
163 0 .0000 e+00 6.1180 e−03
164 0 .0000 e+00 5.8411 e−03
165 0 .0000 e+00 5.5768 e−03
166 0 .0000 e+00 5.3245 e−03
167 0 .0000 e+00 5.0836 e−03
168 0 .0000 e+00 4.8535 e−03
169 0 .0000 e+00 4.6339 e−03
170 0 .0000 e+00 4.4243 e−03
171 0 .0000 e+00 4.2241 e−03
172 0 .0000 e+00 4.0329 e−03
173 0 .0000 e+00 3.8504 e−03
174 0 .0000 e+00 3.6762 e−03
175 0 .0000 e+00 3.5099 e−03
176 0 .0000 e+00 3.3511 e−03
177 0 .0000 e+00 3.1994 e−03
178 0 .0000 e+00 3.0546 e−03
179 0 .0000 e+00 2.9164 e−03
180 0 .0000 e+00 2.7845 e−03
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181 0 .0000 e+00 2.6585 e−03
182 0 .0000 e+00 2.5382 e−03
183 0 .0000 e+00 2.4233 e−03
184 0 .0000 e+00 2.3137 e−03
185 0 .0000 e+00 2.2090 e−03
186 0 .0000 e+00 2.1090 e−03
187 0 .0000 e+00 2.0136 e−03
188 0 .0000 e+00 1.9225 e−03
189 0 .0000 e+00 1.8355 e−03
190 0 .0000 e+00 1.7524 e−03
191 0 .0000 e+00 1.6731 e−03
192 0 .0000 e+00 1.5974 e−03
193 0 .0000 e+00 1.5251 e−03
194 0 .0000 e+00 1.4561 e−03
195 0 .0000 e+00 1.3902 e−03
196 0 .0000 e+00 1.3273 e−03
197 0 .0000 e+00 1.2673 e−03
198 0 .0000 e+00 1.2099 e−03
199 0 .0000 e+00 1.1552 e−03
200 0 .0000 e+00 1.1029 e−03
201 0 .0000 e+00 1.0530 e−03
202 0 .0000 e+00 1.0053 e−03
203 0 .0000 e+00 9.5985 e−04
204 0 .0000 e+00 9.1642 e−04
205 0 .0000 e+00 8.7495 e−04
206 0 .0000 e+00 8.3536 e−04
207 0 .0000 e+00 7.9756 e−04
208 0 .0000 e+00 7.6147 e−04
209 0 .0000 e+00 7.2701 e−04
210 0 .0000 e+00 6.9411 e−04
211 0 .0000 e+00 6.6271 e−04
212 0 .0000 e+00 6.3272 e−04
213 0 .0000 e+00 6.0409 e−04
214 0 .0000 e+00 5.7675 e−04
215 0 .0000 e+00 5.5065 e−04
216 0 .0000 e+00 5.2574 e−04
217 0 .0000 e+00 5.0195 e−04
218 0 .0000 e+00 4.7923 e−04
219 0 .0000 e+00 4.5755 e−04
220 0 .0000 e+00 4.3684 e−04
221 0 .0000 e+00 4.1708 e−04
222 0 .0000 e+00 3.9820 e−04
223 0 .0000 e+00 3.8018 e−04
224 0 .0000 e+00 3.6298 e−04
225 0 .0000 e+00 3.4656 e−04
226 0 .0000 e+00 3.3087 e−04
227 0 .0000 e+00 3.1590 e−04
228 0 .0000 e+00 3.0161 e−04
229 0 .0000 e+00 2.8796 e−04
230 0 .0000 e+00 2.7493 e−04
231 0 .0000 e+00 2.6249 e−04
232 0 .0000 e+00 2.5061 e−04
233 0 .0000 e+00 2.3927 e−04
234 0 .0000 e+00 2.2844 e−04
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235 0 .0000 e+00 2.1811 e−04
236 0 .0000 e+00 2.0824 e−04
237 0 .0000 e+00 1.9881 e−04
238 0 .0000 e+00 1.8982 e−04
239 0 .0000 e+00 1.8123 e−04
240 0 .0000 e+00 1.7303 e−04
241 0 .0000 e+00 1.6520 e−04
242 0 .0000 e+00 1.5772 e−04
243 0 .0000 e+00 1.5059 e−04
244 0 .0000 e+00 1.4377 e−04
245 0 .0000 e+00 1.3727 e−04
246 0 .0000 e+00 1.3105 e−04
247 0 .0000 e+00 1.2512 e−04
248 0 .0000 e+00 1.1946 e−04
249 0 .0000 e+00 1.1406 e−04
250 0 .0000 e+00 1.0890 e−04
251 0 .0000 e+00 1.0397 e−04
252 0 .0000 e+00 9.9263 e−05
253 0 .0000 e+00 9.4771 e−05
254 0 .0000 e+00 9.0483 e−05
255 0 .0000 e+00 8.6389 e−05
256 0 .0000 e+00 8.2479 e−05
257 0 .0000 e+00 7.8747 e−05
258 0 .0000 e+00 7.5184 e−05
259 0 .0000 e+00 7.1782 e−05
260 0 .0000 e+00 6.8534 e−05
261 0 .0000 e+00 6.5432 e−05
262 0 .0000 e+00 6.2472 e−05
263 0 .0000 e+00 5.9645 e−05
264 0 .0000 e+00 5.6946 e−05
265 0 .0000 e+00 5.4369 e−05
266 0 .0000 e+00 5.1909 e−05
267 0 .0000 e+00 4.9560 e−05
268 0 .0000 e+00 4.7317 e−05
269 0 .0000 e+00 4.5176 e−05
270 0 .0000 e+00 4.3132 e−05
271 0 .0000 e+00 4.1180 e−05
272 0 .0000 e+00 3.9317 e−05
273 0 .0000 e+00 3.7538 e−05
274 0 .0000 e+00 3.5839 e−05
275 0 .0000 e+00 3.4217 e−05
276 0 .0000 e+00 3.2669 e−05
277 0 .0000 e+00 3.1191 e−05
278 0 .0000 e+00 2.9779 e−05
279 0 .0000 e+00 2.8432 e−05
280 0 .0000 e+00 2.7145 e−05
281 0 .0000 e+00 2.5917 e−05
282 0 .0000 e+00 2.4744 e−05
283 0 .0000 e+00 2.3624 e−05
284 0 .0000 e+00 2.2555 e−05
285 0 .0000 e+00 2.1535 e−05
286 0 .0000 e+00 2.0560 e−05
287 0 .0000 e+00 1.9630 e−05
288 0 .0000 e+00 1.8742 e−05
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289 0 .0000 e+00 1.7894 e−05;
End file: input-dose to acconc.inc
Begin file: input-dose to ncconc.inc
TABLE ALLNCCONC( spd , d l v l s ) ”Concentrat ions o f 9NC”
1 2
1 0 .0000 e+00 0.0000 e+00
2 0 .0000 e+00 7.5032 e+01
3 0 .0000 e+00 8.9186 e+01
4 0 .0000 e+00 8.7552 e+01
5 0 .0000 e+00 7.8922 e+01
6 0 .0000 e+00 6.7957 e+01
7 0 .0000 e+00 5.7007 e+01
8 0 .0000 e+00 4.7134 e+01
9 0 .0000 e+00 3.8703 e+01
10 0.0000 e+00 3.1733 e+01
11 0.0000 e+00 2.6079 e+01
12 0.0000 e+00 2.1542 e+01
13 0.0000 e+00 1.7920 e+01
14 0.0000 e+00 1.5029 e+01
15 0.0000 e+00 1.2714 e+01
16 0.0000 e+00 1.0849 e+01
17 0.0000 e+00 9.3345 e+00
18 0.0000 e+00 8.0930 e+00
19 0.0000 e+00 7.0645 e+00
20 0.0000 e+00 6.2034 e+00
21 0.0000 e+00 5.4748 e+00
22 0.0000 e+00 4.8522 e+00
23 0.0000 e+00 4.3155 e+00
24 0.0000 e+00 3.8491 e+00
25 0.0000 e+00 3.4409 e+00
26 0.0000 e+00 3.0817 e+00
27 0.0000 e+00 2.7640 e+00
28 0.0000 e+00 2.4820 e+00
29 0.0000 e+00 2.2307 e+00
30 0.0000 e+00 2.0062 e+00
31 0.0000 e+00 1.8054 e+00
32 0.0000 e+00 1.6253 e+00
33 0.0000 e+00 1.4637 e+00
34 0.0000 e+00 1.3185 e+00
35 0.0000 e+00 1.1879 e+00
36 0.0000 e+00 1.0705 e+00
37 0.0000 e+00 9.6471 e−01
38 0 .0000 e+00 8.6949 e−01
39 0 .0000 e+00 7.8372 e−01
40 0 .0000 e+00 7.0644 e−01
41 0 .0000 e+00 6.3681 e−01
42 0 .0000 e+00 5.7406 e−01
43 0 .0000 e+00 5.1751 e−01
44 0 .0000 e+00 4.6654 e−01
156
45 0 .0000 e+00 4.2059 e−01
46 0 .0000 e+00 3.7917 e−01
47 0 .0000 e+00 3.4183 e−01
48 0 .0000 e+00 3.0818 e−01
49 0 .0000 e+00 2.7783 e−01
50 0 .0000 e+00 2.5048 e−01
51 0 .0000 e+00 2.2582 e−01
52 0 .0000 e+00 2.0358 e−01
53 0 .0000 e+00 1.8354 e−01
54 0 .0000 e+00 1.6547 e−01
55 0 .0000 e+00 1.4918 e−01
56 0 .0000 e+00 1.3449 e−01
57 0 .0000 e+00 1.2125 e−01
58 0 .0000 e+00 1.0932 e−01
59 0 .0000 e+00 9.8554 e−02
60 0 .0000 e+00 8.8851 e−02
61 0 .0000 e+00 8.0104 e−02
62 0 .0000 e+00 7.2218 e−02
63 0 .0000 e+00 6.5108 e−02
64 0 .0000 e+00 5.8698 e−02
65 0 .0000 e+00 5.2920 e−02
66 0 .0000 e+00 4.7710 e−02
67 0 .0000 e+00 4.3013 e−02
68 0 .0000 e+00 3.8778 e−02
69 0 .0000 e+00 3.4961 e−02
70 0 .0000 e+00 3.1519 e−02
71 0 .0000 e+00 2.8416 e−02
72 0 .0000 e+00 2.5618 e−02
73 0 .0000 e+00 2.3096 e−02
74 0 .0000 e+00 2.0823 e−02
75 0 .0000 e+00 1.8773 e−02
76 0 .0000 e+00 1.6924 e−02
77 0 .0000 e+00 1.5258 e−02
78 0 .0000 e+00 1.3756 e−02
79 0 .0000 e+00 1.2402 e−02
80 0 .0000 e+00 1.1181 e−02
81 0 .0000 e+00 1.0080 e−02
82 0 .0000 e+00 9.0878 e−03
83 0 .0000 e+00 8.1932 e−03
84 0 .0000 e+00 7.3866 e−03
85 0 .0000 e+00 6.6594 e−03
86 0 .0000 e+00 6.0038 e−03
87 0 .0000 e+00 5.4127 e−03
88 0 .0000 e+00 4.8798 e−03
89 0 .0000 e+00 4.3994 e−03
90 0 .0000 e+00 3.9663 e−03
91 0 .0000 e+00 3.5758 e−03
92 0 .0000 e+00 3.2238 e−03
93 0 .0000 e+00 2.9064 e−03
94 0 .0000 e+00 2.6203 e−03
95 0 .0000 e+00 2.3623 e−03
96 0 .0000 e+00 2.1298 e−03
97 0 .0000 e+00 1.9201 e−03
98 0 .0000 e+00 1.7311 e−03
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99 0 .0000 e+00 1.5606 e−03
100 0 .0000 e+00 1.4070 e−03
101 0 .0000 e+00 1.2685 e−03
102 0 .0000 e+00 1.1436 e−03
103 0 .0000 e+00 1.0310 e−03
104 0 .0000 e+00 9.2952 e−04
105 0 .0000 e+00 8.3801 e−04
106 0 .0000 e+00 7.5551 e−04
107 0 .0000 e+00 6.8113 e−04
108 0 .0000 e+00 6.1407 e−04
109 0 .0000 e+00 5.5362 e−04
110 0 .0000 e+00 4.9912 e−04
111 0 .0000 e+00 4.4998 e−04
112 0 .0000 e+00 4.0568 e−04
113 0 .0000 e+00 3.6574 e−04
114 0 .0000 e+00 3.2974 e−04
115 0 .0000 e+00 2.9727 e−04
116 0 .0000 e+00 2.6801 e−04
117 0 .0000 e+00 2.4162 e−04
118 0 .0000 e+00 2.1784 e−04
119 0 .0000 e+00 1.9639 e−04
120 0 .0000 e+00 1.7706 e−04
121 0 .0000 e+00 1.5963 e−04
122 0 .0000 e+00 1.4391 e−04
123 0 .0000 e+00 1.2974 e−04
124 0 .0000 e+00 1.1697 e−04
125 0 .0000 e+00 1.0545 e−04
126 0 .0000 e+00 9.5073 e−05
127 0 .0000 e+00 8.5713 e−05
128 0 .0000 e+00 7.7275 e−05
129 0 .0000 e+00 6.9667 e−05
130 0 .0000 e+00 6.2809 e−05
131 0 .0000 e+00 5.6625 e−05
132 0 .0000 e+00 5.1051 e−05
133 0 .0000 e+00 4.6025 e−05
134 0 .0000 e+00 4.1494 e−05
135 0 .0000 e+00 3.7409 e−05
136 0 .0000 e+00 3.3726 e−05
137 0 .0000 e+00 3.0406 e−05
138 0 .0000 e+00 2.7412 e−05
139 0 .0000 e+00 2.4714 e−05
140 0 .0000 e+00 2.2281 e−05
141 0 .0000 e+00 2.0087 e−05
142 0 .0000 e+00 1.8110 e−05
143 0 .0000 e+00 1.6327 e−05
144 0 .0000 e+00 1.4719 e−05
145 0 .0000 e+00 1.3270 e−05
146 0 .0000 e+00 1.1964 e−05
147 0 .0000 e+00 1.0786 e−05
148 0 .0000 e+00 9.7242 e−06
149 0 .0000 e+00 8.7669 e−06
150 0 .0000 e+00 7.9038 e−06
151 0 .0000 e+00 7.1257 e−06
152 0 .0000 e+00 6.4242 e−06
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153 0 .0000 e+00 5.7917 e−06
154 0 .0000 e+00 5.2215 e−06
155 0 .0000 e+00 4.7075 e−06
156 0 .0000 e+00 4.2440 e−06
157 0 .0000 e+00 3.8262 e−06
158 0 .0000 e+00 3.4495 e−06
159 0 .0000 e+00 3.1099 e−06
160 0 .0000 e+00 2.8038 e−06
161 0 .0000 e+00 2.5277 e−06
162 0 .0000 e+00 2.2789 e−06
163 0 .0000 e+00 2.0545 e−06
164 0 .0000 e+00 1.8523 e−06
165 0 .0000 e+00 1.6699 e−06
166 0 .0000 e+00 1.5055 e−06
167 0 .0000 e+00 1.3573 e−06
168 0 .0000 e+00 1.2237 e−06
169 0 .0000 e+00 1.1032 e−06
170 0 .0000 e+00 9.9460 e−07
171 0 .0000 e+00 8.9669 e−07
172 0 .0000 e+00 8.0841 e−07
173 0 .0000 e+00 7.2882 e−07
174 0 .0000 e+00 6.5707 e−07
175 0 .0000 e+00 5.9239 e−07
176 0 .0000 e+00 5.3407 e−07
177 0 .0000 e+00 4.8149 e−07
178 0 .0000 e+00 4.3409 e−07
179 0 .0000 e+00 3.9135 e−07
180 0 .0000 e+00 3.5282 e−07
181 0 .0000 e+00 3.1809 e−07
182 0 .0000 e+00 2.8677 e−07
183 0 .0000 e+00 2.5854 e−07
184 0 .0000 e+00 2.3309 e−07
185 0 .0000 e+00 2.1014 e−07
186 0 .0000 e+00 1.8945 e−07
187 0 .0000 e+00 1.7080 e−07
188 0 .0000 e+00 1.5399 e−07
189 0 .0000 e+00 1.3883 e−07
190 0 .0000 e+00 1.2516 e−07
191 0 .0000 e+00 1.1284 e−07
192 0 .0000 e+00 1.0173 e−07
193 0 .0000 e+00 9.1715 e−08
194 0 .0000 e+00 8.2686 e−08
195 0 .0000 e+00 7.4545 e−08
196 0 .0000 e+00 6.7207 e−08
197 0 .0000 e+00 6.0590 e−08
198 0 .0000 e+00 5.4625 e−08
199 0 .0000 e+00 4.9247 e−08
200 0 .0000 e+00 4.4399 e−08
201 0 .0000 e+00 4.0028 e−08
202 0 .0000 e+00 3.6087 e−08
203 0 .0000 e+00 3.2535 e−08
204 0 .0000 e+00 2.9332 e−08
205 0 .0000 e+00 2.6444 e−08
206 0 .0000 e+00 2.3841 e−08
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207 0 .0000 e+00 2.1494 e−08
208 0 .0000 e+00 1.9378 e−08
209 0 .0000 e+00 1.7470 e−08
210 0 .0000 e+00 1.5750 e−08
211 0 .0000 e+00 1.4200 e−08
212 0 .0000 e+00 1.2802 e−08
213 0 .0000 e+00 1.1541 e−08
214 0 .0000 e+00 1.0405 e−08
215 0 .0000 e+00 9.3807 e−09
216 0 .0000 e+00 8.4572 e−09
217 0 .0000 e+00 7.6246 e−09
218 0 .0000 e+00 6.8740 e−09
219 0 .0000 e+00 6.1973 e−09
220 0 .0000 e+00 5.5872 e−09
221 0 .0000 e+00 5.0371 e−09
222 0 .0000 e+00 4.5412 e−09
223 0 .0000 e+00 4.0941 e−09
224 0 .0000 e+00 3.6911 e−09
225 0 .0000 e+00 3.3277 e−09
226 0 .0000 e+00 3.0001 e−09
227 0 .0000 e+00 2.7047 e−09
228 0 .0000 e+00 2.4385 e−09
229 0 .0000 e+00 2.1984 e−09
230 0 .0000 e+00 1.9820 e−09
231 0 .0000 e+00 1.7869 e−09
232 0 .0000 e+00 1.6109 e−09
233 0 .0000 e+00 1.4523 e−09
234 0 .0000 e+00 1.3094 e−09
235 0 .0000 e+00 1.1805 e−09
236 0 .0000 e+00 1.0642 e−09
237 0 .0000 e+00 9.5948 e−10
238 0 .0000 e+00 8.6502 e−10
239 0 .0000 e+00 7.7986 e−10
240 0 .0000 e+00 7.0308 e−10
241 0 .0000 e+00 6.3387 e−10
242 0 .0000 e+00 5.7146 e−10
243 0 .0000 e+00 5.1520 e−10
244 0 .0000 e+00 4.6448 e−10
245 0 .0000 e+00 4.1876 e−10
246 0 .0000 e+00 3.7753 e−10
247 0 .0000 e+00 3.4036 e−10
248 0 .0000 e+00 3.0685 e−10
249 0 .0000 e+00 2.7665 e−10
250 0 .0000 e+00 2.4941 e−10
251 0 .0000 e+00 2.2486 e−10
252 0 .0000 e+00 2.0272 e−10
253 0 .0000 e+00 1.8276 e−10
254 0 .0000 e+00 1.6477 e−10
255 0 .0000 e+00 1.4855 e−10
256 0 .0000 e+00 1.3392 e−10
257 0 .0000 e+00 1.2074 e−10
258 0 .0000 e+00 1.0885 e−10
259 0 .0000 e+00 9.8137 e−11
260 0 .0000 e+00 8.8475 e−11
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261 0 .0000 e+00 7.9765 e−11
262 0 .0000 e+00 7.1912 e−11
263 0 .0000 e+00 6.4833 e−11
264 0 .0000 e+00 5.8450 e−11
265 0 .0000 e+00 5.2696 e−11
266 0 .0000 e+00 4.7508 e−11
267 0 .0000 e+00 4.2831 e−11
268 0 .0000 e+00 3.8614 e−11
269 0 .0000 e+00 3.4813 e−11
270 0 .0000 e+00 3.1386 e−11
271 0 .0000 e+00 2.8296 e−11
272 0 .0000 e+00 2.5510 e−11
273 0 .0000 e+00 2.2999 e−11
274 0 .0000 e+00 2.0734 e−11
275 0 .0000 e+00 1.8693 e−11
276 0 .0000 e+00 1.6853 e−11
277 0 .0000 e+00 1.5194 e−11
278 0 .0000 e+00 1.3698 e−11
279 0 .0000 e+00 1.2349 e−11
280 0 .0000 e+00 1.1134 e−11
281 0 .0000 e+00 1.0038 e−11
282 0 .0000 e+00 9.0494 e−12
283 0 .0000 e+00 8.1585 e−12
284 0 .0000 e+00 7.3553 e−12
285 0 .0000 e+00 6.6312 e−12
286 0 .0000 e+00 5.9784 e−12
287 0 .0000 e+00 5.3898 e−12
288 0 .0000 e+00 4.8592 e−12
289 0 .0000 e+00 4.3808 e−12;
End file: input-dose to ncconc.inc
Begin file: input-objective function.inc
obj . . z =e= + TUMOR( ’4032 ’ )
+ TUMOR( ’6048 ’ )
+ TUMOR( ’8064 ’ )
+ TUMOR( ’10080 ’ )
+ TUMOR( ’12096 ’ )
+ TUMOR( ’14112 ’ )
+ TUMOR( ’16128 ’ ) ;
End file: input-objective function.inc
Begin file: input-parameters.inc
∗
∗ ana l y s i s s p e c i f i c
∗
t imestep d i s c r e t i z a t o i n s tep s i z e /5.00000000 e+00/
numsteps number o f time s t ep s /16128/
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∗
∗ tumor growth parameters
∗
t aue f f a s t growth ra t e /1.94186187 e+04/
taues slow growth ra t e /1.94186187 e+04/
nth swi tch ing s i z e /4.77363886 e+02/
∗
∗ non l inea r pd parameters
∗
k e f f r a t e o f c e l l k i l l /3 .48501281 e−05/
∗
∗ body weight model parameters
∗
tauw ra t e o f mouse doubl ing /2.60497755 e−06/
kd e f f e c t o f drug on bodyweight /2.85795338 e−05/
∗
∗ misca l l eneous parameters
∗
N0 i n i t i a l c ond i t i on /4.00000000 e+01/
B0 i n i t i a l body weight ( treatment ) /2.00000000 e+01/
B0CYCLE i n i t i a l body weight ( cy c l e ) /2.00000000 e+01/
BMIN minimum body weight ( f r a c t i o n ) /9.80000000 e−01/
dose t imes (q ) p o s s i b l e dose t imes /
1 1
2 289
3 577
4 865
5 1153
6 2017
7 2305
8 2593
9 2881
10 3169
11 4033
12 4321
13 4609
14 4897
15 5185
16 6049
17 6337
18 6625
19 6913
20 7201
21 8065
22 8353
23 8641
24 8929
25 9217
26 10081
27 10369
28 10657
29 10945
30 11233
31 12097
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32 12385
33 12673
34 12961
35 13249
36 14113
37 14401
38 14689
39 14977
40 15265
/
d o s e l e v e l s ( d l v l s ) p o s s i b l e dose l e v e l s /
1 1.000000 e+00
/
End file: input-parameters.inc
Begin file: input-sets.inc
k d i s c r e t e time /1∗16128/
q dos ing time /1∗40/
spd s t ep s per day /1∗289/
d l v l s number o f p o s s i b l e dose l e v e l s /1∗2/
End file: input-sets.inc
Begin file: optimal dose profile.gms
∗
∗ SETS
∗
SETS
$ inc lude ” input−s e t s . i nc ”
;
∗
∗ PARAMETERS
∗
PARAMETERS
NMIN lb on tumor volume
NMAX ub on tumor volume
LNS lb on slow tumor growth
UNS ub on slow tumor growth
LNF lb on f a s t tumor growth
UNF ub on f a s t tumor growth
$ inc lude ” input−parameters . i nc ”
;
$ inc lude ” input−dose to ncconc . inc ”
$ inc lude ” input−dose to acconc . inc ”
163
NMIN = . 1 ;
NMAX = 20000 ;
LNS = log (2)/ taue f − l og (2)/ taues ;
UNS = log (2)/ taue f − l og (2)/ taues ;
LNF = log (2)/ taues − l og (2)/ taue f ;
UNF = log (2)/ taues − l og (2)/ taue f ;
∗
∗ VARIABLES
∗
va r i a b l e s
TUMOR(k) tumor growth
BW(k) body weight
BWc(k ) co r r e c t ed body weight
CNC(k ) concent ra t i on o f 9NC
CAC(k ) concent ra t i on o f 9NC
G(k ) d i s cont inuous tumor growth term
BT(k ) sw i t ch ing va r i ab l e f o r tumor growth
BD(q , d l v l s ) binary va r i ab l e to turn on d i f f e r e n t
z ob j e c t i v e func t i on value
;
f r e e v a r i a b l e TUMOR
∗ p o s i t i v e va r i ab l e BW
po s i t i v e va r i ab l e CNC
po s i t i v e va r i ab l e CAC
po s i t i v e va r i ab l e G
po s i t i v e va r i ab l e Du
po s i t i v e va r i ab l e Dl
binary va r i ab l e BT
binary va r i ab l e BD
f r e e va r i a b l e z
;
∗
∗ bounding v a r i a b l e s
∗
TUMOR. up(k ) = log (NMAX) ;
∗∗BW. up(k ) = 2 ;
∗
∗ s e t t i n g i n i t i a l va lue s
∗
TUMOR. fx ( ’ 1 ’ ) = log (N0 ) ;
BW. fx ( ’ 1 ’ ) = B0CYCLE;
∗
∗ i n i t i a l guess f o r v a r i a b l e s
∗
∗ −− no treatment
∗
CNC. l ( k ) = 0 ;
CAC. l ( k ) = 0 ;
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BT. l ( k ) = 0 ;
BD. l (q , d l v l s ) = 0 ;
BD. l (q , ’ 1 ’ ) = 1 ;
TUMOR. l ( ’ 1 ’ ) = log (N0 ) ;
loop (k ,
BT. l ( k ) = (1) $ (TUMOR. l ( k ) l t l og ( nth ) ) ;
G. l ( k ) = ( log (2)/ taue f ) $ (TUMOR. l ( k ) l t l og ( nth ) )
+ ( log (2)/ taues ) $ (TUMOR. l ( k ) ge l og ( nth ) ) ;
TUMOR. l ( k+1) = TUMOR. l ( k ) + t imestep ∗G. l ( k ) ;
∗ s e t t i n g the upper bound on tumor s i z e as the s i z e
∗ o f the tumor at any step ’k ’ i f no drug were admin i s te red
TUMOR. up(k ) = TUMOR. l ( k ) ;
) ;
∗
∗ EQUATIONS
∗
EQUATIONS
dBW(k) ”PD bodyweight”
BWcdef ( k ) ” co r r e c t ed body weight ”
BWcmin(k ) ”minimum on bodyweight”
odpd (q ) ”one dose per day”
CNCdef( k ) ” d e f i n i n g CNC”
CACdef( k ) ” d e f i n i n g CAC”
dTUMOR(k) ”PD tumor volume”
swNS(k ) ” a c t i v e when N > nth”
swNF(k ) ” a c t i v e when N < nth”
swNLS(k ) ” a c t i v e when N < nth”
swNUS(k ) ” a c t i v e when N < nth”
swNLF(k ) ” a c t i v e when N > nth”
swNUF(k ) ” a c t i v e when N > nth”
obj ” ob j e c t i v e func t i on ”
;
∗
∗ Def in ing CNC and CAC
∗
∗
∗ ensur ing that only one dose i s s e l e c t e d per dos ing day
∗
odpd (q ) . . sum( d lv l s , BD(q , d l v l s ) ) =e= 1 ;
CACdef( k ) . . CAC(k ) =e= sum( ( spd , q ) ,
sum( d lv l s ,
BD(q , d l v l s )∗ALLACCONC( spd , d l v l s )
$ ( ord (k ) eq ( dose t imes (q)−1+ord ( spd ) ) )
)
) ;
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CNCdef( k ) . . CNC(k ) =e= sum( ( spd , q ) ,
sum( d lv l s ,
BD(q , d l v l s )∗ALLNCCONC( spd , d l v l s )
$ ( ord (k ) eq ( dose t imes (q)−1+ord ( spd ) ) )
)
) ;
∗
∗ handl ing the d i s c on t i nu i t y in N at nth
∗
swNS(k ) . . TUMOR(k ) − l og ( nth ) =l=
( log (NMAX) − l og ( nth ))∗(1−BT(k ) ) ;
swNF(k ) . . l og ( nth ) − TUMOR(k ) =l=
( log ( nth ) − l og (NMIN))∗BT(k ) ;
swNLS(k ) . . LNS∗BT(k ) =l=
G(k ) − l og (2)/ taues ;
swNUS(k ) . . G(k ) − l og (2)/ taues =l=
UNS∗BT(k ) ;
swNLF(k ) . . LNF∗(1−BT(k ) ) =l=
G(k ) − l og (2)/ taue f ;
swNUF(k ) . . G(k ) − l og (2)/ taue f =l=
UNF∗(1−BT(k ) ) ;
∗
∗ growth
∗
dTUMOR(k) $ ( ord (k ) l t numsteps ) . . TUMOR(k+1) =e=
TUMOR(k ) + t imestep ∗(G(k ) − k e f f ∗(CNC(k ) + CAC(k ) ) ) ;
dBW(k) $ ( ord (k ) l t numsteps ) . . BW(k+1) =e=
BW(k) + t imestep ∗( tauw∗BW(k) − kd∗(CNC(k ) + CAC(k ) ) ) ;
BWcdef ( k ) . . BWc(k ) =e=
BW(k)/B0 − exp (TUMOR. l ( k ) ) / (B0∗1000) ;
BWcmin(k ) . . BWc(k ) =g= BMIN;
$ inc lude ” input−ob j e c t i v e f u n c t i o n . inc ”
z . l = TUMOR. l ( ’ 8 0 6 4 ’ ) ;
opt ion LIMROW = 400000;
opt ion r e s l im = 200000;
opt ion i t e r l im = 200000;
Model dose / a l l / ;
SOLVE dose minimizing z USING MIP;
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d i sp l ay TUMOR. l ;
d i sp l ay BW. l ;
d i sp l ay BWc. l ;
d i sp l ay CNC. l ;
d i sp l ay CAC. l ;
d i sp l ay G. l ;
d i sp l ay BT. l ;
d i sp l ay BD. l ;
d i sp l ay z . l ;
FILE fhd l /output−d o s e l e v e l s . txt / ;
put f hd l ;
f hd l . nd=10;
loop ( ( q , d l v l s ) ,
i f (1 = BD. l (q , d l v l s ) ,
i f ( ord ( d l v l s ) > 1 ,
put ord (q ) , @20 , dose t imes (q ) , @40 ,
d o s e l e v e l s ( d l v l s −1) / ;
e l s e
put ord (q ) , @20 , dose t imes (q ) , @40 , 0 / ;
) ;
) ;
) ;
FILE fhsv /output−s t a t e v a l u e s . txt / ;
put fhsv ;
fhsv . nd=10;
loop (k ,
put ( ord (k )∗ t imestep ) ,
@20 , CNC. l ( k ) ,
@40 , CAC. l ( k ) ,
@60 , exp (TUMOR. l ( k ) ) ,
@80 , BW. l ( k ) ,
@100 , BWc. l ( k ) / ;
) ;
End file: optimal dose profile.gms
Begin file: output-dose levels-min max.txt
1.0000000000 1.0000000000 0.0000000000
2.0000000000 2.8900000E+2 0.0000000000
3.0000000000 5.7700000E+2 1.0000000000
4.0000000000 8.6500000E+2 1.0000000000
5.0000000000 1.1530000E+3 1.0000000000
6.0000000000 2.0170000E+3 1.0000000000
7.0000000000 2.3050000E+3 1.0000000000
8.0000000000 2.5930000E+3 1.0000000000
9.0000000000 2.8810000E+3 1.0000000000
1.0000000E+1 3.1690000E+3 1.0000000000
1.1000000E+1 4.0330000E+3 0.0000000000
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1.2000000E+1 4.3210000E+3 1.0000000000
1.3000000E+1 4.6090000E+3 1.0000000000
1.4000000E+1 4.8970000E+3 1.0000000000
1.5000000E+1 5.1850000E+3 1.0000000000
1.6000000E+1 6.0490000E+3 0.0000000000
1.7000000E+1 6.3370000E+3 0.0000000000
1.8000000E+1 6.6250000E+3 1.0000000000
1.9000000E+1 6.9130000E+3 1.0000000000
2.0000000E+1 7.2010000E+3 1.0000000000
2.1000000E+1 8.0650000E+3 0.0000000000
2.2000000E+1 8.3530000E+3 0.0000000000
2.3000000E+1 8.6410000E+3 1.0000000000
2.4000000E+1 8.9290000E+3 1.0000000000
2.5000000E+1 9.2170000E+3 1.0000000000
2.6000000E+1 1.0081000E+4 0.0000000000
2.7000000E+1 1.0369000E+4 0.0000000000
2.8000000E+1 1.0657000E+4 1.0000000000
2.9000000E+1 1.0945000E+4 1.0000000000
3.0000000E+1 1.1233000E+4 1.0000000000
3.1000000E+1 1.2097000E+4 0.0000000000
3.2000000E+1 1.2385000E+4 0.0000000000
3.3000000E+1 1.2673000E+4 1.0000000000
3.4000000E+1 1.2961000E+4 1.0000000000
3.5000000E+1 1.3249000E+4 1.0000000000
3.6000000E+1 1.4113000E+4 0.0000000000
3.7000000E+1 1.4401000E+4 0.0000000000
3.8000000E+1 1.4689000E+4 1.0000000000
3.9000000E+1 1.4977000E+4 1.0000000000
4.0000000E+1 1.5265000E+4 1.0000000000
End file: output-dose levels-min max.txt
Begin file: output-state values-min max.txt
5.0000000000 0.0000000000 0.0000000000 4.0000000E+1 2.0000000E+1 0.9980000000
1.0000000E+1 0.0000000000 0.0000000000 4.0007140E+1 2.0000260E+1 0.9980126679
. . . . . .
. . . . . .
. . . . . .
8 .0630000E+4 0.0000000000 0.0000000000 7.6661703042 2.0503050E+1 0.9895984014
8.0635000E+4 0.0000000000 0.0000000000 7.6675386452 2.0503317E+1 0.9896054078
8.0640000E+4 0.0000000000 0.0000000000 7.6689072305 2.0503584E+1 0.9896124133
End file: output-state values-min max.txt
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